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SUMMARY 
Despite numerous reports of the physiological importance of the role of 
proteolysis in vivo, it has been difficult to find correlations between the events observed 
and the presence of particular proteinases. The plasminogen-plasmin system, however, 
is important in the degradation of the extracellular matrix glycoproteins and the 
plasminogen activators are implicated as mediators of a proteolytic cascade which 
mammalian cells may employ to degrade the protein macromolecules of their immediate 
environment. 
Four monoclonal antibodies raised against purified human plasminogen were 
characterized for their effects on the activation of plasminogen and on three enzymic 
properties of plasmin viz:- (a) thioesterolysis, (b) fibrinolysis, (c) conversion of 
high molecular weight human urokinase to its low molecular weight form. 
None of the monoclonal antibodies inhibited plasminogen activation by urokinase. 
The monoclonal antibodies characterized in this study fell into three groups. The first 
group represented by anti-pig 1 inhibited (a), (b) and (c), while anti-pig 2, inhibited 
activities (a), (b) and (c) to varying degrees and in addition formed complexes with 
plasmin which were highly stable to sodium dodecyl sulphate. Anti-pig 3 and anti-pig 4 
inhibited activity (c), but not (a) or (b). 
Selective use of these monoclonal antibodies demonstrated unequivocally that 
plasmin mediates the activation of the proenzyme form of urokinase type plasminogen 
activator. Besides their use in affinity chromatography, therefore, these antibodies are 
valuable for defining the role of plasmin in the mechanisms of extracellular matrix 
degradation as shown in their use in Chapters 4-6. 
Total plasminogen activator content (i.e. proenzyme plus active enzyme) was 
I 
I 
,, 
I 
C 
D 
I 
I 
ii 
I 
I 
I 
I 
11 
Ii 
I : 
X 
found to be increased significantly in both colorectal carcinomas (n=20) and the 
premalignant adenomatous polyps (n=27) when compared to autologous normal mucosa. 
Activator content was also found to be increased in adenomatous polyps and autologous 
normal mucosa removed from familial polyposis coli patients. 
The urokinase-type plasminogen activator was shown by a new monoclonal 
antibody technique to be present mainly as the proenzyme form. 
For colon cancers, there was a significant correlation between their grade 
according to the Dukes' classification and the amount of proenzyme present ( P < 0.05). 
Although a similar trend was evident, no significant correlation was, however, observed 
for total plasminogen activator content and the Dukes' grading. 
For adenomatous polyps, no significant correlation was observed between enzyme 
content and the size or degree of dysplasia. However, plasminogen activator expression 
was found to be increased in the upper top or apical third of the polyps relative to the 
basal third or stalk. 
These results suggest that the expression of increased levels of human 
plasminogen activator of 52,000 daltons proenzyme in dysplastic colon epithelial cells 
correlates with the extent of invasion. The polyp studies suggest that expression of 
human plasminogen activator of 52,000 daltons is a pre-requisite for invasion. 
The study of the plasminogen activator content of colonic mucosa therefore offers 
a useful biochemical correlate of epithelial cell transformation. 
The quantitative esterolytic assay incorporating monoclonal antibodies inhibitory 
to plasmin (chapter 3) was also used to elucidate the role of human plasminogen 
activator of 52,000 daltons in inflammatory bowel disease. The levels of proenzyme and 
active forms of human plasminogen activator of 52,000 daltons were compared in 
mucosa from patients with active inflammatory bowel disease (n=13), from 
inflammatory bowel disease patients in remission (n= 7) and from uninvolved mucosa 
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(n=8). Preincubation of tissue homogenates with monoclonal anti-pig 1 and anti-pig 3 
antibodies prevented activation of the proenzyme by plasmin. 
The level (absorbance 412 nm) of total human plasminogen activator of 52,000 
daltons enzyme activity (active + proenzyme) was markedly increased in active 
inflammatory bowel disease homogenates (1 .1 O + 0.39), compared to those found in 
remission (0.48 + 0.17) and in uninvolved mucosa (0.45 + 0.20; P < 0.01 ). Assays of 
proenzyme levels showed a similar highly significant increase in active mucosa (0.80 ±. 
0.27) compared to remission (0.25 + 0.15) and uninvolved mucosa (0.23 + 0.15; P < 
0.01 ). In actively diseased mucosa, 70°/o of the total human plasminogen activator of 
52,000 daltons activity was present in the proenzyme form requiring extracellular 
cleavage by plasmin. These results suggest that human plasminogen activator of 52,000 
daltons may be involved in the pathogenesis of tissue injury in inflammatory bowel 
disease by establishing the presence of a recognised pathway of inflammatory injury 
which is selectively and substantially enhanced in actively diseased tissue. 
Subcellular fractionation of human intestinal macrophages was performed to 
define the localisation of the plasminogen activators and other serine hydrolase. Human 
intestinal macrophages, isolated from lamina propria and purified by centrifugal 
elutriation were disintegrated by nitrogen cavitation. The membranes were separated by 
equilibrium buoyant density using isopycnic centrifugation on a sucrose gradient. The 
subcellular membranes were localized using marker enzymes characteristic for plasma 
and intracellular membranes. 
Mn 2 +-stimulated leucine 2-napthylamidase was identified as a plasma 
membrane enzyme. 
Analysis of membrane fractions identified a membrane bound esterase not 
detected in blood monocytes and exhibiting the same density and release characteristics 
of lysosomal hydrolase fraction. Whilst a portion of the esterase activity may reside in 
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the smooth endoplasmic reticulum, no evidence for plasma membrane esterase was 
btained. Unlike monocytes, the esterase activity was partially resistant to 40 mM 
sodium fluoride. The different properties of the human intestinal macrophages alpha-
naphthyl esterase to that of the blood monocytes may have important significance in the 
light of recent evidence that alpha-naphthyl esterases are involved in the spontaneous 
cytotoxicity of monocytes toward tumour cells (see discussion on chapter 6). 
Arylsulphatase C, an endoplasmic reticulum marker was detected in much denser 
fractions than that reported in monocytes. 
Plasminogen activator of the urokinase-type was detected on the Golgi and plasma 
membranes fractions in human intestinal macrophages. The plasminogen activator was 
found to exist predominantly as proenzyme requiring plasmin for proteolytic activation. 
The findings that the plasminogen activator is membrane associated and exists mainly as 
proenzyme in the plasma and Golgi membrane fractions might have important biological 
implications and suggest a site of enzyme activity which may optimise their 
effectiveness. 
The analysis of human intestinal macrophages plasma and intracellular 
membranes at high purity represents a valuable approach to elucidating the changes that 
characterize the differentiation of intestinal macrophages. 
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CHAPTER 1 
GENERAL INTRODUCTION 
PLASMINOGEN ACTIVATORS 
SINCE the first observations by the pioneers of tissue culture on the 
liquefaction of clotted blood and the enhancement of fibrinolysis in vivo and in vitro in 
the 18th and 19th centuries, supporting experimental evidence accumulated until it 
promptoed Fisher (1925) to postulate about the proteolysis caused by cultured Rous 
sarcomas:-
1 
"We could imagine that the destructive process of the sarcoma cells in vivo 
would be as follows. First the stroma binding the cells together is liquefied. 
Consequently, reorganisation cannot take place as long as the lytic agent, the sarcoma 
cells, is present and because the fixed cells are deprived of their fibrin stroma". 
Twenty years after his postulate, Fisher reported in 1946 that proteolysis 
caused by cultured cancer cells appeared to be due to their activation of an inactive 
proenzyme present in serum. It was left to Goldhaber et al., (1947), to suggest that the 
cancer cells released an enzyme which activated profibrinolysin to fibrinolysin. This 
activating enzyme is now widely known as plasminogen activator (PA), a serine protease 
which catalyses the conversion of inactive plasminogen to the active plasmin. 
1 . 1 . BIOCHEMISTRY OF PLASMINOGEN ACTIVATORS 
In order to appreciate the possible implications of the role of plasminogen 
activators in tumorigenesis, cancer invasion and metastasis, an understanding of the 
biochemistry of these enzymes is necessary. 
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Christensen (1945) and Kaplan (1944; 1946) both demonstrated the 
existence of an inactive proenzyme, designated profibrinolysin or plasminogen which 
could be activated to the active protease fibrinolysin or plasmin. This was soon to be 
followed by demonstration of the presence of substances able to activate plasminogen in 
tissues and tissue extracts (Astrup & Permin 1947; Astrup & Stage 1952; Albreschten 
1957 a,b), urine and blood (Williams 1951; Astrup & Sterndorff 1952; Sobel et al., 
1952; Lewis & Ferguson 1951; Mullertz 1953; Sherry et al., 1959). 
Human plasminogen, an inactive proenzyme, is present in abundant amounts 
, in the extracellular fluid. Its native form is a single chain glycoprotein with a Mr of 
about 92,000 (Collen, 1980), containing about 2°/o carbohydrate and with NH2-
I: 
1111 1, 
terminal glutamic acid (termed Glu-plasminogen). Glu-plasminogen is readily 
converted proteolytically to modified forms with NH2-terminal lysine, valine or 
methionine (Wallen & Wiman, 1970; 1972) and the former therefore being termed 
Lys-plasminogen with Mr about 8000 lower than its native form. These conversions 
occur by hydrolysis of the Arg 67 - Met 68, Lys 76 - Lys 77 or Lys 77 - Val 78 
peptide bonds. The complete plasminogen molecule consists of either 790 or 791 amino 
acids (Sottrup - Jensen et al., 1978a; Wiman 1978), containing 24 disulfide bridges as 
well as five homologous triple loop structures or "Kringles" (Sottrup-Jensen et al., 
1
1 1978b). 
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In vitro activation of Glu-plasminogen to plasmin by plasminogen activator 
in a purified system occurs about 20 times more slowly than activation of Lys-
plasminogen (Claeys & Vermylen 1974; Wallen & Wiman 1975; Thorsen et al., 1974; 
Lijnen & Collen 1982) but in either case, Lys-plasmin is formed. However, activation 
I of the fibrinolytic system in vivo occurs by direct cleavage of the Arg 560 - Val 561 11 
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bond in Glu-plasminogen yielding Glu-plasmin and not via formation of the Lys-
plasminogen intermediates (Holvoet et al., 1985). 
3 
Plasminogen is purified mainly by affinity chromatography with lysine-
Sepharose introduced by Deutsch and Mertz (1970). Plasminogen is an inactive 
proenzyme, while its active form PLASMIN has a wide range of general proteolytic 
ability with a trypsin-like specificity. Plasm in consists of two polypeptide chains held 
together by disulfide bonds. The light chain, with a Mr of about 25,000, contains the 
active site and has considerable amino acid sequence homology with other serine 
I 
1, proteases such as trypsin, chymotrypsin and pancreatic elastase. 
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Two different pathways of plasminogen activation by vertebrate plasminogen 
activators are shown schematically in Figure 1.1. 
Plasminogen 
Activator 
Glu-Plasminogen -- ---------~~ Glu-plasmin 
Plasm in 
Plasminogen 
Activator 
~~ ,~ 
Lys-Plasminogen ---------~~ Lys-Plas 
Figure 1 .1. Activation of Plasminogen by Plasminogen Activator. 
1 . 2 TYPES OF ACTIVATORS OF PLASMINOGEN 
Plasmin 
4 
The existence of 2 different types of plasminogen activators, designated 
urokinase-type (u-PA) and tissue-type (t-PA) has been well documented. They differ 
in Mr, immunological reactivity, genotype and are the products of different genes (Aoki 
& Kaulla 1971; Unkeless et al., 1974b; Christman et al., 1975; Dano & Reich 1978; 
Granelli-Piperno & Reich 1978; Astedt 1979; Vetterlein et al., 1979; Dano et al., 
1980b; Rijken et al., 1980; Roblin & Young 1980; Wilson et al., 1980; Rijken & 
Collen 1981; Gunzler et al., 1982b; Kaltoft et al., 1982; Schaller et al., 1982; Steffens 
et al., 1982; Edlund et al., 1983; Nielsen et al., 1983; Pennica et al., 1983). The 
human urokinase-type plasminogen activator has a Mr of about 50,000 - 52,000 
(HPA52) while the tissue type has a Mr of about 70,000 (HPA66). Tissue-type 
plasminogen activator has also been termed extrinsic plasminogen activator (Collen 
1980) although this term is less commonly used. In this and the following chapters, the 
term u-PA will be used to designate urokinase-type PA of any species while HPA66, 
HPA52 and HPA36 will be used to designate human PA of 66,000, 52,000 and 36,000 
daltons respectively; HPA36 being the active breakdown product of HPA52. 
Because of mounting evidence (including our own studies) implicating mainly 
urokinase-type plasmingen activator involvement in the role of malignant 
transformation, this literature review will be mainly concerned with u-PA and a brief 
mention oft-PA whenever it is deemed necessary. 
1 . 2. 1 Urokinase-Type Plasminogen Activator:- Purification and 
Occurence of u-PA 
The presence of a high concentration of u-PA in human urine has for many 
years enabled its use as a commercial source for purification of the enzyme, although 
5 
some has been produced by cultures of kidney cells. More recently, recombinant 
urokinase has been produced after cloning of the human gene (Heyneker et al., 1983b; 
Verde et al., 1984), and this method will inevitably become the major commercial 
procedure. 
Purification of u-PA to homogeneity from urine by a tedious sequence of 
precipitations and conventional chromatography steps was first described by Lesuk .et 
.aL., (1965) and White et al., (1966). Since then, purification involving the use of 
affinity chromatography, especially the use of immobilized monoclonal antibodies, has 
been widely used (Kaltoft et al., 1982; Nielsen et al., 1982; Herion & Bollen 1983; 
Vetterlein & Calton 1983;). The purification of u-PA from human blood plasma and 
serum, human seminal plasma and from hyperplastic and malignant prostate tissue has 
also been reported. Because only very low concentration of u-PA are found in 
conditioned culture fluid of several types of cell lines, even after treatment of the cells 
with agents enhancing u-PA production e.g. phorbol esters (Goldfarb & Quigley 1980), 
urine is still the main source for the purification of u-PA. However, recently, 
Grondahl-Hansen et al., (1985), using a one-step procedure with monoclonal antibody 
immobilized on Sepharose, have been able to purify human u-PA to apparent 
homogeneity from the conditioned culture fluid of a human glioblastoma cell line. 
As mentioned above, u-PA, or a plasminogen activator with similar 
properties, has been found in a number of biological fluids or tissue extracts (Kucinski 
et al., 1968; Granelli-Piperno & Reich 1978; Dano et al., 1980b; Astedt et al., 1977; 
Rijken et al., 1981; Astedt 1978; Shakespeare & Wolf 1979; Tissot et al., 1982; 
Wijngaards et al., 1982; Wun et al., 1982a; Casslen et al., 1981; Oshiba & Ariga 
1983; Markus et al., 1980, 1983; Camiolo et al., 1984; Nakamura et al., 1984; 
Corasanti et al., 1980). 
Figure 1 .2 Schematic arrangement for the covalent structure of (a) 
prourokinase (b) urokinase and (c) low molecular weight urokinase. Plasmin cleavage 
sites are indicated by arrows. The A-chain of the human u-PA contains a "kringle" 
structure in its C-terminal part. The N-terminal of the B-chain contains the sequence 
lle-lle-Gly-Gly. The A-chain has Arg or Phe as its C-terminal amino acid. Nucleotide 
sequence around the cleavage site is Arg-Phe-Lys-lle-Gly-Gly. Activation of 
prourokinase is effected by cleavage of a single bond resulting in the formation of A and B 
chains linked by a disulphide bridge. The Ser, His and Asp residues forming the active 
site in u-PA are marked with stars. Plasmin also cleaves urokinase A-chain at residues 
Lys 135-Lys 136 removing the kringle and N-terminal region, leaving only 21-23 
residues linked to the B chain (Adapted from Heyneker et al., 1983a). 
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6 
lmmunocytochemical studies of normal mouse tissues has localized u-PA to a 
variety of cell types, in particular connective tissue cells with a fibroblast-like 
morphology (Larsson et al., 1984) and occurring in high frequency in the lamina 
propria of the gastrointestinal tract. No other cell types, other than fibroblast-like 
cells displayed u-PA in the gastrointestinal tract. These fibroblast-like cells may be 
macrophages, although a definitive answer would require double staining, possibility 
using a range of known macrophage surface markers. 
U-PA is also produced in a number of primary cultures established from 
tissues and cells of neoplastic origin. 
1.2.2. Molecular and Enzymatic Properties of U-PA 
Urokinase-type plasminogen activator has a Mr of about 50,000 - 52,000 
and occurs in a single polypeptide chain form as an inactive proenzyme, while the two-
chain form is an active enzyme (Nielsen et al., Skriver et al., 1982; Wun et al., 1982b; 
Eaton 1984). The heavy B chain (Mr about 30,000) and the light A chain (Mr about 
20,000) have apparent Mr's varying somewhat between species (Christman & Acs 
1974; Unkeless et al., 1974b; Holmberg et al., 1976; Aasted 1981; Nielsen et al., 
1982; Skriver et al., 1982; Wun et al., 1982b; Sumi & Robbins 1983; Sudol & Reich 
1984) and are held together by one disulfide bridge (Sumi & Robbins 1983; see also 
Fig. 1.2). 
Amino acid sequence studies of human 2 chains u-PA have shown that the B 
chain contains a heavy chain identical to that of the two chain 50,000 Mr forms and a 
light chain that is identical to the C-terminal 21 residues of the light chain of the native 
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50,000 Mr form. These findings demonstrate that the B chain (Mr about 30,000) is 
formed from the native 50,000 Mr form by proteolytic conversion (Gunzler et al., 
1982a). This conversion probably occurs during storage and purification due to 
proteases present in urine and other biological fluids (Soberano et al., 1976b). The 
studies described in Chapter 3 showed that this conversion is mediated through plasmin 
1
1 and not by autocatalysis. 
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U-PA is a glycoprotein (Mclellan et al., 1980; Steffens et al., 1982) with 
an isoelectric point of between 8.4 and 9.7. However, the exact value varies according to 
the species from which the enzyme originated and between different reports on u-PA 
from the same species (Christman & Acs 1974; Soberano et al., 1976a; Dano et al., 
1980a; Nobuhara et al. 1981; Miwa et al., 1982). 
Although plasminogen is the only well-documented protein substrate for u-
PA, studies by Quigley et al., (1980) and Keski-Oja & Vaheri (1982) have suggested 
the existence of cellular non-plasminogen substrates. U-PA also hydrolyzes a variety of 
arginine and enzyme esters and amides and other low Mr substrates (Kjeldgaard & Ploug 
1957; Ascenzi et al., 1982; Lottenberg et al., 1981; Friberger 1982). 
The high degree of substrate specificity shown by u-PA is probably related to 
the presence of a specific binding pocket (Schoellman et al., 1982). U-PA also exhibits 
to some degree species specificity with respect to the plasminogen substrate (Reich, 
1975). 
Inhibition of the esterolytic activity (Landmann & Markwardt 1970) and 
plasminogen activating activity (Christman & Acs 1974; Unkeless et al., 1974b; Dano & 
Reich 1975; Astedt & Holmberg 1976) of u-PA from various species by the active-site 
1a 
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reagent for serine proteases diisopropylfluorophosphate (DFP) has indicated that these 
activators are serine proteases (Walsh and Wilcox, 1970). 
8 
The heavy B chain (Mr about 30,000 - 253 residues) carries the active site 
residues as demonstrated by affinity labelling with peptidyl choloromethyl ketone 
inhibitors (Ong et al. 1976) or [3H] DFP (Christman & Acs 1974; Unkeless et al., 
1974b; Nielsen et al., 1982; Skriver et al., 1982; Wun et al., 1982b), followed by 
SDS-polyacrylamide gel electrophoresis under reducing conditions. 
The strong homology of the active site residues of u-PA with trypsin and the 
plasmin B-chain, is also illustrated by the fact that several compounds inhibiting u-PA 
11 also inhibit plasmin (Dano & Reich 1975, 1979). But as expected from the highly 
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different substrate specificities of u-PA and plasmin, some inhibitors have different 
affinities for the two (Walton 1967; Dano & Reich 1975, 1979; Summaria et al., 
1975). 
1. 2. 3 Proenzyme of u-PA 
There are several examples of serine proteases which are released from cells 
as inactive proenzymes which are converted to the corresponding active enzymes by 
limited proteolysis (for a review, see Neurath & Walsh 1976). 
Studies by Bernik et al. (1974) and Nolan et al., (1977) suggested the 
presence of a latent form of u-PA in the conditioned medium from cultured cells, but 
definitive identification of an inactive u-PA proenzyme could not be achieved due to the 
lack of sufficient purified protein. Since then several authors (Sumi et al., 1982, 
Husain et al., 1983, Skriver et al., 1982, Eaton et al., 1984, Wun et al., 1982b, 
9 
Nielsen et al., 1982) have demonstrated a one-chain inactive polypeptide form of u-PA 
both in human and murine systems. This question is answered definitively by 
experiments using monclonal antibodies inhibitory to plasmin as reported in Chapter 3. 
ihe identification of proenzyme form of HPA52 has led to several proposed regulatory 
implications (see Chapters 4-6). 
From the work described in Chapter 3 and that of others (Nielsen et al., 
1982, Wun et al., 1982b) it is likely that the presumed mechanism of activation of 
pro-uPA is as depicted in Figure 1.3 below. 
One chain 
Inactive 
Pro-uPA 
PLASMIN 
PLASMINOGEN 
Two chains 
Active PA 
PLASMIN 
PROTEINS PEPTIDES 
Fig. 1.3 Cascade reaction leading to u-PA initiated extracellular proteolysis. Pro-
urokinase (Pro-u-PA) is an inactive single chain precursor molecule which 
is converted to an active two-chain polypeptide (Mr 20,000 and 30,000) 
linked by a single disulfide bridge, by cleavage of the Lys 158-lle 159 
peptide bond. The active u-PA activates plasminogen to plasmin by cleavage 
of the Arg 560 - Val 561 peptide bond. 
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The above reports, together with the findings that plasminogen activators of 
the urokinase type are present predominantly in proenzyme form in the colonic 
adenomatous polyps and carcinomas, in inflammatory bowel disease (see Chapters 4 and 
5), extracellularly in a murine tumour (Skriver et al. 1984) and in various murine 
tissues and urine (Kielberg et al., 1985), strongly suggest that u-PA is generally 
released to the extracellular milieu in its inactive form, requiring plasmin mediated 
extracellular proteolysis to its active form. This inactive form is the predominant form 
of u-PA in intracellular stores and comprises a sizeable fraction of the u-PA in 
extracellular fluids in the intact organism. 
1 . 2. 4 Amino Acid Sequence. cDNA and Genes of u-PA 
The first reported complete amino acid sequence of human two-chain u-PA 
from protein sequence analyses was by Gunzler et al., (1982b) and Steffens et al., 
(1982), and agreed generally with the structure deduced from the base sequence of u-
PA cDNA reported recently (Heyneker et al., 1983b; Verde et al., 1984). Nagamine .ru 
.a.1., (1984) also recently provided the first evidence of close homologies between 
porcine and human u-PA as determined from the nucleotide sequence of the porcine u-PA 
gene. 
The sequencing of the cDNA for both u-PA and its comparison with that of t-
PA has definitively established that each activator is the product of different genes as 
previously speculated. 
The single structural gene for urokinase has been reported to be present on 
human chromosome 6, and nucleotide sequencing of genomic libraries indicated the 
presence of up to 13 introns (Kucherlapati et al., 1978, Holmes et al., 1985). 
However, Tripputi et al., (1985) using somatic cell hybrids and detection of genomic u-
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PA DNA on Southern blots and in situ with a cDNA probe localized the human u-PA gene 
to the long arm of chromosome 10. 
1 . 2. 5 Tissue Type Plasminogen Activator 
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Tissue-type plasminogen activator (t-PA) can now be isolated quite readily 
from various sources and indeed milligram quantities had been purified from the tissue 
culture media of Bowes human malignant melanoma (Rijken & Collen 1981, Wallen fil 
.aL., 1 983) . 
Although the Mr to be expected from the nucleotide sequence of the 
corresponding cDNA of t-PA is 59,000, the Mr as determined by SDS-polyacrylamide 
gel electrophoresis is 66,000 daltons. Glycosylation of the t-PA molecule could account 
for this apparent discrepancy (Mclellan et al., 1980). 
Like u-PA, t-PA exists in two forms, a one-polypeptide chafn form and a 
two-polypeptide chain form, the two chains in the latter, which is an active enzyme, 
being held together by disulfide bridges (Binder et al., 1979; Rljken & CoUen 1981; 
Rijken et al., 1979; Aasted 1980; Wallen et al., 1981, 1982, 1983; Ranby et al., 
1982· Nielsen et al., 1983). Howeverl unlike u-PA, conflicting results as to the 
enzyme actrvity of the one-chain polypeptide form have been reported (Rljken & Collen 
1981; Wallen et al., 1981, 1982, 1983; Ranby 1982; Rijken et al., 1982; Andreasen 
et al., 1984· Ichinose et al., 1984). Using monoclonal antibodies against human t-PA 
and a linear regression analysis using 3[H]-DFP labell[ng, Andreasen et al., (1984) 
reported that the single chain t-PA represents a fibrlnolytically inactive proenzyme; 
while Rljken et al.. (1982) using a 1251-labelled plasminogen conversion assay 
reported that the 2 forms of human t-PA had nearly identical acttvlties. Others reported 
that the one chain from of both human and porcine t-PA appeared to have considerable 
activity (Rijken & Collen, 1981; Wallen et al., 1981, 1982, 1983; Randy 1982). 
Irrespective of whether it is accepted that the one chain form of t-PA is 
partly or completely inactive proenzyme, it could be converted by plasmin to a two chain 
form by the cleavage of an Arg 274-lle bond, resulting in A and B chains linked by a 
single disulphide bond (Edlund et al., 1983; Pennica et al., 1983; Jornvall et al., 1983; 
Wallen et al., 1983). The B chain with a Mr of between 28,000 - 33,000 comprises 
the c-terminal region of the enzyme and is homologous with trypsin, plasmin and u-PA 
B chains and carries the active centre residues. An increase in amidolytic activity as a 
result of this bond cleavage (which does not affect the PA activity) has been used as an 
assay to measure the proportions of one and two-chains forms. The A-chain of human t-
PA has a Mr of 37,000 - 40,000 with carbohydrate content differences or slight 
proteolytic modification at the N-terminal residues probably accounting for the small 
degree of heterogeneity (Wallen et al., 1983; Pennica et al., 1983). Whereas the A-
chain of human u-PA contains one triple-loop kringle structure, the A-chain of human 
t-PA contains two triple loop kringle structures similar to those found in urokinase, 
plasminogen and prothrombin. Closer to the N-terminus, t-PA, like u-PA, contains a 
cysteine-rich domain like that found in blood coagulation factors IX and X and epidermal 
growth factor (Banyai et al., 1983; Pennica et al., 1983). However, controversy still 
persists as to whether the fibrin and lysine binding properties of t-PA reside in one or 
both kingles since these same properties are also exhibited by plasminogen, where they 
reside in the kringle structures (Banyai et al., 1983). Unlike u-PA, the one and two 
chain forms of t-PA and plasminogen both bind to Sepharose-bound L-lysine, arginine 
and to fibrin. Comparison of the four lysine-binding kringles (Reich 1978b) of 
plasminogen with the t-PA kringles, however failed to explain the lack of lysine or 
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fibrin-binding properties exhibited by urokinase kringle (Gunzler et al., 1982a; 
Pennica et al., 1983, Collen 1980). 
As for u-PA, t-PA is a highly specific enzyme and plasminogen is the only 
known protein substrate. However, t-PA differs from u-PA in having very strong 
affinity for fibrin (Thorsen et al., 1972; Rijken & Collen 1981 ), an affinity that has 
even been used for purification of the enzyme by Wallen et al., (1982). Fibrin has also 
been found to strongly stimulate plasminogen activation by t-PA (Camiolo et al., 1971; 
Wallen 1978; Hoylaerts et al., 1982; Ranby 1982; Radcliffe 1983; Suenson et al., 
1984). 
Using Bowes melanoma cells, sufficient specific mRNA was synthesized to 
allow complete gene cloning of t-PA (Opdenakker et al., 1982; Edlund et al., 1983; Ny 
et al., 1984; Pennica et al., 1983). Like u-PA, t-PA is found in a number of places and 
is particularly prominent in the endothelial regions of tissues (Cano et al., 1985). 
1 . 3 ASSAYS AND DETECTION METHODS FOR PLASMINOGEN ACTIVATORS 
Because of the findings that u-PA is generally released from producer cells as 
an inactive proenzyme form requiring conversion to its active counterpart by limited 
proteolysis involving plasmin (see Chapter 3), methodological approaches in the 
enzymatic detection and quantitation of u-PA will therefore be highly influenced by the 
trace amounts of plasmin that are usually present in the plasminogen preparation used 
in the assay. Detection and quantitation of plasminogen activator activity could be 
further complicated by the presence of inhibitors of PA and plasmin since even minute 
amounts of plasmin inhibitors could strongly inhibit the assay when u-PA is present in 
its proenzyme form. 
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The increased interest during the past decade in PA involvement in 
fibrinolysis, tumorigenesis, inflammatory responses and the expression of hormonal 
regulation has led to a rising interest in the development of sensitive and precise 
methods for the specific assay of PA. The optimal assay method for PA obviously depends 
on the purpose for which it is to be used. 
ENZYMATIC ASSAYS AND DETECTION METHODS 
1 . 3. 1 Plasminogen as Substrate 
In these assay methods where plasminogen is used as the substrate, the PA 
activity is measured either directly by the amount of plasmin molecules formed or 
indirectly through the enzymatic activity of the plasmin generated, taking advantage of 
the amplification involved. 
By the use of specific inhibitory antibodies against t-PA or u-PA, it is 
possible to distinguish between t-PA and u-PA since antibodies against the respective PA 
inhibit activation of plasminogen catalysed by that activator but not that catalysed by the 
other type (Kucinski et al.. 1968; Aoki 1974; Astedt & Holmberg, 1976; Vetterlein .e.1 
.al..., 1979; Mackie et al., 1981; Corasanti et al. 1980; Rijken & Collen, 1981; Dano fil 
.al..., 1980b; Kaltoft et al., 1982; Berger & Tuttle, 1983; Nielsen et al. 1983; Ossowski 
& Reich 1983). 
Table 1.1 shows the common types of assays used to detect and quantitate PA 
activity using plasminogen as substrate:-
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TABLE 1.1 
ASSAY TYPE & GENERAL COMMENTS 
(a) FIBRIN PLATE 
Quantitation possible. 
Most widely used assay. 
Very sensitive to t-PA. 
(b) 
Detects about 1 o-16 mol u-PA. 
Could be time consuming. 
Quantitation depended on area 
of a lysis zone in comparison 
with standard PA preparation. 
1251-LABELLED FIBRIN PLATE 
Detects about 1 o-7 mol u-PA. 
Based on radioactivity release 
being proportional to 
concentration of PA. 
Can be used to demonstrate 
inactive pro-u-PA. 
Can be modified to detect both 
pro-u-PA and u-PA in biological 
samples containing inhibitors 
of pro-u-PA. 
Can detect t-PA as well. 
Assay quantitate total PA (i.e. 
REFERENCES 
Jespersen & Astrup 1983 
Astrup & Mullertz 1952 
Lassen 1953 
Albrechtsen 1957b 
Brakman 1967 
Haverkate & Brakman 1975 
Larsson et al., 1984 
Unkeless et al., 1973, 1974b 
Barrett et al., 1977 
Skriver et al., 1982 
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active plus proenzyme). 
Not suited for kinetic studies. 
Several modifications based 
on these method e.g. [3H] 
labelled fibrin. 
( c) CASEINOLYTIC 
Casein used as a substrate 
for plasmin. 
Based on absorbance. 
Sensitivity 2 x 1 o-15 
mol for u-PA. 
Quantitation possible but 
measures only total PA. 
Has low sensitivity for t-PA. 
( d) SYNTHETIC PLASMIN SUBSTRATES 
Also based on absorbance. 
Quantitation possible. 
Measured total PA but can be 
modified using monoclonal 
antibodies to quantitate either 
pro-u-PA and active u-PA. (See 
Chapter 4 & 5). 
Specific for u-PA in the absence 
of added fibrin. 
Synthetic substrate commonly 
Markus et al., 1980 
Kline 1971 
Kline & Reddy 1977 
Lottenberg et al., 1981 
Friberger 1982 
Coleman & Green 1981 
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used are S-2251 (H-D-Val-Leu 
-Lys-p-nitroanilide) and 
thiobenzyl benzyloxycarbonyl 
-L-lysinate (ZLS). 
Can be used for kinetic and 
binding studies. 
Sensitivity 2 x 1 o-1 7 mol u-PA. 
( e) DIRECT PLASMINOGEN CONVERSION 
PA activity estimated directly by 
( f ) 
the number of native plasminogen 
molecules converted to 
2-polypeptide chains plasmin 
under reducing conditions. 
Measured total PA only and can 
used to demonstrate pro-t-PA. 
Measurement of u-PA also 
possible. 
Useful for kinetic sudies and 
studies of inhibition of plasminogen 
activation. 
FIBRIN OVERLAY 
Distinction amount different types 
of PA can be obtained by use of 
specific inhibitory antibodies. 
Quantitation not possible. 
Reddy & Markus 1972 
Dano & Reich 1975, 1979 
Eaton & Baker 1983 
Lucas et al., 1983 
Suenson et al., 1984 
Mussoni et al., 1984 
Rijken et al., 1980 
Ljunger et al., 1983 
Soreq & Miskin 1981 
Smith et al., 1985 
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Assay influenced by inhibitors of 
PA and plasmin. 
Can be used to detect proenzyme. 
Several modifications based on 
this assay. Inferior to immuno-
assay when used to detect PA 
in tissues. 
( g) ZYMOGRAPHIC DETECTION OF PA 
Can differentiate types of PA. 
Assay based on diffusion of PA 
into gel containing plasminogen 
and fibrin leading to lysis zone. 
However, assay semi-quantitative. 
Effect of protease inhibitors 
minimal. 
1 o-14 mol of u-PA & t-PA 
detectable. 
Modification of this method with 
125-labelled casein which detects 
about 1 o-18 mol u-PA. 
Can be modified to detect and 
demonstrate PA inhibitors and 
proenzyme forms of PA 
particularly u-PA. 
Granelli-Piperno 
& Reich 1978 
Dano et al., 1 980b 
Miskin & Soreq 1981 b 
Erickson et al., 1984 
1 . 3. 2 Enzymatic Assays with Synthetic PA Substrates 
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Although plasminogen is the only well-documented protein substrate for 
plasminogen activators, the ability of the enzymes to hydrolyze amide and ester 
derivatives of arginine and lysine in certain small peptides is being used in some assay 
methods. 
The conversion of N-acetyl-L-lysine methyl ester into N-acetyl-L-lysine 
and methanol is one example. The methanol generated is then oxidized to formaldehyde 
which when mixed with chromotropic acid can be quantitated spectrophotometrically 
(White & Barlow 1970). In amidolytic assays, tripeptides derivatized with p-
nitroaniline at the C-terminal amino acid (Friedman et al., 1977; Claeson et al., 1978; 
Lottenberg et al., 1981; Friberger 1982) are commonly used. Hydrolysis of the p-
nitroanilide bond with the release of p-nitroaniline can then be measured spectro-
photometrically. 
In particular, such assays have been used to measure the conversion of 
proactivators to the active enzymes (Wun et al., 1982b; Andreasen et al., 1984) but 
their use in biological samples is limited by their non-specificity in cleavage by 
proteases other than PA. 
11 3. 3 Active-Site Titration 
Active-s i e titration assays can only be used for the analysis of purified 
preparations of PA since the act ive-s i e titrants are not specific for PA. Rijken and 
Collen (1981) used incorporation of [3 ] DFP , an irreversible inhibitor of the active 
si e of serine pro eases as a measure of the numbers of active sites in the preparation of 
PA. Si ilarly, alien e al., (1 981 ) and Andreasen et al. , (1984) used [3 HJ DFP 
19 
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incorporation, together with SDS-polyacrylamide gel electrophoresis to quantitate the 
relative amouns of one and two chain forms of human t-PA in preparations containing 
both; while Some no et al., (1982) used a combination of the inhibitor and 
chromatography to quantitate the relative amouns of low and high Mr u-PA. 
1 . 3. 4 Immunological Assay and Detection Methods 
The specificity of antigen-antibody interaction, coupled with the recent 
production of monoclonal antibodies (McAbs) against both types of human PA and 
plasmin (Kaltoft et al., 1982; Herion et al., 1981, 1983; Nielsen et al., 1983, 
Vetterlein & Calton, 1983; Salerno et al., 1984, and Chapter 3) is likely to enhance the 
specificity of assays employing antibodies, provided that inhibitors of PA do not compete 
with antibodies for binding. 
Immunological assays may be superior since enzymatic assays for PA can 
often be prejudiced by the presence of interfering inhibitors of proteolytic enzymes in 
many biological fluids. These may interfere through direct inhibition of PA or through 
inhibition of the plasmin formed indirectly in coupled plasminogen activation-plasmin 
assays. Furthermore inhibitors of plasmin complicate the measurement of proenzymes 
due to interference with the plamin catalysed activation of proenzymes. 
Commonly used immunological assays using both polyclonal and 
monoclonal antisera against PA are:-
( i ) Radioimmunoassays (Astedt et al., 1975, 1981; Vetterlein et al., 1980, 
Urden & Blomback 1984, Wun et al., 1982a; Huber et al., 1984) with a 
detection limit of 1 o-15 mol for both human u-PA and t-PA. 
( i i ) 
( i i i ) 
( i V) 
(v) 
1 . 4 
Two-Site lmmunoradiometric Assay (Holmberg et al., 1982; Rijken et al., 
1983) Sensitivity 2 x 1 o-15 mol for both u-PA and t-PA. 
Enzyme-Linked lmmunosorbent Assay (ELISA) - Sensitivity 2 x 1 o-15 mol 
for both human u-PA and t-PA. (Bergsdorg et al., 1983, Rijken et al., 
1984, Matsuo et al., 1983, Herion et al. 1983.) 
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lmmunocytochemical Detection Although not really an "assay", nevertheless, 
the recent availability of strong and specific antibodies (polyclonal and 
monclonal) have seen their use in the localisation of murine u-PA and human 
u-PA and t-PA in tissues by immunofluorescence and peroxidase-
antiperoxidase staining (Dano et al., 1982, Markus et al., 1983, Kristensen 
et al., 1984, 1985; Larsson et al., 1984; Nakamura et al., 1984; Salerno .et. 
aL., 1984.) 
lmmunoblotting This technique employed both SOS-PAGE and the transfer of 
separated proteins onto nitrocellulose paper followed by detection with 
antibodies for specific proteins. This has been used as a screening method for 
McAb production against t-PA (Nielsen et al., 1983), as a chain specificity 
assay of McAb against u-PA (Salerno et al., 1984) and for distinguishing 
between one-chain pro-u-PA and two chain active u-PA in impure biological 
products (Kielberg et al., 1985; Skriver et al., 1984). 
OCCURRENCE AND FUNCTION OF u-PA IN NON-NEOPLASTIC 
CONDITIONS 
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The correlation of in vivo and in vitro studies of inflammatory processes and 
normal invasive or remodelling events, whether regulated temporally or/and 
hormonally have suggested the functional significance and occurrence of PA in non-
neoplastic conditions and likely involvement of u-PA in extra-cellular proteolysis. In 
all the biological processes, the event and the associated extracellular proteolysis and 
tissue matrix degradation have been found to be coordinately controlled. 
1.4.1 TISSUE INVASION AND DEGRADATION IN THE NORMAL ORGANISM 
1.4.1.1 Ovulation 
The ovum contained in the ovary follicle is enmeshed in several layers of 
cells and basement membrane. The presence of plasminogen in the follicular fluid and 
the temporal correlation between PA production and disruption in ovulation provided 
unambiguous evidence that PA is involved in the tissue degradation of the follicle wall 
(Strickland 1978; Beers et al., 1975; Strickland & Beers 1976; Beers 1975). 
Granulosa cells when stimulated with gonadotrophins in vivo and in vitro at 
physiological levels that induce ovulation have been shown to produce significant levels 
of PA. It is postulated that the plasmin generated by the activation of plasminogen 
present in the follicular fluid by gonadotropin-induced PA disrupts the follicular wall 
and digests, with the help of other proteases like collagenase, the extracellular matrix 
leading to the eventual release of the ovum (Rohrlich & Rifkin 1979). 
1.4.1 .2 Implantation 
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Implantation of the fertilized egg into the uterine wall involves the invasion 
of the trophoblast through the uterine epithelium and the underlying basement 
membrane and into the stromal tissue of the endometrium (Kirby 1965, Schlafke & 
' 
Enders 1975). The work of Strickland et al., (1976) with the in vitro pre-
implantation of mouse blastocysts was later confirmed by Sherman (1980) and Kubo .et. 
.al.:., (1981 ), who also found that the trophoblast cells expressed cell-associated PA as 
well as secreting the enzyme. 
This activity was detectable only from days 6-10, during which time the 
mouse trophoblast was invasive in vivo, and was unrelated to the emergence of the 
embryo from the zona pellucida. 
1 . 4. 1 . 3 Mammary Gland Involution 
Involution of the mammary glands after cessation of lactation is a classic 
example of tissue remodelling. The findings of Ossowski et al., (1979) indicated a 
positive temporal correlation between the onset of involution and the concomitant 
increase in the level of PA secretion by glandular epithelium. Various hormones such as 
hydrocortisone, aldosterone, prolactin and/or oxytocin which prevented the 
postlactational involution in vivo, also prevented PA increase in the mammary gland 
tissue. Similarly, factors such as epidermal growth factor or insulin which promoted 
glandular degeneration in organ cultures of mammary gland fragments induced high PA 
secretion especially after prolactin potentiation. U-PA but not t-PA was detected in the 
extracts of involuting mammary gland. Recent immunocytochemical studies by Larsson 
et al., (1984) confirmed previous indirect evidence that the u-PA was produced by the 
epithelial cells and also the lack of immune reactive staining in the non-involuting 
glands. 
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1.4.1 .4 Inflammation 
The possible role(s) of PA and plasmin in inflammation has been of 
longstanding interest. Macrophages are derived from precursors in the bone marrow 
and circulate in the blood as monocytes and ultimately take up specific locations in 
tissues as macrophages. In sites of inflammation, these macrophages can become 
'activated' to kill micro-organisms and tumour cells. However, in chronic 
inflammatory lesions, these cytocidal activities can be directed against the host to 
mediate tissue injury. Both in vivo and in vitro studies of the response of macrophages 
and polymorphonuclear leukocytes to inflammatory and inhibitory stimuli suggest the 
some effects of these agents influence the ability of the phagocytic cells to regulate the 
synthesis and secretion of plasminogen activators, collagenase and elastase. The findings 
reported by Unkeless et al., (1974a) and Gordon et al., (1974) that unstimulated 
murine macrophages produced PA of barely detectable levels, while cultured 
thioglycollate-stimulated murine macrophages produced and secreted PA of 1 O times the 
resting amount, had renewed interest in the role of proteolytic proteases in 
inflammation. Since then, a number of agents have been found to either stimulate or 
inhibit the production/secretion of PA in macrophages. Exposure of macrophages to 
lymphokines (Klimetzek & Sorg 1977; Nogueira et al., 1977; Vassalli & Reich 1977; 
Gordon 1978; Gordon & Cohn 1978; Gordon et al., 1978; Greinder et al., 1979), 
asbestos (Hamilton et al., 1976), interferon (Hovi et al., 1981), colony-stimulating 
factor derived from cultured murine cells (Lin & Gordon 1979), Concanavalin A, and 
phorbol myristate acetate, a potent irritant, inflammatory agent and tumour promoter 
(Vassalli et al., 1977; Neumann & Sorg 1983) have all shown ability to stimulate the 
production of PA several-fold. PA synthesis and secretion by stimulated macrophages 
were inhibited and suppressed by physiological levels of anti-inflammatory steroids, 
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glucocorticoids, pharmacological agents like colchicine, vincristine and compounds 
affecting cyclic nucleotide metabolism and cholera toxins (Hamilton et al., 1976; 
Vassalli et al., 1976, 1977, 1980; Neumann & Sorg 1983). Similar findings have 
been reported for polymorphonuclear leukocytes, with respect to PA stimulation by 
concanavalin A and phorbol myristate acetate and inhibition by glucocorticoids 
(Granelli-Piperno et al., 1977). 
All these observations pointed to the physiological importance of PA and led to 
the proposal that PA plays a role in inflammation and, in particular, in the migration of 
inflammatory cells to the sites of inflammation as well as subsequent plasmin formation 
by macrophages in the recruitment phase of the inflammatory response in vivo (Reich 
1978a). 
Since inflammation often involves degradation of the injured tissue, the u-PA 
released by macrophages and polymorphonuclear leukocytes may contribute to this 
process, with the help of other proteases, by extracellular degradation of proteins in a 
manner parallel to that proposed for cancer cells (see Section 1.5.2 in this Chapter}. 
Hence, it should be noted that the secretion of elastase, collagenase and other serine 
proteases by stimulated macrophages and not by unstimulated macrophages have also 
been well documented (Unkeless· et al., 1974a; Werb & Gordon 1975a,b; Werb et al., 
1980; Wahl et al., 1974, 1975). 
1 . 4. 2 PLASMINOGEN ACTIVATOR lN NON-NEOPLASTIC PATHOLOGJCAL 
CONDITIONS 
The possible implications of proteolytic enzymes, in particular PA and 
plasmin have been briefly outline in Section 1.4.1 of this Chapter. Other non-neoplastic 
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pathological conditions in which PA has been implicated include the following, some of 
which involve inflammation and/or tissue degradation:-
Allergic vasculitis (Toki et al., 1982), Xeroderma pigmentosum (Miskin & 
Ben lshai, 1981 ), rheumatoid arthritis (Berger, 1977; Meats et al., 1980 Hamilton & 
Slywka 1981; Hamilton et al., 1982), pemphigus (Hashimoto et al., 1982; 1984), 
experimental murine leprosy (lzaki et al., 1983), chronic inflammatory bowel disease 
(Doe & Dorsman, 1982; see Chapter 5), corneal ulceration (Berman et al., 1980), 
diabetes mellitus (Almer et al., 1975), demyelinating diseases (Cammer et al., 1978; 
1981 ), chronic sinusitis (Kosugi et al., 1982) and protein-losing gastroenteropathy 
(Kondo et al., 1976). 
1 . 5 OCCURRENCE AND FUNCTION OF PLASMINOGEN ACTIVATOR IN 
NEOPLASIA 
Neoplastic cells display a diverse range of biochemical and physiological 
changes in comparison to their normal counterparts. Invasiveness and metastatic 
potentials are two features commonly associated with neoplastic cells. Destruction of the 
surrounding tissues and extracellular matrix that are normally 'cemented' together, by 
lytic enzymes, has been proposed to account for the invasiveness of tumour cells. One 
such lytic enzyme proposed is PA. It should, however, be stressed that in the following 
discussion, the attribution of definitive roles to PA and plasmin in various aspects of 
neoplasia/malignancy in NO WAY implies that these functions are specific to cancer-
related events. Hydrolysis of the elaborated extracellular matrix that normally would 
serve as a barrier to the movement of tumour cells, would presumably allow migration 
of these cells and hence invasion. This view has been supported with ultrastructural 
evidence obtained from in vivo studies (Franks 1973) and immunocytochemical studies 
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(Markus et al., 1984; Camiolo et al., 1984; Skriver et al., 1984) where intensive 
staining and hence localisation of PA (u-PA) have been observed in areas with invasive 
growth and degradation of normal tussue. By contrast, no demonstrable staining has been 
observed in the larger parts of tumours where no invasion and degradation of normal 
tissue were occuring. 
Early demonstration of PA in intact tumours using fibrin overlay methods 
most probably measured t-PA since fibrin stimulates t-PA activity and furthermore, no 
distinction was made between u-PA and t-PA. Recently, the production of high affinity 
specific antibodies has enabled the visualisation of the occurrence and distribution of u-
PA in human colon adenocarcinomas and melanoma cells (Markus et al., 1983; 1984) 
and in transplantable murine Lewis lung tumours (Skriver et al., 1984). In the study 
by Skriver et al., (1984), these authors also noted that some immunoreactivity was 
localized in the cytoplasm of the tumour cells, often with a perinuclear localization. 
However, most of the immunoreactivity appeared to be localised extracellularly or near 
to the cell membrane. 
To date, the occurrence of u-PA in benign tumours and of t-PA in malignant 
and benign tumours in immunocytochemical studies has yet to be demonstrated. 
Extractable u-PA enzymatic activity has also been reported in human lung, 
colon and breast cancer (Corasanti et al., 1980; Markus et al., 1980; Evers et al., 
1982), aspirates from patients with endometrial carcinomas (Niklasson et al., 1981 }, 
virus-induced mammary tumours and chemically induced rat mammary tumours 
(Mira-y-Lopez et al., 1983). PA of non-determined type has also been demonstrated 
for other types of tumours other than those mentioned above. 
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So far we have mentioned the occurrence of PA in intact tumours and tumour 
extract. PA has also been reported to occur in explants and cell cultures of neoplastic 
origin. PA of the urokinase type has been found in cultured cells from an ovarian 
carcinoma (Astedt & Holmberg 1976), in conditioned medium of tissue cultures derived 
from endometrial carcinomas (Astedt et al., 1978; Svanberg & Astedt 1979), mouse and 
rat mammary tumours (Mira-y-Lopez et al., 1983) and a number of cells lines of 
neoplastic origin (Hisazumi et al., 1977; Wu et al., 1977; Dano et al., 1980a, 1982; 
Naito et al., 1980, 1982; Rossman & Troll, 1980; Wilson et al., 1980, 1982, 1983; 
Harvey et al., 1982; Shyamala & Dickerman 1982; Strickland et al., 1983; Azzarone .e.t 
.al.:., 1983; see also Chapter 3). 
1 . 5. 1 Plasminogen Activator and Transformed Cells 
Cellular transformation that occurs spontaneously in culture (Sanford et al., 
1954), or by infection with oncogenic viruses (Termin & Rubin, 1958) or 
carcinogenic chemicals (Chen & Heidelberger, 1969) is believed to be closely related to 
malignancy in vitro. 
PA has been shown to be elevated in primary turmour cells, cells 
transformed by both oncogenic viruses and chemical carcinogens and in a number of 
turmorigenic cell lines (Unkeless et al., 1974a, 1973; Ossowski et al., 1973; Rifkin .e.t 
al, 1974; Goldberg 1974; Pollack et al., 1975). While there are a number of 
exceptions (Gallimore et al., 1977; Jones et al., 1975; Rifkin & Pollack 1977; 
Rosenthal et al., 1978; Wolf & Goldberg 1976), there is strong evidence in many cases 
that PA production often accompanies or precedes malignant transformation. This 
relationship has been most thoroughly studied in Rous sarcoma viruses (RSV), where 
malignant transformation of chicken embryo fibroblasts by the virus and with 
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temperature sensitive mutants, has clearly indicated a direct correlation between 
transformation and enhanced PA production (Unkeless et al., 1973; Rifkin et al., 1975; 
Quigley 1979). Studies with inhibitors of macromolecular synthesis indicated that 
induction of PA synthesis by RSV required both RNA and protein synthesis (Unkeless .e.t 
.aL., 1973; Rifkin et al., 1975; Rifkin 1980). 
Elevation of PA to very significant levels has also been reported in primary 
cultures of cells transformed by oncogenic DNA viruses e.g. simian virus (Ossowski .fil 
.a.L., 1973; Christman & Acs 1974; Quigley et al., 1974), primary cultures of tumours 
cells, cells transformed by carcinogens, chemically induced tumours and in numerous 
cell lines, including tumour cell lines of human origin (Christman et al., 1977; Reich 
1978a; Quigley 1979; Goldfard, 1982). By contrast, cytocidal DNA or RNA viruses and 
non-transforming avian leukosis viruses have no PA enhancing effect (Quigley 1979). 
1 . 5. 2 Functions of Plasminogen Activators in Neoplasia 
The invasion and/or destruction of surrounding normal tissues that often 
characterised invasive growth of malignant tumours has always implicated the 
production and release of proteases responsible for the local and rapid hydrolysis of the 
extracellular matrix proteins (see Section 1.4). The availability of a large and widely 
distributed substrate for PA in the form of the zymogen plasminogen, and the finding that 
virus-induced transformation of embryonic chick fibroblasts was closely correlated 
with the synthesis of u-PA made it highly conceivable that the plasmin generated by the 
proteolytic cleavage of plasminogen by tumour-associated PA, together with other 
proteolytic enzymes, could play a major role in the breakdown of the complex 
extracellular matrices. As tissue degradation could play an important role in the 
invasive property of tumours and hence may be part of the process of metastasis (Fidler 
et al., 1978), the above speculation could be extended to postulate a role for PA in 
invasion and metastasis. 
Indeed, there is a large body of experimental evidence to support the above 
speculation/hypothesis:-
(a) Purified laminin, a major g lycoprotein of the basement membrane has been 
shown to be susceptible to degradation by plasm in (Liotta et al., 1981 a). 
Bogenmann & Jones (1983) have demonstrated a role for plasminogen in the 
degradation by tumour cells of an extracellular matrix elaborated in vitro. 
( b) The ability of tumour promoters to induce plasminogen activators in cell culture 
(Wigler & Weinstein 1976). 
( c) The findings that solid tumours contained significantly higher levels of PA 
(urokinase type) than their normal autologous tissues (See Section 1.5, see also 
Chapter 4; Corasanti et al., 1980; Evers et al., 1982; Markus et al., 1980). 
( d) Transformation of cells by oncogenic DNA and RNA viruses induces a rapid 
synthesis of PA (See Section 1.5.1 ). Furthermore, only viruses that are 
oncogenic for the particular cell line induce PA; others, while they infect the 
ceHs, do not affect PA synthesis. 
( e) The demonstration of the hormonal regulation of u-PA production resulting in 
controlled tissue degradation as part of physiological tissue injury events such as 
ovulation or breast involution (See Sect[on 1.4). 
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( f) The immunocytochemical findings of intensive staining (u-PA) in areas of 
invasive growth and tissue degradation in experimental murine tumours. By 
contrast, no detectable staining was observed in large parts of the tumour where 
no invasion and degradation of the normal tissues was taking place (Skriver .e..t 
.aL., 1984). 
( g) The demonstration that the use of specific antibodies against human u-PA 
activity inhibited lung metastasis but not local growth of a human u-PA 
producing tumour, HEp-3, transplanted onto the chorioallantoic membrane of 
chicken embryo. 
All the experimental evidence listed above supports a "prima facie" case that 
PA, in particular u-PA, through the generation of plasmin can play a causal and 
permissive role in cell invasiveness and metastasis. However, it should be pointed out 
that the role of other proteases, especially in combination with plasmin in tissue 
degradation and hence metastasis by invasive malignant cells should also be considered. 
Plasmin, produced by the proteolytic activation of plasminogen by 
plasminogen activator, has been shown to have the ability to degrade laminin and 
fibronectin, both of which are glycoproteins components associated with the basement 
membrane (Goldfard 1982; Liotta et al., 1981 a,b). In addition, plasmin also activates 
latent forms of type IV and type V collagenase that play a role in degradation of the 
collagenous components of the basement membrane (Goldfard 1982; Liotta et al., 
1981 a). Although native col lag ens (types 1-111) in the extracellular matrix are 
resistant to plasmin degradation, PA could still play a role in the degradation of these 
types of collagen via a plasmin-mediated activation of latent collagenases (Stricklin .e..t 
al, 1977; Werb et al., 1977; Dano et al., 1978; Paranjpe et al., 1980; O'Grady et al., 
1981 ). The collagenase can then initiate the catalytic cleavage of the collagen molecules, 
leaving them vulnerable to degradation by plasmin and other proteases (Burleigh 
1 9 77). 
1 . 6 ROLE OF THE PLASMIN SYSTEM IN THE INVASIVE AND 
METASTATIC PROPERTIES OF NEOPLASIA 
The association of PA and malignant cells and the role of PA, particularly u-
PA in a variety of invasive and degradative biological processes has already been 
mentioned (See Section 1.5). 
The PA activity associated with malignant transformation is dependent upon 
the interaction of PA, produced by transformed cells and the serum zymogen, 
plasminogen. Plasmin, the product of the proteolytic activation of plasminogen can be 
put to use for attacking purposes by cancer cells. 
The implication of the plasmin/PA system in the invasive and metastatic 
properties of neoplasia although circumstantial, is supported by many observations. It 
is generally considered that dissolution of the fibrin in tumours by the plasmin-PA 
system enhances the local spreading of tumours. Identifiable fibrin (or fibrinogen) has 
been found in transplanted rat tumours (Day et al., 1959) and human tumours 
(Hiramoto et al., 1960; Bale et al., 1960) where it was localised within the tumour 
mostly in macroscopically identifiable clots as well as in necrotic areas (Markus 
1983). Dvorak et al., (1979) suggested that a fibrin 'wrapping' found around tumour 
cell suspensions injected into syngeneic guinea pigs provided the angiogenesis factors 
required for blood vessel growth into the tumour. Yet, the contradictory reports of 
several studies (Wood 1958; Agostino & Cliffton 1963; Boeryd 1965; Brown 1973; 
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Grossi et al., 1960; Kodama & Tanaka 1978a) have also indicated that the formation of 
microthrombus was necessary for the successful lodgement of tumours and hence 
metastatic foci. Kodama & Tanaka (1978b) also reported that degradation of fibrin 
layers surrounding tumours by plasmin was necessary for migration of tumour cells 
into neighbouring areas and it has also been shown in numerous studies that primary 
tumours contained a significantly higher levels of u-PA activity compared to adjacent 
normal tissues. Such release of PA by cancer cells in circulation would tend to degrade 
the peripheral microthrombus deemed necessary for their arrest and subsequent 
invasion through the capillary wall. Following this hypothesis, then, metastatic cells 
should possess lower fibrinolytic potential than primary tumour cells and such findings 
had been reported (Markus et al., 1983). 
Other functions thought to be mediated through the PA-plasmin system in the 
invasive and metastatic properties of neoplasia ·included the activation of latent 
collagenase, which could then degrade the collagen in the basement membrane (O'Grady .et 
.al.:., 1981; Paranjpe et al., 1980), degradation of laminin, a glycoprotein component in 
basement membrane and the release of cells from the primary tumour as the result of 
breakdown of cohesion between tumour cells. 
1. 7 SUBCELLULAR DISTRIBUTION OF PA 
Defining the subcellular localisation of PA is of fundamental importance to 
the understanding of the many roles of the enzymes, in particular in the control of its 
production and release which may be regulated by some extracellular signal. In general, 
PA exists in a cell-associated form in addition to a soluble, extracellular form that is 
released into cell culture medium and body fluids. 
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The localisation of PA in the cells has been done mainly using cell 
homogenates separated by differential and gradient centrifugation and assay of the 
separated fractions with a series of marker enzymes specific for different subcellular 
organelles and PA activity. Early studies showed that the PA was localized in two 
particulate subcellular fractions:-
the lysosomal-rich fraction and the microsome fraction (Ali & Lack 1965). 
However, more recent studies since than have all indicated that PA is associated with 
membrane-rich fractions, rather than the cytosol fraction. Such fractions included 
plasma membrane-like and, in few cases, lysosomes and Golgi elements of the cell 
(Unkeless et al., 1974b; Quigley 1976; Loskutoff & Edgington 1977; Dvorak et al., 
1978; Solomon et al., 1980; Fulton & Hart, 1981; O'Donnel-Tormey & Quigley 1981; 
Zisapel et al., 1982; Laug et al., 1983a,b; Lemaire et al., 1983). 
lmmunocytochemical studies at electron microsopic level by Paul et al., 
(1979) also indicated a plasma membrane association for PA in a wide variety of cells, 
but a recent immunofluorescence study (Dano et al., 1982) suggested that PA might be 
found in intracellular granules contaminating membrane fractions (Golgi ??) . In tissue 
sections of murine Lewis long tumour, Skriver et al., (1984) demonstrated unevenly 
distributed intracellular staining in the cytoplasm with the highest staining at the 
perinuclear region. 
Thus, in summary, most studies suggest that PA is closely associated with 
plasma membrane or Golgi membrane-like cellular elements. All recent studies concur 
that PA is not found in the lysosomal fractions. However, it should be noted that at the 
present moment, it has not been possible to determine if PA is an intergral membrane 
protein, or a secretory protein inside intramembrane granules on their way from their 
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intracellular site of synthesis to the extracellular space. Alternatively, the cell 
fractionation results could be simply artifactual due to the receptor-mediated or 
hydrophobic interaction of UK with plasma membrane subsequent to cell rupture, and 
not representative of the intracellular distribution in living cells. 
The presence of membrane receptors fro the human u-PA or its amino acid 
fragment (residues 1-135) has been recently demonstrated on human blood monocytes, 
cells of the monocyte line U937 and on normal and RSV mouse fibroblasts (Vassalli .el 
.aL., 1985; Stoppelle et al., 1985; Rosso et al., 1985). 
1.8 SIGNIFICANCE AND AIMS 
The PA system provides the means for correlation between the 2 essential 
features of malignancy namely (i) invasion (ii) metastasis. 
The question therefore arises as to whether the transformation of human 
benign into neoplastic cells involves the expression of the PA enzymes since virus-
transformed murine cells of neoplastic origin had been shown to produce and secrete u-
PA. 
The colonic polyp-cancer sequence and the inherited disorder multiple 
polyposis coli thus offer suitable models which can be exploited to address this question. 
Because of the implication of PA in the mediation of tissue injury, it was also 
important to determine whether this enzyme also initiates inflammatory tissue injury. 
Inflammatory cells are recuited to sites of inflammation by a variety of factors including 
lymphokines and the complement fragment C5a (Hugli & Muller-Eberhard, 1978). A 
crucial step in the migration of these inflammatory cells is believed to be mediated by 
plasmin, which is the end product of a cascade of reactions mediated by PA. The plasmin 
beside mediating the migration of inflammatory cells, also lyses fibrin to release 
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biologically-active fibrin degradation products and also activates complement and kinin 
generation and initiation of the coagualtion cascade which all contribute to tissue injury. 
The influx of the inflammatory cells also assist in tissue injury by releasing degradative 
and hydrolytic enzymes as well as generating free oxygen radicals. 
The inflammatory disorders of colon offered the opportunity to answer this question. 
Several studies (see chapter 1) using in ~ cell cultures have shown the 
release of the proenzyme form of PA into the medium and implicated plasmin as a 
mediator involved in the proteolytic activation of the proenzyme into its active form. 
The specific aims of this project were therefore to :-
( 1 ) Develop a quantitative assay for the pro and active forms of HPA52 by raising 
monoclonal antibodies inhibitory to human plasmin and hence study the form of HPA52 
in the extracellular environment. 
( 2) To explore the colonic polyp-cancer sequence and the inherited condition of 
polyposis coli to determine whether the expression of HPA52 is a correlate of malignant 
transformation. 
( 3) To determine the role of HPA52 in the mucosa! tissue injury that 
characterises lesion of inflammatory bowel disease . 
( 4) To study intestinal macrophages as a possible source of HPA52 and its 
subcellular localization. 
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CHAPTER 2 
MATERIALS AND METHODS 
Unless otherwise stated, all chemicals and reagents were obtained from the 
best commercially grade available either from Sigma Chemical Co; Aldrich or BDH 
Chemicals. All solvents and acids/akaline were obtained from BDH Chemicals. All tissue 
culture media were from either Flow or Gibco Laboratories. All other 
methylumbelliferyl substrates were from Koch-Light or Sigma Chemical Co. 
Na 1251, [2-3H]AMP, [7-14c]-tyramine, [carbony1-14c]NAD and UDP[6-
3 H] galactose were from Amersham. Protein A, CN-Br activated Sepharose 48, 
Sephadex G25, Lysine-Sepharose, Percell and Ficoll-hypaque were all from Pharmacia. 
A Perkin-Almer 500 Spectrophotometer was used to measure fluorescence. 
2.1 ENZYMATIC ASSAYS 
2. 1 . 1 5'-Nucleotidase 
5'-Nucleotidase was assayed by the method of Avruch and Wallach (1971) as 
implemented by Edelson and Cohn (1976). 1 OOul of gradient fraction was added to 
500ul of 54 mM Tris-HCI pH 9.0/12 mM MgCl2 containing 0.15 umoles 5' adenosine 
monophosphate and 1 o5 dpm adenosine-[2-3H]-5' monophosphate (ammonium salt). 
After incubation for 2 hr at 370 C, the reaction was stopped by the addition of 0.2 ml of 
0.25 M zinc sulphate and mixed. Then 0.2 ml of 0.25 M barium hydroxide was added, 
vortexed and spun at 600 g for 1 O min. An aliquot (400 ul) of the supernatant was 
removed and counted in 5 ml of toluene scintillation fluid. Control samples contained 
gradient fractions with 0.2 ml of 0.25 M zinc sulphate added at zero time. 
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2. 1 . 2 Mn2+.stimulated Leucine 2-Naphthylamidase 
This enzyme was assayed by addition of 10-100 ul gradient fraction to 100 
ul buffer (0.1 M Hepes pH 7 .0, 0.1 °/o Triton X-100) with a final concentration of 1 mM 
MnCl2 and 0.2 mM L-leucine 2-naphthylamide (Sigma Chemical Co.). After incubation 
at 370 C for 1 hr, the reaction was terminated by the addition of 2 ml 50 mM 
NaOH/glycine pH 10.4 containing 5 mM EDTA. The fluorescent product, 2-
naphthylamide, was detected at 41 O nm using an excitation wavelength of 340 nm. 
2. 1 . 3 NAD+ Nucleosidase 
NAD+ nucleosidase was assayed by a modification of the method of Nakazawa m 
.aL., (1968). The reaction mixture contained 10 ul gradient fraction plus 1.6 nmol 
[carbony1-14c] NAD (5 nCi) in 15 ul 0.2 M Tris-HCI pH 8.0 containing 60 mM MgCl 2. 
After 60-90 min at 370 C, the tubes were placed on ice and 2 ul of the reaction mix was 
spotted onto Whatman no:1 paper (Bioscientific Supplies) together with 1 ul of a 100 
mM nicotinamide solution. Chromatrography was carried out with a solvent of 1 M 
ammonium acetate pH 5.0/ethanol (3:7). The nicotinamide spots were detected under 
ultraviolet light and cut out for liquid scintillation counting of [14c] nicotinamide. 
2.1.4 Alpha-naphthyl Acetate Esterase 
This enzyme was determined at pH 7.5 by the method of Laug et al., (1983b) 
where 50-100 ul gradient fraction were added to 400 ul buffer (67 mM sodium 
phsophate pH 7.5, 0.01 °/o Triton X-100) containing 1 mM alpha-naphthyl acetate 
(Sigma Chemical Co.) in final concentration. After incubation at 370 C for 45 min, the 
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reaction was stopped by the addition of 1 ml 0.1 M sodium acetate buffer pH 4.5/0.1 °/o 
Triton X-100 containing 1 O mM mercury chloride and 4 mg Fast Red ITR (Sigma 
Chemical Co.) in final concentration. After 15 min, the absorbance was read at 550 nm. 
2. 1. 5 Cata lase 
This was detected by a fluorimetric assay of Fayle et al,, (1985). Gradient 
fraction (50 ul) was added to 100 ul buffer (0.1 M Hepes pH 7.0, 0.1 °/o Triton X-100) 
containing 150 ul hydrogen peroxide, and incubated at room temperature for 20 min. 
Oxidation of the fluorescent compound scopoletin (7-hydroxy-6-methoxy-coumarin) 
(Sigma Chemical Co.) by hydrogen peroxide in the presence of horseradish peroxidase 
(Boehringer) was used to detect remaining hydrogen peroxide. 0.8 ml Hepes buffer 
containing 15 uM scopoletin and 80 ug horseradish peroxidase was added, and the 
fluorescence was measured at 460 nm using an excitation wavelength of 350 nm. 
2. 1 . 6 Monoamine Oxidase 
Deamination of [14c]tyramine was used to detect this enzyme (Summers & 
Hume, personal communication). 100 ul of gradient fraction was added to 100 ul of 1 O 
mM sodium phosphate pH 7.0, 0.15 M NaCl containing 0.2 mM tyramine (Sigma 
Chemical Co.) and 2 uCi[14c]tyramine. After incubation for 1-2 hr at 370 C, the 
reaction was stopped by the addition of 0.2 ml 2 M citric acid. 1 ml of benzene/ethyl 
acetate (1 :1) was added, and the tubes mixed vigorously on a vortex mixer (Scientific 
Instruments). An aliquot (600 ul) of the upper organic phase (containing p-hydroxyl 
[14c] phenylacetaldehyde) was counted in 5 ml of scintillation fluid (0.5°/o 2,5-
diphenyloxazole in xylene/Triton X-114, 2:1 ). Control samples contained gradient 
fraction, with citric acid added at zero time. 
2. 1. 7 Aryrsurtatase c 
The method of Canonico et al., (1978), using a buffer stock to give 0.15 M 
Hepes pH 7.5, 0.13 M Na2S04 and 0.13 M NaCl, with the addition of 0.1°/o Triton X-100 
was used to detect arylsulfatase C. 25 ul of 100 mM barium chloride and 125 ul of 
buffer stock was added to 100 ul gradient fraction and allowed to incubate for 1 O min. 
The sa2+ and so2- and c1- inhibited sulphatase A and B respectively. After incubation, 
1 O ul of 0.38 mM methyl-umbelliferyl sulphate in final concentration was added and 
incubation continued for a further 1 hr at 370 C. Reaction was terminated with 2 ml 50 
mM glycine/NaOH buffer pH 10.4 and the fluorescence was detected at 460 nm using an 
excitation wavelength of 363 nm. 
2. 1. 8 Gara ctosyrtransferase 
Galactosyltransferase was assayed according to Baxter and Durham (1979) 
but in a buffer of 0.1 M Hepes/NaOH pH 7.0 containing 0.03%, Triton X-100, 50 mM 
MnCl2, 20mM ~-mercaptoethanol (Sigma Chemical Co.) and with ovomucoid (Sigma 
Chemical Co; 1 O mg/ml buffer) rather than desialo, degalacto-fetuin as acceptor 
(Jasaitis et al., 1982). 50 ul of buffer containing ovomucoid was added to 35 ul of 
gradient fraction and incubated for 1 O min at 37° C, after which 5 ul of 200 uM UDP-
galactose (Sigma Chemical Co.) and 1.2uCi[3H]-UDP galactose was added and incubation 
continued for a further 60 min at 370 C. The reaction was stopped with 20 ul of 0.8 M 
EDTA and 45 ul of the reaction mixture was spotted onto a Whatman no:2 filter paper 
discs, dried and subsequently washed 3 times with 10°/o trichloroacetic acid at room 
temperature. The washed and dried paper counts were then used for liquid scintillation 
counting of [14c] galactose. 
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2. 1 . 9 Lactate Dehydrogenase 
Lactate dehydrogenase was assayed according to the method of Kornberg 
(1955), using 0.75 mM sodium pyruvate and 0.33 mM NADH (Boehringer). The 
enzymatic reaction was initiated by the addition of 100 ul sodium pyruvate to a mixture 
of gradient fraction (100 ul), NADH (100 ul) and 1.2 ml 0.1 M phosphate buffer pH 
7.4. Absorbance was measured at 340 nm every 30 seconds for 3 min. 
2 .1. 1 o Lysosomal Enzymes 
p-glucuronidase was assayed by the fluorimetric method of Mead et al., 
(1955) using 0.1 M acetate buffer pH 4.5 containing 0.1 °/o Triton X-100. 
The p-N-acetyl-D-galactosaminidase activity was measured according to 
Leaback and Walker (1961) using 4-methyl umbelliferyl-2-acetamido-2-deoxy-P-D 
galactopyranoside as substrate and 0.5 M citrate pH 4.5/0.1 °/o Triton X-100 buffer. 
The respective substrate solution (250 ul/30uM) was added to 100 ul gradient 
fractions and incubated for 1 hr at 370 C. The reaction was terminated by addition of 2 
ml cold 0.1 M glycine/NaOH pH 10.4 buffer. The fluorescence was measured at 460 nm 
using an excitation wavelenght of 363 nm. 
2.2. PROTEIN ESTIMATION 
Protein concentration was assayed by a modified Lowry method (Peterson 
1977). One ml of water was added to standard protein solution, control and samples (50 
ul) and mixed, followed by addtion of 100 ul 0.15°/o deoxycholate (BDH) and allowed to 
stand for 1 O min. Then 100 ul of 72°/o trichloroacetic acid was added, mixed and 
centrifuged for 20 min at 1000 g. The supernatant was carefully decanted and 400 ul of 
reagent A (comprising equal volume of 10°/o SDS, 0.8 N NaOH, water and CTC solution 
[0.2°/o sodium tartrate, 0.1 °/o copper sulphate, 10°/o sodium carbonate]). After 10 min, 
200 ul of 1 :5 dilution of Falin reagent (Ajax Chemicals) was added and the absorbance 
read at 750 nm after 30 min at room temperature. 
2.3 HYBRIDOMA (MONOCLONAL ANTIBODIES) PRODUCTION 
Hybridoma production was performed under sterile conditions in a laminar 
air flow cabinet throughout. 
2.3.1 Media 
All media were sterilised by filtration through Sterifil Aseptic System 
(Millipore). 
D ME M - This was prepared using a packet of Dulbeccos Modified Eagle 
Medium (Gibco) with addition of 74 ml of 5o/o NaHC03, 984 ml of distilled water and 
adjusting the media to pH 7.2 with 1.5 ml of 5N HCI. 
DMEM + 10°/o Heat inactivated FCS - One ml of 1 OOmM sodium 
pyruvate, 125 ul gent (Commonwealth Serum Lab.), 50 ul pen (Glaxo), 50 ul strep 
(Glaxo), 1 O ml heat-inactivated FCS and 1 ml of 200mM glutamine (Sigma Chemical 
Co.) were added per 100 ml of DMEM. 
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DMEM + 2 x Gent/Pen/Strep/Fungizone - This was made up in 
identical manner to that described for DMEM with addition of 250 ul gent, 50 ul pen, 50 
ul strep and 1 ml fungizone (Flow). 
DMEM-HAT + 10°/o Heat inactivated FCS - This was prepared as 
described for DMEM + 10°/o heat inactivated FCS with addition of 1 ml aminopterin 
(Lederle Lab. Division), 1 ml thymidine (Sigma Chemical Co.) and 1 ml hypoxanthine 
(Sigma Chemical Co.). 
Aminopterin (methotrexate) 1 o-4 M - Two ml of distilled water were 
added to a 50 mg commercial vial of methotrexate sodium injection and then 178 ul of 
this solution was added to 100 ml distilled water. This was then used as described above. 
Thymidine - A 1.5 mM thymidine was made up in PBS pH 7.0. 
Hypoxanthine - A 1 mM solution of hypoxanthine was made up in distilled 
water and pH to 11 with 1 O M NaOH. 
2.3.2 Preparation 
( 1 ) An immunized mouse (John Curtin School Animal House; see Chapter 3 
for immunization regimen) was boosted 3-4 days before fusion with 60 
ug of plasminogen in saline. 
( 2) Myeloma cells (X63 Ag8.653) that has been growing in mid-log phase 
at 3-5 x 1 o5 cells/ml and were at least 95°/o viable. 
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2.3.3 
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( 3) All media were warmed to 370 C on the day of fusion and polyethylene 
glycol (Koch-light 1540) were placed on 56 o C water bath to melt. A 
solution of 30 + 2°/o polyethylene glycol was prepared by adding 1 ml of 
warmed DMEM containing no FCS to 0.6 g of polyethylene glycol 
previously melted at 560 C. 
Thymocytes 
( 1 ) 4-6 thymus glands from 4-8 week old mice were required to give a 
final suspension of at least 106 thymocytes/ml DMEM-HAT. 
(2) Thymus glands were removed sterilely into a petri dish (Sterilin) of 
approximately 10 ml DMEM with 2 x gent/pen-strep/fungizone that 
had been previously warmed up to 370c. 
(3) In the sterile hood and using sterile technique, the thymus glands were 
rinsed through 4 more petri dishes of approximately 1 O ml DMEM/2 x 
gent/pen-strep/fungizone and finally minced with scissors before 
straining through wire mesh into a final dish of medium using the 
rounded end of a spatula. 
( 4) The cells were resuspended and transferred to 15 ml sterile centrifuge 
tube (Sterilin) and centrifuged for 8 min at 300 g in room 
temperature. 
2.3.4 
( 5) After centrifugation, the thymocytes were resuspended in 5-1 O ml HAT 
and finally added to 250 ml DMEM-HAT (37o C) in 500 ml bottle which 
was then stored at 370 C (5°/o CO2) until needed. 
Spleen Cells 
( 1 ) The spleen from the immunized mouse was removed sterilely and placed 
in a petri dish of 5 ml DMEM/2 x gent/pen-strep/fungizone. 
( 2) The spleen was then transferred to a dish of fresh medium. Any fatty 
connective tissues were removed from around the organ, taking care to 
avoid breaking the sac. 
( 3) The spleen was rinsed through 4-5 more dishes of the same medium. 
( 4) In a final dish of this medium, spleen cell suspension was prepared by 
cutting the spleen close to one end with sterile scissors and teasing the 
cells out of the sac with 2 x 19G needles (Terumo) bent to 
approximately 900. The spleen sac was discarded and the extruded cells 
resuspended and transferred to a 15 ml centrifuge tube. 
( 5) The cell suspension was allowed to settle for 5 min at room 
temperature, during which time large clumps settled to the bottom. The 
supernatant was removed and centrifuged at 300 g, 8 min at room 
temperature. The supernatant was discarded and the cell pellet 
resuspended in 1 O ml of fresh DMEM/gent/pen-strep. The total cell 
count was normally 0.5-2 x 108 cells. 
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2.3.5 Myeloma Cells 
The myeloma cell line X63 Ag8.653 was used in the fusion and had been 
maintained in mid-log phase by adjusting the cell count to 2 x 1 o5 cells/ml every 2 
days. 
On the day of fusion, the myeloma cells were resuspended and placed in 50 ml 
centrifuge tube (Corning). The number of cells per ml and viability were determined, 
after which the appropriate number of myeloma cells were taken (ratio of 5:1, 
spleen:myeloma) and spun down at 300 g for 8 min. The cell pellet was then 
immediately resuspended in 1 O ml OM EM/gent/pen-strep containing Il.Q. FCS. 
2.3.6 Spleen and Myeloma (Fusion) 
The spleen and myeloma cell suspension (viability greater than 95°/o) were 
spun together at 300 g for 8 min and the supernatant removed by aspiration. The cell 
pellet was resuspended in DMEM/gent/pen-strep and recentrifuged. This process was 
repeated twice, before aspiration of all liquid from the cell pellet after the last spun. 
The pellet was loosened by gentle tapping of tube and then placed at 370 C water bath to 
warm briefly. 
One ml of 35°/o polyethylene glycol was added over a 1 min period, pipetting 
in a few air bubbles during the last 1 O sec slowly to mix. This was then followed 
immediately by the addition of 1 ml DMEM containing 10°/o heat-inactivated FCS over 1 
min, again mixing evenly, using a few air bubbles to finish. At any stage, pipetting of 
the cell suspension up and down was avoided. Addition of 1 ml DMEM containing 10% 
heat-inactivated FCS was repeated , followed by a further 8 ml of the same medium over 
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the next two minutes. After the addition, the fusion mix was spun at 300 g for 8 min. 
The supernatant was carefully removed by aspiration and the cell pellet resuspended in 
5-1 O ml of DMEM-HAT medium containing thymocytes(see 2.3.3). This was then added 
to 250 ml DMEM-HAT containing thymocytes, mixed gently by swirling the bottle and 
immediately plated out in 96-well plates (12 plates, 4 drops/well from 1 O ml pipette, 
approximately 22 ml/plate, Flow Laboratories). 
2.3.7 Maintenance 
The plates were checked routinely for contamination. The fastest growing 
cells/hybridomas were visible at 5-6 days following fusion. On Day 7 after fusion, the 
plates were fed with HAT containing thymocytes prepared as in 2.3.3. Feeding was done 
by aspirating out approximately 100 ul of supernatant from each well and adding 2 
drops of HAT containing thymocytes. At 2 1/2 weeks after fusion, the hybridomas were 
assayed using ELISA as detailed in Section 2.8 of this Chapter. Sometimes, slow-growing 
clones (usually stable antibody producing hybridomas) were positive only after 5-6 
weeks. 
2.3.8 Subcloning by Limiting Dilution 
One ml of the primary hybridoma culture, harvested in mid-log phase, is 
adjusted to the concentration of 1 x 1 as cells/ml. Ten fold serial dilutions in HAT 
medium containing thymocytes were prepared to obtain 23 ml of each of the following 
cell concentrations: 1 x 1021ml and 1 x 1 O 1 /ml. Each of these cell suspensions was 
distributed at 100 ul/well in a 96 well tray. In 1-2 weeks, cloned colonies were 
detectable; according to the Poisson distribution, clones found in trays with less than 
37°/o of clone-containing wells per tray are likely to arise from a single cell. Among the 
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subclones positive for antibody production, the ones showing better characteristics of 
growth and rate of antibody secretion were chosen for further subcloning and large scale 
expansion. 
2.3.9 Freezing and Growth of Hybridomas as Ascites Tumours 
Hybridomas were frozen in liquid nitrogen (according to standard cell 
freezing procedures) in 1 ml aliquots at a density of 1 x 1 O 7 cells/ml, in 95°10 heated-
inactivated FCS and 5°10 dimethylsulfoxide (Sigma Chemical Co.). 
Mice (Balb/C strain) were injected intraperitoneally with 0.5 ml pristane 
(2,6, 1 O, 14-tetramethylpentadecane, [Sigma Chemical Co.]) and then rested for 10-14 
days. Hybridomas cells (0.2 ml, containing 1 x 106 to 1 x 1 o7 cells in saline) were 
injected intraperitoneally. Ascites fluid was tapped several times after the tumour 
became palpable. 
2.4 COUPLING OF MONOCLONAL ANTIBODIES TO CN-BR ACTIVATED 
SEPHAROSE 48 
The required amount of freeze-dried cyanogen bromide activated Sepharose 
48 powdered (1 g approximately 3.5 ml, and 1 ml bound 5-10 mg protein) was swollen 
for 15 min in 1 mM HC1. The swollen gel was then washed on a sintered glass filter 
{porosity G3) with 1 mM HC1 (200 ml/g dry gel) in several aliquots, followed by 
washing with coupling buffer (0.25 M NaHC03 pH 8.5/0.5 M NaCl). This was then 
immediately transferred to a solution of the purified monoclonal antibody which had been 
previously dialysed against coupling buffer. A gel ratio of 1 :2 gave suitable coupling 
ratio. The protein solution with gel suspension was mixed by rotation at 40 C overnight. 
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After mixing, the coupling buffer was removed and replaced with 0.2 M glycine buffer 
pH 8.0 and mixing continued overnight. Following mixing, the gel suspension was 
transferred to a column and washed with coupling buffer followed by acetate buffer (0.1 
M pH 4.0 with 0.5 M NaCl). This step was repeated for a further 2 times and then 
finally washed with 0.1 M Tris-HCI pH 8.1 containing 0.1 °/o Triton X-100. Anti-pig 1 
monoclonal antibody ( 600 ug) had been coupled in this manner and has been used for 
immunoaffinity purification of plasminogen as described in Section 2.4 of this Chapter. 
2.5 GLUCOSE-OXIDASE COUPLING TO PROTEIN A AND TO F(ab)'2 
The method was based on Ternynck and Avrameas (1976). Initiation of the 
benzoquinone activation of glucose-oxidase (Boehringer Grade 1) involved dissolving 20 
mg of glucose-oxidase in phosphate buffered saline pH 7.4 and dialysing against 
phosphate buffered saline pH 7.4 overnight, after which the dialysed glucose-oxidase 
was placed in a small tube with 300 ul 1 M phosphate buffer pH 6.0 and 500 ul of p-
benzoquinone (Ajax Chemicals) solution (30 mg/ml in ethanol, spun at 8000 g for 25 
min, then supernatant used) and shaken at 37° C for 1 hr wrapped in foil. After 
shaking, it was centrifuged at 8000 g for 20 min and the supernatant (containing 
benzoquinone-activated glucose oxidase) was placed over Sephadex G25 column in 60 ml 
syringe (Terumo) containing 35 ml of gel. The protein (brown band) was eluted after 
the void volume, while the benzoquinone was retarded. 
The benzoquinone-activated glucose oxidase eluate was then mixed with 2 mg 
F(ab)'2 [Cappel Lab.] (previously dialysed overnight against phosphate buffered saline 
pH 7.4) or 2 mg Protein A (Cappel Lab.) and 200 ul of 1 M NaHC03 pH 8.8 and reacted 
for 48 hr at 40 C with shaking. After 48 hr, 1 ml of 1 M lysine in phosphage buffered 
saline pH 7.4 was added to react with remaining unreacted benzoquinone groups and 
shaking continued for 4 hr at 4° C. Finally, the solution was dialysed against several 
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changes of phosphate suffered saline pH 7.4 overnight and concentrated to 1-2 ml by 
drying the dialysis bag in an air stream at room temperature. The final volume was 
recorded and an equal volume of glycerol (Ajax Chemicals) was added and then stored in 
several aliquots at -200 C, where it remained unfrozen. 
2.6 FIBRIN-PLATE OVERLAY GEL 
The fibrin-overlay gel was prepared on a acid-washed glass plate (20 x 20 
cm) which was equilibrated at 37° C for about 15 min prior to pouring of the agarose 
gel mixture. The agarose gel mixture was made up in the following order:- 135 ul of 
thrombin (0.675 NIH units, Sigma Chemical Co.) was added to 1 ml of plasminogen 
(400 ug), after which it was mixed with 5 ml of agarose (125 mg in phosphate buffered 
saline; Sea-Plaque) previously melted at 650 C in a water bath and then equilibrated at 
40° C. Finally, a 5 ml aliquot of fibrinogen (30 mg dissolved in 2 M glycine/0.1°/o 
Triton X-100 buffer pH 8.3; Sigma Chemical Co.) was added to the agarose mixture and 
mixed thoroughly before the final mixture was poured onto the centre of the plate and 
quickly spread evenly between layers of tape 14 cm apart by using a pipette as a roller. 
The gel (0.3-0.4 mm thick) was covered to prevent drying and allow 30 min at 370 C 
for the clotting reaction to take place and a further 30 min at 4° C for the agarose to 
harden. 
After electropheresis of the SDS-polyacrylamide gel as described in Section 
2.13, the gel slabs were washed in 0.1 °/o Triton X-100 and developed by contact lysis of 
fibrin in an agarose gel. The development time for the fibrin lysis was usually 5 hr at 
37° C. Commercial enzymes and the position of stained standard proteins (Pharmacia 
HMW Kit) in the acrylamide gel were used to estimate the molecular weight of enzyme 
lysis bands. 
2.7 PLASMINOGEN PURIFICATION 
Plasminogen was purified on 2 cycles of lysine Sepharose affinity 
chromatography based on Deutsh and Mertz (1970). 
One litre of plasma containing protease inhibitors (3mM EDTA, 10000 KIU 
Trasylol [Bayer], 0.3mM p-nitrophenylguanidinobenzoate [NPGB, Sigma Chemical Co.]) 
was applied to 25 x 3 cm column of lysine-Sepharose which had been previously washed 
with 0.1 M K2HP04 pH 7.8/3 mM EDTA buffer and then equilibrated with 0.34 M 
K2HP04 pH 7.8/0.3 M EDTN0.3 mM NPGB containing 10000 KIU of Trasylol. The 
column was run at 50 ml/hr. When the plasma had completely run through the column, 
it was then washed with 0.34 M K2HP04 pH 7.8/3 mM EDTN0.3 mM NPGB/10000 KIU 
Trasylol until the 00280 was less than 0.3. The column was then eluted with 0.1 M 
K2HP04 pH 7.8/3 mM EDTN30 uM NPGB/0.2 EACA buffer and fractions with 00280 
greater than 0.8 were collected and pooled. The eluate was dialysed against 0.1 M 
K2HP04 pH 7.8/3 mM EDTN30 uM NPGB overnight before reapplying to the column 
which had been previously regenerated with the same buffer used for dialysis and 
equilibrated with 0.34 M K2HP04 pH 7.8/3 mM EDTN30 uM NPGB buffer. The column 
was then eluted with the same elution buffer that had been used previously and fractions 
with 00280 greater than 0.5 were pooled together before dialysing against 50 mM 
glycine buffer pH 7.8 with several changes overnight. The dialysed plasminogen was 
then diluted with 50 mM glycine buffer pH 7.8 to give an absorbance 0.7 at 280 nm 
which is approximately equivalent to 400 ug/ml. It was then stored at -200 C until use. 
2.8 ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) 
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Enzyme-linked immunosorbent assay (ELISA) was used as a primary screen 
for antibodies binding to plasminogen. Affinity-purified human plasminogen (50ng) in 
50 ul 0.01 M sodium phosphate buffer pH 7.4 containing 0.15 M NaCl was incubated for 
3 hr in each well of a Titertek "activated" immunoassay plate (Flow Laboratories) at 
200 C, followed by blocking of non-specific binding sites with 0.2°/o gelatin (Ajax 
Chemicals) in 10 mM sodium phosphate buffer pH 7.4 containing 0.15 M NaC1, for 3 hr 
at 20° C. Hybridoma culture supernatants were then added and the plates incubated at 4 o 
C for 16 hr, followed by washing with phosphate buffered saline pH 7.4/0.05°/o Tween 
20 (Sigma Chemical Co). Each well was then incubated with 30 ul (12 ug) of F(ab') 2 -
sheep anti-mouse lgG (heavy & light chain; Cappel Lab.) covalently coupled to glucose 
oxidase. Alternatively, a three-step assay was employed, in which an incubation with 
30 ul rabbit anti-mouse lgG+M+A (Cappel) for 3 hr at 200 C was followed by a further 
incubation for 1 hr at 200 C with 30 ul (12 ug) Protein A (Pharmacia) covalently 
coupled to glucose oxidase. 
In both cases, the wells were washed before application of 100 ul of reaction 
mixture (0.4 mg/ml o-phenylene diamine [Sigma Chemicals Co.], 20 mg/ml glucose, 
and 7.5 ug/ml horseradish peroxidase [Boehringer Grade 1] in 0.1 M citrate - 0.2 M 
phosphate buffer pH 5) in the dark. Colour development was stopped by the addition of 
35 ul of SN H2S04. 
2.9 CHARACTERIZATION OF ANTIBODIES (OUCHTERLONY) 
The heavy and light chain types of the monoclonal antibodies were determined 
by Ouchterlony analysis on agarose gel of 50 times-concentrated antibody culture 
supernatant against commercial antisera specific for mouse lgM, lgA, lgG, subclasses of 
lgG and K and A light chains (Bionectics). Three ml of a 1 °/o purified agar (Oxoid) 
53 
solution with 1 °/o NaCl was layered onto a clean glass microscope slide. Approximately 
15 ul of the concentrated antibody culture supernatant was added to adjacent, small 2 
mm holes punched into the agar layer. The slide was incubated overnight in a humidified 
atmosphere at room temperature to allow formation of precipitin lines which were only 
observed when the immunoglobulin present in the concentrated culture supernant was of 
the correct specificity to allow complexing with the antiserum. 
2 .1 0 ISOLATION OF PURE lgG BY PROTEIN A-SEPHAROSE 
CHROMATOGRAPHY 
Staphyloccal protein A, covalently linked to Sepharose CL-48 (Protein A-
agarose), [Pharmacia] was washed and equilibrated with 0.1 M Tris-HCI pH 8.1 buffer. 
A column of bed volume 5 ml was prepared and used at 40 C. 
Ascites fluid or ammonium-sulphate concentrate of tissue culture 
supernatant was adjusted to pH 8.0 and applied to the column. The column was then 
washed with 0.1 M Tris-HCI buffer pH 8.1 until all unbound proteins were eluted. lgG 
was eluted with 0.1 M sodium acetate buffer pH 4.0 containing 0.15 M NaC1 at a flow 
rate of 12 ml/hr. Fractions of 1 ml were collected into tubes and neutralised with 600 
ul of 1 M Tris-HC1 pH 9.0. Mouse lgG of all four subclasses was prepared using this 
technique. The lgG fractions were then pooled and dialysed overnight against 50 mM 
glycine pH 7 .8 and used in all the experiments as described. 
2. 11 BINDING STUDIES 
Plasminogen was dissolved to a concentration of 15 ug/ml in 1 O mM sodium 
phosphate buffer, pH 8.0, containing 0.15 M NaCl and 100 ul (1.5 ug) of the dissolved 
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plasminogen was incubated for 4 hr at 200 C in each well of a Titertek "activated" 
immunoassay plate (Flow Laboratories). Non specific binding sites were blocked with 
250 ul of a 1 °/o BSA solution, in the same buffer, for 3 hr at 200 C. Various 
concentrations of the 1251-labelled antibody, dissolved in 200 ul of 1 O mM sodium 
phosphate buffer pH 8.0, containing 0.15 M NaCl were added to the coated wells and 
allowed to incubate at 370 C for 2 hr, followed by several washings with a 1 % (w/v) 
solution of BSA. After the final wash, the wells were individually placed in test tubes 
and counted in a Packard Auto 500 gamma counter. These counts were then subtracted 
from controls in which the same concentration of 1251-labelled antibody was incubated 
in the wells of a plate fully coated with bovine serum albumin. In the wells precoated 
with BSA, no more than 1 °/o of the counts were found in any of the sample wells. 
2 .1 2 COLORIMETRIC ASSA V (YELLOW ASSA V) 
Human plasmin was generated by incubating human urokinase (20 ul, 
containing 4 mPU; Sigma Chemical Co.), human plasminogen (20 ul containing 2 ug) and 
assay buffer (20 ul) for 45 min at 370 C. The assay buffer consisted of 50 mM glycine 
pH 7.8 containing 0.1°/o Triton X-100 and 0.1°/o gelatin. The reaction was stopped by 
the addition of 2.0 M KC1 (20 ul) so that continued activation of plasminogen to plasmin 
was inhibited by the high salt concentration. Either glycine buffer (for controls) or 
purified monoclonal antibodies (20 ul, 12 ug) that had been extensively dialysed against 
50 mM glycine buffer pH 7.8 were then added and incubated for 1 hr at 200 C. The 
residual plasmin activity was then measured by the thioesterase colorimetric method of 
Coleman and Green (1981 ). Plasmin assay reagent (1 ml) containing 0.2 M phosphate 
(pH 7.5), 0.2 M KC1, 220 uM 5,5'-dithiobis [2-nitrobenzoic acid], 200 uM 
thiobenzyl benzyloxycarbonyl-L-lysinate (Peninsula Laboratories) and 0.1 °/o Triton 
X100 was added and the mixture incubated for 1 hr at 370 C. The thioesterolytic 
54 
55 
reaction was stopped by the addition of Trasylol (20 ul containing 15 ug) and the 
absorbance was read at 412 nm. 
To test if preincubation of plasminogen with monoclonal antibodies had any 
effect on its activation by urokinase, dialysed monoclonal antibody (20 ul containing 12 
ug) or assay buffer (in controls) was incubated with plaminogen (20 ul containing 2 
ug) for 1 hr at 200 C. Urokinase was then added and the mixture incubated at 370 C for a 
further 45 min, after which 2.0 M KC1 (20 ul) was added and the assay continued as 
above. 
Modification of the colorimetric assay for use in assays for pro and total HPA 
52 was performed by incubating dialysed anti-pig 3 antibody (20 ul containing 12 ug 
lgG; for measuring active HPA52) or assay buffer (for total content of HPA52) with 
affinity purified (Deutsch & Mertz 1970) human plaminogen (20 ul, 2 ug) for 1.5 hrs 
at 20° C. Diluted samples (20 ul) of the tissue homogenates which had been prepared in 
the presence or absence of anti-pig 3 antibody were then added and the mixture 
incubated for a further 45 minutes at 37° C. The assay buffer consisted of 50 mM 
glycine pH 7.8 containing 0.1 °/o Triton X-100 and 0.1 °/o gelatin. The plasm in produced 
as a result of the activation of the plasminogen by the plasminogen activator was assayed 
as described above. The difference in the level of absorbance between the total HPA52 
and the active HPA52 is equal to the amount of HPA52 proenzyme present. 
Results for plasminogen activator activity were expressed after correction 
for the presence of plasminogen-independent proteases in the tissue extracts by 
subtraction of absorbances obtained in an indentical system to which neither 
plasminogen nor antibody was added. 
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2. 1 3 POL YACRYLAMIDE GEL ELECTROPHORESIS IN THE PRESENCE OF 
SQS. 
The SOS-PAGE was performed in slab gels according to Laemmli (1970). 
The casting frames (two) were set up according to the manufacturer's notes (LKB 
instrument). 
The lower separating gel was 3 mm thick, 15 cm wide and 13 cm tall and 
contained 11 °/o acrylamide. The gel was prepared by mixing 14.8 ml 1.5 M Tris-HC1 
pH 8.8, 0.4°/o SOS (Sigma Chemical Co.), 22 ml 30°/o acrylamide stock (Kodak), 2.5 g 
sucrose, 21 ml distilled water, 24 ul N,N,N',N'-tetramethylethylenediamine (Terned) 
[Ajax Chemical] and 100 ul of 10°/o ammunium persulphate [Ajax Chemical]. Twenty 
eight ml were poured into each frame and overlaid gently with water and left to 
polymerise for at least 1 hr. After the separating gel has set, the water overlay was 
poured off and overlaid with stacking gel with the appropriate comb inserted between the 
frames. The upper stacking gel consisted of 4°/o acrylamide and was prepared by mixing 
5 ml stacking gel buffer (0.5 M Tris-HC1 pH 6.8/0.4°/o SOS), 2.6 ml 30°/o acrylamide 
stock and 12.5 ml distilled water. The stacking gel was left to polymerise for 1 hr 
before the comb was carefully removed and the sample wells washed out with distilled 
water. The samples were then carefully layered into the wells of the stacking gel, 
ensuring that mixing with the electrophoresis buffer was kept to an absolute minimum. 
The gels were then electrophoresed for 18 hr at 70V and at constant current using 
power-pack according to manufacturer's instruction (LKB). 
2 .1 4 AUTORADIOGRAPHY AND SOS-PAGE 
SOS-PAGE was performed in slab gels according to Laemmli (1970) as 
described above (Section 2.13). 
Samples containing 1251-plasminogen, urokinase and Trasylol and the 
various additions were incubated at 37° C for various times as discussed in the results 
Section of Chapter 3. After incubation, the samples were boiled for 3 min in sample 
buffer (0.06 M Tris-HC1 pH 6.8 containing 20°/o v/v glycerol, 6°/o w/v SOS and 
0.012°/o bromophenol blue) containing 5°/o beta-mercaptoethanol and subjected to SOS-
PAGE for 18 hr at 70V, constant current and at room temperature. After 
electrophoresis, the gels were fixed and stained in 50°/o trichloroacetic acid, 0.1 °/o 
coomassie brilliant blue for 30 min and destained in 1 Oo/o glacial acetic acid and dried 
with a slab gel drier (Hoeffer Scientific Instruments). The dried gels were placed on 
Kodak X-omat films at -70° C to localise the radiolabelled protein. 
2 .1 5 AMINO ACID SEQUENCING 
The terminal amino-acid sequence of lysine-Sepharose and antibody-affinity 
purified plasminogen was determined on 600 picomoles protein to ten residues on a 
Beckman 890 M amino-acid sequencer using a 0.1 M Quadrol program. The 
phenylthiohydantoin (PTH)-amino acids were identified by high-performance liquid 
chromatography (HPLC) on a Hewlett-Packard 10848 instument with an Altex 165 
variable wave-length detector using a reverse phase C-18 column and sodium acetate-
acetonitrile elution (Bledsoe & Pisano 1981 ). 
2 .1 6 FIBRIN AGAROSE RADIAL DIFFUSION GELS 
A 1.25°/o agarose (Sea Plaque, FMC Corp. Rockland, Maine) gel matrix, 1.2 
mm thick, containing fibrinogen (Sigma type X) and thrombin (Sigma Grade 1) was used 
for the detection of fibrinolysis. Wells of 3 mm diameter were cut for the application of 
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5 ul of plasmin/monoclonal antibody mixture which had been preincubated for 3 hr at 
20° C. Radial diffusion was carried out in a humidified box for 20 hr at 370 C and then 
the gels were washed thoroughly in saline and stained with amide black. 
2 .1 7 PREPARATION OF COLO 394 CELL CULTURES 
The human colonic epithelial cell line COLO 394 was a gift from Dr. R. 
Whitehead, Ludwig Cancer Research Institute, Melbourne (Frampton et al., 1982). 
These cells were grown in tissue culture medium (RPMl-1640; Flow Laboratories) 
with 10°/o heat-inactivated fetal calf serum containing 50 ug/ml gentamycin, 60 ug/ml 
penicillin and 20 ug/ml streptomycin and passaged twice a week and were maintained for 
several months. The secretion of the PA by these cells remained stable and constant 
throughout the period of culture as assessed every month using SDS-PAGE and fibrin 
plate overlay gel method as described in section 2.6 of this chapter. 
For studies on proenzyme activation, 2 x 106 cells/well were plated in 6-
place multi-well plates (Linbro). After adherence overnight, the cells were washed 
with serum-free RPMl-1640 and cultured in this for 24 hr before additions were made 
and incubations continued for a further 24 hr. Additions to the 3 experimental cultures 
were: (1) plasminogen (20 ug), (2) Buffer control (50 mM glycine pH 7.8), (3) 
plaminogen (20 ug), and anti-pig 1 (138 mg) mixture which had been previously 
incubated for 2 hr at 200 C. 
2 .1 8 EFFECT OF DFP ON PRO-ACTIVATOR AND ACTIVATOR 
COLO 394 cell culture supernatants (30 ul) containing additions as described 
in legend of Fig. 3.6 were incubated with diisopropylfluorophosphate (10 ul, 0.25 mM) 
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(Sigma Chemical Co.), an irreversible inhibitor of serine proteases, for 5 hr at 200 C 
and the incubation stopped with SOS sample buffer to give a final volume of 80 ul. 
Untreated and treated samples were then applied to an 11 °/o SOS electrophoresis gel 
under non-reducing conditions and detection of the proteases was performed using a 
fibrin overlay gel as described above (Section 2.6). 
In the case of colorectal carcinomas, adenomatous polyps and inflammatory 
lesions, mucosa! specimens were homogenised with (a) anti-pig 1 (1 ug/mg wet 
tissue), (b) buffer alone or (c) Trasylol (4 ug/mg wet tissue) and diluted 1 :2 prior to 
assay. The diluted homogenates (20 ul) were then incubated with 20 ul (2 ug) of 
affinity-purified plasminogen for 45 minutes at 370 C which had been previously 
preincubated with 20 ul of either (a) anti-pig 1 (20 ug), (b) Trasylol (16 ug) or (c) 
buffer alone for 2 hr at 200 C. 
Homogenates (30 ul) containing these additions were incubated with DFP or 
propylene glycol (Sigma Chemical Co.) as control (15 ul, 3.7 mM) for 5 hr at 200 C and 
the incubation stopped with SOS sample buffer to give a final volume of 85 ul. Untreated 
and treated samples were then applied to an 11 °/o SOS electrophoresis gel under non-
reducing conditions and detection of the proteases was performed using the fibrin-
overlay gel described above (Section 2.6). 
2 .1 9 IODINATION 
Iodination was performed according to the method of Morrison et al., (1971 ). 
The Enzymo-beads (BioRad) were rehydrated with 0.5 ml distilled water at least 1 hr 
before use. Into a disposable eppendorf tube (Bioscientific Supplies) were added 100 ul 
of 0.2 M phosphate buffer pH 7.2, 20 ul protein solution (500 ug), 100 ul Enzymo-
bead reagent, 50 ul 1 °/o beta-D-glucose (BDH) and 30 ul 2 mCi Na 1251. 
The reagents were mixed and iodination allowed to proceed at room 
temperature for 15 min. The appropriate fractions containing radioactivity were 
collected after desalting on a Sephadex G-25 fine column with phosphate buffered saline 
pH 7.4/0.1 °/o gelatin. 
2. 20 ISOLATION OF HUMAN INTESTINAL MACROPHAGES FROM LAMINA 
PROPRIA 
A single cell suspension of human intestinal lamina propria cells was 
prepared according to Golder & Doe (1983). Briefly, histologically normal mucosa 
resected from patients undergoing surgical resection for colonic carcinoma was 
immediately transported to the laboratory in ice-cold RPMI 1640 (Gibco, Grand Island 
Biological Co; Grand Island, N.Y.) supplemented with 100 IU/ml penicillin, 100 ug/ml 
streptomycin and 100 ug/ml neomycin. The muscularis mucosa was dissected free from 
the mucosa which was washed several times in calcium and magnesium-free Hank's 
balanced salt solution (CMF-HBSS) and then cut into small pieces. Sequential 
treatments of the tissues in CMF-HBSS supplemented with 1 mM dithiothreitol (Sigma 
Chemical Co; St. Louis, M.O.) and then 0.75 mM EDTA were continued until all epithelial 
cells were removed. After incubation overnight in 2 U/ml purified collagenase (CLSPA, 
Worthington Biochemical Corp; Freehold, N.J.), 5 U/ml DNase II (Calbiochem-Behring 
Corp.} and 5°/o human AB serum (Woden Valley Hospital Blood Bank), lamina propria 
cells were separated from the fragments of undigested tissues by filtration through 
surgical gauze. The supernatant was then centrifuged (300 g) for 15 min at room 
temperature. Viability of the cells from the disaggregation for all speciments was 
always greater than 95°/o. 
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2. 21 PURIFICATION OF HUMAN INTESTINAL MACROPHAGES 
Lamina propria cells were resuspended in a minimal volume of CMF-HBSS 
and introduced into the sample chamber for centrifugal elutriation which was carried 
out in a Beckman J2-21 centrifuge using a JE-6B rotor fitted with the standard 
elutriation chamber under sterile conditions. The elutriation buffer was 1 O mM sodium 
phosphate pH 7 containing 0.15 M NaC1, 1 mM EDTA and 0.2°/o crude human serum 
albumin (Commonwealth Serum Laboratories, Melbourne, Australia). The temperature 
was maintained at 20° C and the rotor speed at 2500 + 1 O rpm throughout the run. The 
elutriation separation chamber and the separation reservoir were pretreated with 1 °/o 
Aquasil (Pierce Chemical Co; Rockford, IL, USA) and rinsed well prior to introduction of 
the lamina propria cells. 
Cells were introduced into the elutriator when the elutriation pump was 
running at a flow rate of 9.0 ml/min and 65 ml were then collected. The flow rate was 
adjusted to 12.5 ml/min and a further 200 ml containing mainly erythrocytes and a 
small percentage of lymphocytes was collected. The pump flow rate was then increased 
to 15.0 ml/min and a fraction of 500 to 600 ml containing the majority of the 
lymphocytes was collected. The pump and then the rotor were stopped and the fraction 
collected from the elutriation chamber contained mainly neutrophils, some eosinophils, 
a small proportion of large lymphocytes, and the majority of the human intestinal 
macrophage population. Macrophages were further purified by underlaying with an 
equal volume of Percell (Pharmacia, 1.064 g/ml, adjusted with CMF-HBSS) before 
centrifugation at 750 g for 40 min at 40 C. Purified human intestinal macrophages 
were collected from the interface and washed in CMF-HBSS at 0-40 C by successive 
centrifugations at 750 g for 1 O min and 300 g for 1 O min. The cells were then 
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resuspended in 1 O ml of homogenisation buffer (1 OmM Hepes pH 7.4, 0.34 M sucrose, 
1 mM EDTA, 0.1 mM MgC12). 
2. 2 2 SURFACE LABELLING OF PLASMA MEMBRANE USING WHEAT GERM 
AGGLUTININ 
For cell surface-labelling with 1251-labelled wheat germ agglutinin ( 1 2 51-
WGA), the purified human intestinal macrophages were resuspended in cell 
resuspension buffer (Jesaitis et al., 1982) containing 0.1 °/o human serum albumin and 
incubated with the 1251-WGA for 5 min at oo C. After centrifugation at 300 g for 1 O 
min, the cells were washed successively with 30 ml cell resuspension buffer and 30 ml 
homogenisation buffer. The cells were then resuspended in 1 O ml homogenisation buffer 
for nitrogen cavitation. 
For routine plasma membrane preparation, 20 uM p-
nitrophenylguanidinobenzoate and 100 Kl U/ml Trasylol (bovine pancreatic trypsin 
inhibitor, Bayer) were included to reduce surface antigen degradation by serine 
proteinases. These inhibitors were omitted for gradients involving assays of 
plasminogen activators. 
2. 23 NITROGEN CAVITATION AND SUBCELLULAR FRACTIONATION BY 
ISOPYCNIC CENTRIFUGATION 
The nitrogen cavitation and subcellular fractionation methods of Fayle et al., 
(1985) employed for human blood monocytes were applied to intestinal macrophages. 
Surface-labelled intestinal macrophages with 1251-WGA in a 50 ml centrifuge tube and 
a stir bar were placed in a pre-cooled Parr cell disruption bomb (model 4635, Parr 
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Instruments, Moline, IL, USA) and then pressurized with nitrogen to 2750 KPa (400 lb 
in -2) and stirred at 4° C for 15 min before disintegration. The homogenate was then 
centrifuged at 1000 g for 10 min 4° C and the supernatant collected. The pellets of 
1000 g, containing cell debris, broken nuclei and most of the DNA, were discarded. 
Subcellular fractionation by isopycnic centrifugation was performed on 
sucrose density gradients containing 1 O mM Hepes pH 7.0 and formed with 3 ml 60°/o 
(w/w) sucrose overlaid with 22 ml or 25 ml of a linear gradient of 55-20o/o sucrose. 
After overnight equilibration of gradients at 40 C, 1 O ml of the cell homogenate was 
layered onto the gradient and centrifuged in a Beckman SW27 rotor at 25,000 rpm 
(108,000 g) for a minimum of 3 hr, by which time the gradient was at equilibrium. 
Fractions were then collected in equal volume by pumping at 1 ml/min from a thin tube 
lowered onto the bottom of the gradient. In experiments to test the effects of digitonin 
(Merck), sucrose density gradients were formed as before but with 1 ml 60°/o (w/w) 
sucrose overlaid with 8 ml of a linear gradient of 55-20°/o sucrose. Digitonin was added 
to one half of the membrane preparation at 0.51 mg/108 human intestinal macrophages, 
in a volume of 3 ml homogenisation medium before subcellular fractionation. 
2. 24 IMMUNOFLUORESCENCE STAINING OF HUMAN INTESTINAL 
MACROPHAGES 
lmmunofluorescence was carried out in 96 well trays according to Loken & 
Stall (1982). A total of 1-2 x 106 cells in medium (200 ul) were added to round 
bottom titertek 96 well plates at 0-40 C. This was spun at 250 g for 5 min at 4 o C and 
the supernatant removed by tilting the plate and using suction system with needle 
attachment. 50 ul (monoclonal antibodies, 1 °/o BSA, 0.1 °/o Na N3) in PBS were added and 
the cells resuspended by aggitation of bottom of wells. This was then left to incubate for 
30 min on ice. After incubation, 100 ul of 2.5°/o BSA/0.1 °/o NaN3 in PBS were added and 
the wells spun at 250 g for 10 min at 4 o C. The supernatant was removed and 50 ul of 
FITC second antibody (Cappel Laboratories) added and the cells resuspended as before. 
This was again left to incubate for 30 min on ice after which 100 ul of 1 o/o BSA/0.1 °/o 
NaN3 were added and the wells spun as before. The supernatant was removed and the 
cells resuspended in 50 ul containing 1 °/o BSA/0.1 °/o NaN3/0.2 ug per ml propridium 
iodide (Sigma Chemical Co.). The cells were counted under fluorescent microscope (8-
1 O ul per coverslip). 
2. 25 PREPARATION OF POOLED PA ENRICHED MEMBRANES FRACTIONS 
The pooled peak PA enriched membrane fractions were prepared from a 
standard sucrose gradient fractions after assaying for PA activity using the colorimetric 
assay. Pooled sucrose gradients fractions enriched for PA activity were diluted with 
4.4°/o NaC1 in 1 O mM Hepes and centrifuged at 220,000 g for 18 hr at 40 C. The 
precipitate which contained the PA enriched membranes were resuspended in 200 ul of 
50 mM glycine pH 7.8 containing 0.5°/o Triton X-100 and then used straight away for 
the experiments to determine the types and nature of the plasminogen activators in the 
pooled PA enriched membrane fraction using anti-pig 1 monoclonal antibody. 
2. 2 6 STATISTICS 
Results have been expressed as mean + SD. Statistical analysis of the data 
was performed using the non-parametric analysis of Wilcoxon and Mann-Whitney. 
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CHAPTER 3 
MONOCLONAL ANTIBODIES INHIBITORY TO HUMAN PLASMIN: DEFINITIVE 
DEMONSTRATION OF A ROLE FOR PLASMIN IN ACTIVATING THE PROENZYME 
OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR. 
INTRODUCTION 
Plasmin is a non-specific serine protease of the trypsin type which has an 
important role in a variety of both physiological and pathological processes. While its 
best studied action is in thrombolysis (fibrinolysis), it has also been proposed to 
facilitate a range of other proteolytic events involved in embryonic development, tissue 
remodelling and tumour invasion (Astrup 1978; Reich 1978a; Collen 1980). 
Plasmin is generated under the action of plasminogen activating enzymes from 
the zymogen plasminogen which is present in abundant amounts in many extracellular 
fluids. Two distinct types of plasminogen activator have been characterised and shown to 
be the products of different genes (Aoki & Von Kaulla 1971; Unkeless et al., 1974b; 
Christman et al.,1975). They differ in immunological reactivity and have Mr of 
52,000 daltons (U-PA) and 66,000 daltons (t-PA). Several reports (Skriver et al., 
1982; Nielsen .et.fil., 1983; Wun fil...fil., 1982b; Andreasen .et.al., 1984) have indicated 
that the plasminogen activating enzymes are themselves produced as inactive 
proenzymes, requiring proteolytic conversion for the expression of plasminogen 
activator activity. A role for plasmin as the mediator of this conversion was indicated by 
experiments which employed purified preparations of plasmin and the potent serine 
protease inhibitor, trasylol. However, the participation of minor contaminant proteases 
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could not be absolutely ruled out by either the purity of the plasmin or the specificity of 
trasylol. 
Although monoclonal antibodies have been developed against human plasmin 
(Ploplis et al., 1982), their use as selective inhibitors to study the actions of plasmin 
has not been explored. Nor has their potential for the affinity purification of 
plasminogen been exploited. 
In this chapter, the production and characterisation of four monoclonal antibodies 
against human plasminogen are reported. The identification of plasmin as the enzyme 
molecule responsible for conversion of inactive pro-urokinase to active urokinase is 
unequivocally established, and the use of immunoaffinity chromatography for 
plasminogen purification is demonstrated. 
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METHODS AND MATERIALS 
Monoclonal Antibody Production 
Human blood was obtained from the Venesection Clinic, Woden Valley Hospital. 
Human plasminogen was purified by two cycles of affinity chromatography on lysine-
Sepharose ( Deutsch & Mertz 1970) as described in Chapter 2 Section 2. 7. Eleven 
week-old Balb/c mice (Animal House, John Curtin School of Medical Research, ANU) 
were hyperimmunized with 5 weekly intraperitoneal injections of 15 ug plasminogen 
in Freund's adjuvant (Difeo Laboratories). Fusion was carried out 4 days after the last 
injection. 
Production of hybridomas was carried out between immune splenic lymphocytes 
and X63-Ag 8.653 murine myeloma cells (Kearney et al., 1979) according to the 
procedure as described in Chapter 2, Section 2.3. Enzyme-linked immunosorbent assay 
(ELISA) was used as a primary screen for antibodies binding to plasminogen as described 
in Chapter 2, Section 2.8. 
Immediately after fusion, the cells were dispensed into twelve 96-well tissue 
culture plates (Nunc) in Dulbecco's modified minimal essential medium (DMEM) (Flow 
Laboratories) supplemented with hypoxanthine, aminopterin and thymidine (HAT) 
(Littlefield 1964), 10°/o heat inactivated fetal calf serum (FCS) (Flow Laboratories), 2 
mM glutamine and antibiotics. Thymocytes (at least 2 x 1061ml) from 4-8 week old 
Balb/c mice were added at each feeding. Of 1,152 wells, 953 wells displayed vigorous 
hybridoma growth after 1 O days. The hybridomas were grown for a total of 14 days in 
DMEM-HAT medium with a feeding at day 7 and adapted to DMEM with 1 Oo/o FCS by 
gradually phasing out aminopterin and then hypoxanthine and thymidine. Antibodies 
against human plasminogen were detected in 41 culture supernatants. Cultures 
secreting antibodies were cloned by limiting dilution as described in Chapter 2, Section 
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2.3.8. However, only four of the monoclonal antibodies were selected since these four 
hybridomas were stable and continued to secrete antibodies after freezing and thawing. 
Furthermore, all these hybridomas still continued to show high secretion of antibodies 
even after being frozen in liquid nitrogen for a period of up to 6 months. 
Characterisation and Purification of antibodies 
Monoclonal antibodies were characterised using the Ouchterlony analysis on 
agarose gel as described in Chapter 2, Section 2.9. Monoclonal antibodies (lgG) were 
purified by precipitation from ascites fluid or hybridoma culture supernatant by 50°/o 
saturation with ammonium sulphate. After dialysis of the resuspended pellets against 
0.1 M Tris-HCI pH 8.1, antibodies were purified by protein A-Sepharose (Pharmacia) 
chromatography as described in Chapter 2, Section 2.10. 
Antibodies of irrelevant specificities, and of the same class and light chains as of 
the anti-pig monoclonals were used for control experiments. WVH-1 is a monoclonal 
lgG antibody raised against human intestinal macrophages which reacts with an 
uncharacterised surface antigen present on monocytes and neutrophils (D. Fayle, 
unpublished). GAP-8.3 is a pan-leukocyte monoclonal lgG antibody (Berger .e.1....al., 
1981, American Type Culture Collection, Rockville, Maryland, USA). 
Binding (dissociation) constants for the 1125-labelled monoclonal anti-
plasminogen antibodies to human plasminogen were assessed by a solid-phase assay 
previously described by Frankel & Gerhard (1979) and Ploplis et al., (1982) as 
described in Chapter 2, Section 2.11. 
Affinity Chromatography 
Anti-plasminogen monoclonal antibody was coupled to cyanogen bromide-
activated Sepharose 48 as described in Chapter 2, Section 2.4. In the experiment shown 
in Figure 3.2, a 1 ml column containing 600 ug of lgG, was run at a flow rate of 12 
ml/hr. 
Colorimetric Assay was performed according to the method of Coleman & Green 
(1981) as in Chapter 2, Section 2.12. 
SDS-PAGE and Fibrin Overlay Detection of Proteases was carried out by the 
method of Granelli-Piperno & Reich (1978) as described in Chapter 2, Section 2.6. 
Fibrin Agarose Radial Diffusion Gels 
This was performed as described in Chapter 2, Section 2.16. 
Preparation of COLO 394 cell cultures was carried as described in Chapter 2, 
Section 2.17. 
Effect of DFP on Pro-activator and Activator was assessed as described in 
Chapter 2, Section 2.18. 
Iodination of purified plasminogen and monoclonal anti-plasminogen antibodies was 
performed using Enzyme-Beads (BioRad) as desribed in Chapter 2, Section 2.19. The 
specific activities of the plasminogen and monoclonal antibodies were 1 x 1 o5 cpm/ug 
and 0.5 - 1 x 1 o5 cpm/ug respectively. 
Autoradiography 
The direct, plasmin-independent assay of Mussoni et al., (1984) employing 
SOS-PAGE and 2-mercaptoethanol was used to monitor urokinase-mediated conversion 
of single chain, 1251-plasminogen to two chain plasmin as described in Chapter 2, 
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Section 2.14. The method was also used to determine the content of native plasminogen 
prepared by both the lysine and antibody affinity methods. 
Protein was determined by a modified Lowry method (Peterson 1977) as 
described in Chapter 2, Section 2.2. 
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RESULTS 
Affinity purification of human plasminogen from crude plasma 
The monoclonal antibody anti-pig 1 (600 ug) was coupled to cyanogen bromide-
activated Sepharose 48 and used to purify human plasminogen from fresh whole plasma 
by affinity chromatography. After extensive washing of the column, the applied 
plasminogen could be eluted by 0.1 M glycine-HCI pH 2.5/0.1 °/o Triton X 100 containing 
0.5 M NaCl. The eluate contained pure plasminogen as evaluated by SOS-PAGE. Under 
reducing conditions, two very closely spaced Coomassie blue stainable bands were seen 
(Figure 3.2). Although only one band was visible as shown in the photograph in Figure 
3.2, two very closely bands were nevertheless seen in the gel, one with much higher 
intensity than the other. Unfortunately, the photographic techniques used only managed 
to pick up the major band of higher intensity. The Mr was estimated from the 
electrophoretic mobility relative to stained standard marker proteins and was not 
significantly different from the agreed Mr of human plasminogen of about 94K 
(Sottrup-Jensen et al., 1978a). The immunoaffinity method gave a 26°/o higher 
relative yield than the lysine-Sepharose method. The immunoaffinity purified 
plasminogen preparation was comparable with that obtained from lysine-Sepharose 
affinity chromatography when assayed by the colorimetric method using urokinase. 
The cleavage of 1125_plasminogen was used to assess the content of native 
plasminogen purified by the two methods. Quantitative data on 1251-plasminogen 
cleavage by urokinase was obtained by removing the portions of the SOS-PAGE gel 
containing radio-labelled plasminogen and plasmin (the position of the radio-labelled 
polypeptides was determined by placing the X-ray film directly onto the gel) and 
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Figure 3.2 Affinity purification of plasminogen: Anti-plg l 
was coupled to Sepharose as outlined in Materials and 
Methods. The 1ml column was washed with Tris-HCl pH 
8.1/0.1% Triton-X and the plasminogen eluted with O.lM 
glycine pH 2.5 buffer. Starting material (lane A), Eluant 
fraction (lane B). 
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counting them in a Packard Auto Gamma 500 counter. Using 150 mPU of urokinase and 
2 ug of the radio-labelled plasminogen prepared by either method, (in the presence of 
80 ug/ml Trasylol) with an incubation period of 24 hr at 370 C, 96°/o of the antibody-
purified plasminogen was converted to plasmin compared with 93°/o of the lysine-
purified plasminogen. The predominant form of plasminogen from both methods was 
Glu-plasminogen as determined by the terminal amino acid sequence and was present at 
greater than 95°/o. 
Affinity Studies 
Binding (dissociation) constants for the 1251-labelled monoclonal antibodies to 
human plasminogen were estimated as described under Materials and Methods of Chapter 
2, Section 2.11. Figure 3.1 shows representative plots of 3 experiments in duplicate 
samples of the binding analysis for anti-pig 1 and anti-pig 2. The dissociation constants 
(Ko) for each were determined from the slopes of the lines and are summarized in Table 
3.1. Anti-pig 1 has a slightly higher affinity than the other 3 antibodies which were 
similar to each other in their Ko values. 
No competitive binding studies using the ELISA assay were performed with 
plasmin, OFP-plasmin, trypsin or chymotrypsin. 
Effect of monoclonal anti-plasminogen antibodies on the susceptibility of 
plasminogen to activation by urokinase 
The two-step coupled colorimetric assay of urokinase (Coleman & Green 1981) 
was used to determine whether the binding of monoclonal antibodies to human 
plasminogen altered its rate of activation by urokinase, or affected the subsequent assay 
of thioesterolytic activity by the plasmin formed. These two effects could be 
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Figure 3.1 Modified Scatchard analysis of the binding of 
125
1-labelled anti-plg 1 (A) and anti-plg 2 (B) to human 
plasminogen. In each case, the ratio of the concentration of 
(A)Bound to (A)Free antibody is plotted against (A)Bound. 
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TABLE 3.1 
Dissociation constants (Ko) for the 4 anti-plasminogen monoclonal antibodies to human 
plasminogen at 37° C. 
-------------------------------------------------------------
Antibody Ko x 1 o-s M 
------------------------------------------------------------
Anti-pig 1 0.35 
Anti-pig 2 1.07 
Anti-pig 3 0.86 
Anti-pig 4 0.73 
-------------------------------------------------------------
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distinguished by virtue of the two-step nature of the assay where, in the first step, 
plasminogen was activated to plasmin, and this reaction was then inhibited by the 
addition of 2 M KCI so that the plasmin activity already produced could be assayed by 
lysis of thioester in the second step. 
When the protein-A purified monoclonal antibodies were preincubated with 
human plasminogen before the first (activation) step, both the monoclonal anti-pig 1 
and anti-pig 2 antibodies produced a marked decrease in the colour yield of the 
subsequent plasmin assay step when compared with the antibody-free control (Table 
3.2, Column 1 ). Monoclonal anti-pig 1 was somewhat more potent than anti-pig 2. Two 
other monoclonal anti-plasminogen antibnodies, anti-pig 3 and anti-pig 4, had no effect 
or gave a slight increase in colour yield. (Table 3.2, Column1 ). 
Because the inhibitory effect of anti-pig 1 and anti-pig 2 could have resulted 
either from interference with the urokinase activation of plasminogen, or from direct 
.; 
inhibition of plasmin, the same antibodies were added to the incubation mixture after 
plasminogen activation, but before the plasmin assay step. Both anti-pig 1 and anti-pig 
2 again produced a similar decrease in colour yield (Table 3.2, Column 2). Anti-pig 3 
and anti-pig 4, however, either had no effect, or increased the colour yield to some 
extent, when compared with the antibody-free control (Table 3.2, Column 2). It was 
therefore apparent that while none of the monoclonal antibodies tested affected the 
susceptibility of human plasminogen to activation by urokinase, anti-pig 1 and anti-pig 
2 strongly inhibited the thioesterase activity of pre-formed human plasmin. Direct 
colorimetric assay of the thioesterase activity of commercial porcine plasmin and bovine 
trypsin showed that none of the antibodies affected the activity of these enzymes (data not 
shown). 
The observation that the monoclonal antibodies did not inhibit plasminogen 
activation was confirmed by examining the cleavage of 1251-plasminogen by 
TABLE 3.2 
Inhibition of Colorimetric assay by monoclonal anti-plasminogen antibodies 
-------------------------------------------------------------
PRE-INCUBATION POST-INCUBATION 
Absorbance 0/o Inhibition Absorbance 0/o Inhibition 
Antibody 
Anti-Pig 1 0.115 101 0.143 95 
Anti-Pig 2 0.390 53 0.357 57 
Anti-Pig 3 0.868 -2 9 0.644 6 
Anti-Pig 4 0.790 - 1 6 0.730 -9 
No Ab 0.695 0.679 
No urokinase 0.118 0.112 
-------------------------------------------------------------
Dialysed antibodies (20 ul containing 12 ug) were preincubated with plasminogen (20 
ul containing 2 ug) for 1 hr at 20° C. In the case of post-incubation, the pre-formed 
plasmin was incubated with antibody in 0.4 M KCI for 1 hr at 20° C. Plasmin assay 
reagent was then added and the colorimetric assay continued. 
75 
, ' 
1 2 3 4 5 6 
97K. 
78K 
28K 
Figure 3.3 Autoradiogram showing the effect of monoclonal anti-plg 
t 'b d' 1 . 1 125 r 1 . (2 1 6) an 1 o 1es on p asm1nogen c eavage: -p asm1nogen ug, ane 
was incubated for 5 hrs with 150 mPU urokinase in the absence (lane 
1) or presence of preincubation of plasminogen with the monoclonal 
anti-plg antibodies (16 ug/20ul). anti-plg 3 (lane 2), anti-plg 2 
(lane 3), anti-plg 4 (lane 4) and anti-plg 1 (lane 5). 
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autoradiography after electrophoresis. In this assay, inhibition of plasminogen 
activation would have been indicated by the ability of the monoclonal antibodies to block 
urokinase-mediated cleavage of single chain plasminogen to the characteristic plasmin 
"heavy" and "light" chains (Dano & Reich 1979; Summaria et al., 1967). The results 
obtained (Figure 3.3) showed that none of the antibodies blocked the cleavage of 
plasminogen. 
Effect of monoclonal anti-plasminogen antibodies on fibrinolytic activity 
of plasmin 
The ability of the protein-A purified monoclonal antibodies to inhibit the 
fibrinolytic activity of plasmin was investigated using a fibrin radial diffusion method 
(Golder & Stephens 1983). Small amounts of human plasmin were generated by 
treatment of plasminogen with urokinase and the resulting preparation was incubated 
with each antibody for 3 hr at 20° C. The plasmin-antibody mixtures were then applied 
to microwells cut in an agarose gel containing fibrin. Zones of fibrin lysis were formed 
as the diffusing plasmin degraded the insoluble fibrin to soluble fibrinopeptides. 
As shown in Figure 3.4, anti-pig 1 (well 1) and anti-pig 2 (well 4) inhibited 
the fibrinolytic activity of human plasmin, with the former showing almost complete 
inhibition when compared with the irrelevant antibody WVH-1 (well 2) and the 
antibody-free (well 3) controls. Neither anti-pig 3 nor anti-pig 4 (wells 5 and 6 
respectively) had any effect on the ability of plasmin to degrade fibrin. 
Effect of monoclonal anti-plasminogen antibodies on plasmin-mediated 
conversion of HPA52 to HPA36 
I. 
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Active urokinase is a protein of 52,000 daltons which is readily cleaved by 
plasmin to a 36,000 dalton product that retains plasminogen activating activity (Barlow 
.et.al., 1981 ). Because anti-pig 1 and anti-pig 2 inhibited both the thioesterolytic and 
fibrinolytic activities of plasmin, the possibility arose that these antibodies interfered 
with the plasmin-catalysed cleavage of HPA52 was also investigated. 
Each monoclonal antibody was preincubated with plasminogen for 2 hr at 200 C, 
then urokinase was added to generate small amounts of plasmin, which in turn cleaved 
some of the urokinase. The reaction was terminated with SOS and the proteins were 
separated by SOS-PAGE. Contact lysis of an overlay gel, containing fibrin and 
plasminogen was used to determine the position in the SOS-PAGE gel of plasminogen 
activators and plasmin from the incubated samples. 
As shown in Figure 3.5, the urokinase preparations used contained both the high 
(HPA52) and low (HPA36) Mr forms of the enzyme (lane 1 ). When urokinase was 
incubated with plasminogen (in the absence of antibody), the plasmin produced by 
plasminogen activation cleaved almost all of the HPA52 form into the HPA36 form (lane 
2). The plasmin responsible for this cleavage (Barlow .e.Lal., 1981) was evident by the 
lysis zone A at 85,000 daltons (lane 2-6, except lane 4 in the case of anti-pig 2 see 
below). All four anti-plasminogen antibodies (lanes 3 to 6) substantially inhibited tha 
plasmin-catalysed cleavage of the HPA52, indicating that this proteolytic activity of 
plasmin was inhibited by plasmin bound antibodies. This was not due simply due to 
substrate competition for plasmin between the protein of urokinase and the added lgG, 
since equivalent amounts of the irrelevant antibody had no effect (data not shown). 
The stability of plasmin-antibody complexes 
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F i g u r e  3 . 4  E f f e c t  o f  m o n o c l o n a l  a n t i b o d i e s  o n  f i b r i h o l y s i s :  H u m a n  
p l a s m i n  ( l O u l )  w a s  p r e i n c u b a t e d  w i t h  l O u l  o f  t h e  r e s p e c t i v e  a n t i b o d y  
( 7 u g )  f o r  3  h r s  a t  2 0 ° c  a n d  t h e  m i x t u r e  ( S u l )  a p p l i e d  t o  w e l l s  c u t  
i n  a  p l a s m i n o g e n - s u p p l e m e n t e d  f i b r i n / a g a r o s e  g e l .  T h e  r e s p e c t i v e  
a n t i b o d i e s  u s e d  w e r e : - a n t i - p l g  1  ( w e l l  1 ) ,  W V H - 1  ( w e l l  2 ) ,  p l a s m i n  
o n l y  ( w e l l  3 ) ,  a n t i - p l g  2  ( w e l l  4 ) ,  a n t i - p l g  3  ( w e l l  5 )  a n d  a n t i - p l g  
4  ( w e l l  6 ) .  T h e  g e l  w a s  i n c u b a t e d  f o r  2 0  h r s  a t  3 7 ° c .  
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Figure 3.5 Effect of monoclonal antibodies on plasmin 
mediated cleavage of urokinase: SDS-PAGE after preincubation 
with antibodies. Plasminogen (lOul, containing 2ug) was 
preincubated with anti-plg antibodies (2lug) or with the 
assay buffer (control) for 2 hrs at 20°c and then further 
incubated with 30ul (6mPU) of urokinase at 37°c for 45 min 
before application to SDS-PAGE. The bands were developed in 
a fibrin overlay gel by incubation for 20 hrs at 37°c. 
Urokinase (lane 1), Urokinase incubated with plasminogen 
treated with:- control (lane 2), anti-plg 3 (lane 3), 
anti-plg 2 (lane 4), anti-plg 4 (lane 5) and anti-plg 1 
(lane 6). Zones of lysis are: (A) Mr 85000 (plasmin), (B) 
Mr 52000 (urokinase-type plasminogen activator) and (C) Mr 
36000 (degraded plasminogen activator). 
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In the experiment shown in Figure 3.5, (lane 4), it was also apparent that anti-
pig 2 prevented the appearance of the band at 85K arising from plasmin formed in the 
incubation before electrophoresis, indicating the formation of a proteolytically-inactive 
antibody-plasmin complex which was stable to SOS treatment. The absence of the band 
was not due to inhibition of plasminogen activation by anti-pig 2, since anti-pig 2 did 
not inhibit plasminogen activation (see Fig. 3.3). The other anti-pig monoclonals 
formed complexes which were dissociated during SOS-PAGE, and active plasmin bands 
were produced at 85K. 
Effect of monoclonal anti-pig 1 and DFP on the generation of COLO 394 
plasminogen activator from the proenzyme 
Plasminogen activators from several sources have now been shown to be produced 
as proenzymes (see Chapter 1 ). These proenzymes can be activated by plasminogen 
preparations containing traces of plasmin, but definitive evidence for this role of 
plasmin has not been reported. 
In order to determine unequivocally whether plasmin was responsible for the 
conversion of the COLO 394 proenzyme to its active form, the ability of the anti-pig 
monoclonal antibodies to selectively inhibit plasmin activity was exploited for 
investigating this possible role of plasmin. 
When the human colonic epithelial cell line COLO 394 was grown with serum-
free RPMI 1640 medium, an appreciable amount of plasminogen activator activity was 
produced and secreted into culture supernatant. This activity consisted principally of 
HPA52 (Figure 3.6. lane 1) and was present as a proenzyme, since it gave the same 
lysis band after treatment with OFP, an irreversible inhibitor of serine proteases 
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Figure 3.6 SOS-PAGE analysis of the role of plasrnin in the 
conversion of proenzyrne of COLO 394 plasrninogen activator to active 
enzyme in cell culture incubated with :- assay buffer only (lane 1), 
assay buffer and treated with DFP (lane 2), plasrninogen (lane 3), 
plasrninogen and treated with DFP (lane 4), plasrninogen pretreated 
with anti-plg 1 (lane 5), plasrninogen pretreated with anti-plg 1 and 
treated with DFP (lane 6). Zones of lysis are:- (A) Mr 52000 
(urokinase-type PA), (B) Mr 36000 (degraded urokinase-type PA). 
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(Figure 3.6, lane 2). The potentially active site in the proenzyme is inaccessible to 
DFP, in contrast to the active site in the active enzyme (Skriver et al., 1982). 
However, when untreated plasminogen was added to the COLO 394 cell culture growing in 
serum free RPMl-1640 and incubated for 24 hr, some of the high Mr activator (Zone A, 
lane 3) was cleaved to an active form of lower Mr (HPA36; Zone B, Lane 3). When this 
supernatant was treated with DFP both bands were absent (Figure 3.6. lane 4). This 
result indicated that the proenzyme had been activated, since the active site had become 
accessible to DFP. 
To determine if the proenzyme activation observed could be attributed to traces of 
plasmin in the plasminogen, the preparation of plasminogen was preincubated with anti-
pig 1 for 2 hr at 200 C and then added to the COLO 394 cell culture and incubated for 24 
hr. Only one band of HPA52 was seen (Lane 5) and there was no cleavage of the activator 
to the lower Mr form of HPA36 (cf Lane 3, where no anti-pig 1 was present). When 
this same culture superntant was treated with DFP, this HPA52 band was still present 
showing that the proenzyme was still present and that the antibody had therefore 
inhibited conversion of proenzyme to active enzyme. Since anti-pig 1 specifically 
inhibited plasmin, these results demonstrated that the plasmin present as a trace amount 
in the plasminogen preparation was responsible for the conversion of the pro-activator 
to its active form. 
The above observation was confirmed by the coupled clorimetric assay of Coleman 
& Green using anti-pig 3 and anti-pig 4, which unlike anti-pig 1 and anti-pig 2, did not 
inhibit plasm in thioesterase activity, or the fibrinolytic activity of plasmin. Anti-pig 3 
and 4 did, however, inhibit the plasmin-catalysed cleavage of active HPA52 (Figure 
3.5). Plasminogen was therefore preincubated with anti-pig 3 or anti-pig 4 for 2 hr at 
20° C before the addition of COLO 394 proenzyme and assay buffer to the incubation. 
Table 3.3 shows that in the presence of anti-pig 3 or anti-pig 4, the colour yield was 
markedly reduced compared to the control in which plasminogen was preincubated alone. 
When an irrelevant monoclonal antibody (GAP-8.3) was used, this reduction in colour 
yield was not seen. These results therefore confirmed that plasmin was responsible for 
the conversion of the proenzyme of COLO 394 plasminogen activator to its active form. 
Beside secreting proenzyme into the culture supernatant, the COLO 394 cells 
themselves also have pro-PA present (unpublished observations) . 
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TABLE 3.3 
Inhibition of Conversion of COLO 394 Proenzyme to active plasminooen activator 
-------------------------------------------------------------
Antibody 
Anti-pig 3 
Anti-pig 4 
No Antibody 
No Proenzyme 
GAP-8.3 
Absorbance 
0.375 
0.309 
1 .318 
0.095 
1.034 
-------------------------------------------------------------
Dialysed anti-plasminogen monoclonal antibodies (20 ul containing 12 ug) were 
preincubated with plasminogen (20 ul, containing 2 ug) for 2 hr at 20° C, followed by 
incubation with proenzyme (20 ul) at 37° C for 45 min. 
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DISCUSSION 
This chapter reports the properties of four monoclonal antibodies, all of lgG 1 / K, 
raised against human plasminogen, which proved useful as selective inhibitors of 
plasmin. The use of ELISA as a primary screening method allowed the selection of all 
monoclonal antibodies that bound to plasminogen, while the effects on plasminogen 
activation and the enzymic properties of plasmin produced by these antibodies were 
demonstrated by three other methods. Definitive evidence that plasmin activates the 
proenzyme form of HPA52 secreted by a cancer cell line is described. 
The dissociation constants obtained for the antibodies were of the same order of 
magnitude. However, the overall binding constants were obtained using a solid state 
binding assay and are thus only approximations. They may not be representative of those 
that could be obtained under equilibrium conditions. These antibodies were of slightly 
higher affinity than those of monoclonal antibodies 1 OF1 and 1 OVI, reported by Ploplis 
and co-workers (1982), which bind to human Glu-plasminogen and certain isolated 
fragments. 
After coupling to Sepharose, one of these antibodies, anti-pig 1, was found to 
have an appropriate affinity and specificity for the purification of plasminogen to 
homogeneity from whole plasma by immunoaffinity chromatography. Anti-pig 1 did not 
bind significantly to any other proteins present in substantial amounts in plasma. The 
purification of plasminogen by one-step immunoaffinity chromatography provided an 
alternative to the current method of 2 cycles of affinity chromatography on lysine-
Sepharose (Deutsch & Mertz 1970). The immunoaffinity method is rapid, minimizing 
the possibility of plasminogen degradation, and therefore conveniently provides highly-
purified plasminogen. All the other three anti-pig monoclonal antibodies were also able 
to purify plasminogen although not as effectively as anti-pig 1. The immunoaffinity 
purification of plasminogen by these monoclonal antibodies is a good indication of its 
specificity although a definitive demonstration would ideally also involve nitrocellulose 
immunoblotting with either serum or plasma. 
Manipulation of the colorimetric assay of plasmin was used to distinguish 
antibody effects on plasminogen activation from effects on plasmin activity. From these 
experiments, it was clear that none of the antibodies interfered with the activation of 
plasminogen by the plasminogen activator, urokinase. This observation was confirmed 
by examining the effects of antibodies on the susceptibility of 1251-plasminogen to 
cleavage, using autoradiography after electrophoresis. The autoradiogram clearly 
revealed that none of the antibodies blocked the urokinase-mediated cleavage of single 
chain plasminogen to the characteristic plasmin "heavy" and "light" chains. 
By contrast, anti-pig 1 and anti-pig 2 bound to both human plasminogen and 
plasmin and strongly inhibited the fibrinolytic and esterolytic activities of plasmin, but 
bovine trypsin and porcine plasmin activities were unaffected. 
In the experiments to investigate the cross reactivity of the anti-pig monoclonal 
antibodies, bovine and porcine plasmin as well as bovine chymotrypsin and trypsin were 
used. Even though only two species were tested, all these serine proteases beared 
structural similarity to other members of the group, including plasmin and elastase as 
well (Gunzler et al., 1982). 
The anti-plasminogen antibodies were also evaluated by the SOS-PAGE fibrin 
overlay gel system which made it possible to examine not only their effect on the 
83 
fibrinolytic activity of plasmin but also on the proteolytic cleavage of urokinase that is 
mediated by plasmin. It was demonstrated that all the antibodies against plasminogen 
inhibited somewhat the plasmin cleavage of urokinase. However only anti-pig 2 was 
effective in inactivating plasmin by the formation of a complex stable in SOS. 
The inhibition of human plasmin is likely to result from steric interference with 
the binding of substrate. It was therefore a little surprising that anti-pig 1 and anti-
pig 2 were able to inhibit the action of plasmin on such a small substrate as the lysine 
thioester used in the colorimetric assay. Although no evidence is offered at this stage, it 
is tempting to speculate that the antibodies may have bound to the non-protease part of 
plasminogen, which contains the five closely homologous triple-loop structures, the so 
called kringles (Sottrup-Jensen et al., 1978b). These play important roles in the 
interaction of plasminogen with the w-aminocarboxylic acids, fibrin and alpha2-anti 
plasmin (Wiman & Wallen 1977; Wiman et al., 1979; Markus et al., 1979). Only 
kringle 5 may be excluded as the antibody combining site, since cleavage of the Arg 560-
Val 561 bond by urokinase (Summaria et al., 1967, 1975; Robbins et al., 1967) still 
occurs in the presence of anti-pig antibodies. Furthermore, a recent report (Marti .et. 
.a.t., 1985) shows that the sequence of porcine miniplasminogen consisting of kringle 5 
and the light chain portion of plasmin does not differ substantially from that of the 
known sequence of human miniplasminogen. It is therefore unlikely that the inhibition 
of plasmin produced by the monoclonal antibodies was due to binding at the catalytic site, 
since the amino acid sequence at the active site does not differ substantially between 
human and porcine plasmin (Marti .e.1...a.l., 1985) and in the experiments reported in this 
chapter, the antibodies failed to inhibit porcine plasmin. In this respect, it would be 
interesting to test whether the anti-pig monoclonal antibodies would bind to DFP-
plasmin, since DFP is a irreversible inhibitor of the active site of serine proteases. 
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In a recent report by Ploplis fil...a!., (1982) on the anti-plasminogen monoclonal 
antibnodies 1 OF1 and 1 OV1, it is worth noting that 1 OF1 was specific for an epitope on 
the kringle 4 domain of plasminogen or its fragments while 1 OV1 recognised an epitope 
in the kringle 1-3 domain of the plasminogen molecule. It had also been shown recently 
that the antibody 1 OF1 which interacted with a particular e-amino caproic acid (EACA) 
binding site on the kringle 4 region of human Glu1 -plasminogen also enhanced the 
activation of Glu1 -plasminogen by urokinase, but not Lys 77-plasminogen (Cummings 
& Castellino 1985). In this respect, it is worth mentioning that anti-pig 3 appeared to 
enhance plasminogen activation (see Table 3.2, Column 1 ), although this enhancement 
was not significant. This enhancement was not attributed to either plasminogen or 
antibody being rate limiting or different preparations of plasminogen, since a dose-
response curve (data not shown ) was performed with various dilutions of the 
monoclonal antibodies and the concentration of the monoclonal antibody used in the 
experiments reported in this chapter was maximal. No changes was observed when 
different preparations of plasminogen and of the same concentration were used. A 
precedent for activation of an enzyme by a monoclonal antibody has been found before in 
the case of ~-Galactosidase, where inhibitory, neutral and activating antibodies were 
demonstrated (Frackelton & Rotman 1980). 
Previous work has identified a requirement for protease activity in enabling 
expression of plasminogen activator activity by cell lines in vitro (see Chapter 1 ). 
Plasmin has been indicated as one probable mediator of the conversion of inactive 
proenzyme to active plasminogen activator, and it has a specificity consistent with the 
proposed cleavage of the amino acid sequence of single-chain proenzyme to that of active 
two-chain enzyme. Thus, the peptide bond at lysine 158-isoleucine 159, as well as the 
Arg 156-phenylalanine 157 are likely plasmin cleavage sites (Gunzler et al., 
1982a,b). The N-terminal amino acid of the B chain of active enzyme is isoleucine, and 
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the C-terminal amino acid of the A chain is arginine (Frackelton & Rotman 1980; 
Gunzler .e.Lal., 1982a,b). Since the amino acid sequence of urokinase is known (Gunzler 
fil...al., 1982a,b), the conversion of HPA52 into HPA36 can be explained on molecular 
basis. The Lys-Lys bond at positions 135-136 in the urokinase A-chain is prone to 
attack by plasmin (Gunzler fil...al., 1982b; Cederholm-Williams 1984; Sumi & Robbins 
1983), resulting in the removal of the kringle and N-terminal region. Cleavage by 
plasmin at this position therefore results in the formation of a high (HPA52) and a low 
(HPA36) Mr form. This low Mr form of urokinase (HPA36) is enzymically similar to 
the large form with respect to retaining plasminogen activating activity (Barlow fil.....al., 
1981). 
By selective use of these antibodies, it was possible to elucidate the role of 
plasmin in plasminogen activator expression in cell cultures of COLO 394. These cells 
secreted an inactive form of a urokinase type activator, which was converted to its active 
form when plasminogen containing traces of plasmin was present. The monoclonal 
antibodies employed here to investigate this conversion had absolute specificity 
compared with similar studies carried out previously using Trasylol. 
The anti-pig antibodies completely inhibited the conversion of the proenzyme of 
plasminogen activator secreted by COLO 394 cells to active enzyme, thereby establishing 
a definitive role for plasmin in activating the proenzyme of plasminogen activator in 
this in vitro system. 
Plasmin could be an in vivo physiological activator of urokinase proenzyme 
secreted by both malignant and normal cells because of the abundance of plasminogen in 
the extracellular fluid and because plasmin can enter the interstitial fluid (Fahey & 
McLanghlin 1963). Furthermore, only trace quantities of this protease are sufficient to 
activate urokinase proenzyme. It also appears that one chain urokinase PA (i.e. 
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proenzyme) is the most abundanVcommon form of PA produced by malignant human 
cells as our studies demonstrated (chapter 4). 
Other proteases were not tested as activators of the proenzyme of COLO 394 cells 
but plasmin has been shown to be 20 fold more potent in the activation of pro-urokinase 
PA in HF cell than is trypsin or thrombin (Eaton et al.,1984). Wun et al., (1982) 
noted that plasmin was a more effective activator of HEP2 cell urokinase proenzyme PA 
than was thrombin, plasma kallikrein or factor Xlla. 
In the study reported in this chapter, it was shown that plasmin could be a 
physiological activator of urokinase proenzyme secreted by both malignant and normal 
cells because plasmin can enter the interstial fluid (Fahey & Melaughlin, 1963). 
Studies by others have shown that pro-urokinase from normal human foreskin 
fibroblasts or HEP 2 cells could be activated by thrombin, plasma kallikrein or factor 
Xlla, although much less efficiently. Werb & Aggeler (1978) have also shown that 
tissue kallikrein, activated factor X and a tissue kallikrein-like enzyme from 
conditioned medium of cultured melanoma cells could convert the single chain t-PA to the 
two-chain form. Others, as yet undiscovered, exogenous proteases could also activated 
pro-urokinase PA. The early increase of t-PA activity after injection with live but not 
lethally irradiated, tumorigenic cells into a mouse model by Colombi et al., (1986) is 
compatible with the hypothesis that tumorigenic cells might release factors able to 
activate the proenzyme. 
In addition to their use in affinity purification, the availability of these 
monoclonal antibodies will facilitate the definition of the role of plasmin in the 
mechanisms of extracellular matrix degradation mediated by inflammatory cells as well 
as by tumour cells and in other functional processes thought to be mediated by plasmin. 
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CHAPTER 4 
PROENZYME CONTENT OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR IN 
COLORECTAL CARCINOMAS AND ADENOMATOUS POLYPS: QUANTITATIVE 
EXPRESSION AND RELATIONSHIP TO DEGREE OF INVASION 
INTRODUCTION 
Human plasminogen activating enzymes (HPA) exist in at least two forms 
distinguish from each other by Mr, immunological reactivity (for reviews see 
Christman .et..fil., 1977; Astrup 1978; Collen 1980; Dano et al., 1985) and genomic 
composition (Steffens .fil...al., 1982; Edlund .fil...al., 1983; Pennica .eLat., 1983; Ny fil..fil., 
1984). Where as the human PA of Mr 66,000 (HPA66) is mainly found in vascular 
endothelium and has specialised fibrinolytic activity (Matsuo .e.La1 ., 1981; Mattsson .e.t 
.a.1.., 1981 ), the enzyme of 52,000 (HPA52), also known as urokinase, has been 
identified at sites of physiological and pathological tissue injury (see Chapter 1 ). 
Increased levels of HPA52 have been found in extracts of human cancer tissues 
(Markus et al., 1980; Camiolo et al., 1981; Evers et al., 1982; Corasanti et al., 
1980; Elliot et al., 1984; Nagy et al., 1977) and there is evidence that secretion of 
HPA52 provides an important mechanism by which cancer cells invade and digest the 
intercellular matrix to permit invasion of normal tissue (see Chapter 1 ). 
Recently, HPA52 has been identified in homogenates of colon cancer tissue 
(Corasanti .et..a.1., 1980; Elliott .et..aJ.., 1984) and in the supernatant of neoplastic cell 
lines (Nielsen et al., 1982). Several studies suggest, however, that HPA52 is 
secreted as an inactive proenzyme which, as shown definitively in Chapter 3, requires 
proteolytic cleavage by plasmin to express activity. Because previous assays of 
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HPA52 in tissue homogenates used methods which do not permit the independent assay 
of active and proenzyme forms, this Chapter reports the development of a method 
which enables us to quantify the proportion of enzyme present in each form in order to 
provide a more detailed insight into the relationship between HPA52 expression, its 
molecular form and the development of colon cancer. 
Clinico-pathological observations suggest that the majority of colon cancers 
arise from pre-existing adenomatous polyps by evolution through identifiable stages of 
epithelial dysplasia from mild to severe to carcinoma in situ (Muto .e.t_al., 1975). The 
aim of this study was to determine whether the expression of HPA52 is a correlate of 
malignant transformation in the colonic epithelium by comparing active and proenzyme 
levels of HPA52 in colon cancers and adenomatous polyps exhibiting different stages of 
dysplasia with those in metaplastic polyps, which do not predispose to malignant 
change (Kaye .e.t_al., 1973), and histologically normal tissues from the same patients 
and from control subjects. 
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MATERIALS AND METHODS 
Tissue Samples and Homogenisation 
Fresh polyps together with autologous normal mucosa were obtained 
immediately after removal from patients undergoing colonoscopic polypectomies while 
normal mucosa, polyps (when present) and carcinoma were also obtained from surgical 
resection for colon carcinoma. The tissues were dissected free from the muscularis 
mucosa and washed with Hank's balanced salt solution before they were divided into 2 
parallel tissues. Two samples of each tissue specimen were obtained. One was fixed 
in buffered formalin for histology and Dukes' grading for carcinomas and the other 
piece was stored frozen at -20 ° C in homogenisation buffer (50 mM glycine buffer pH 
7.8 containing 0.5°/o Triton X-100). Pedunculated polyps were cut into sections 
comprising the apical, middle, lower thirds and the stalk and stored frozen in 
homogenisation buffer at -20° C until assayed. 
Twenty seven adenomatous polyps comprising 14 tubular, 9 tubulovillous and 4 
villous and 7 metaplastic polyps were processed by conventional histological 
techniques and their epithelial dysplasia and types were classified according to the 
criteria described by Konishi and Morson (1982). Polyp size was measured in freshly 
isolated specimen as the largest diameter. Twenty colon cancers were studied and 
graded by Dukes' classification (Morson & Dawson 1979). 
Thawed materials were later gently blotted, weighed and hand homogenised 
with a glass homogeniser in the presence or absence of 600 ng of the monoclonal 
antibody anti-pig 3, using 1 O ul of homogenisation buffer per mg (wet weight) of 
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tissues. After centrifugation for 4 minutes at 8000 g using a Zentrifuge 3200 
(Eppendorf), the supernatants were removed for assay and diluted 1 :1 O with 
homogenisation buffer prior to assay. 
Monoclonal Antibodies 
The monoclonal antibodies inhibitory to human plasmin, anti-pig 1 and anti-pig 3 
as described in Chapter 3, were used to distinguish the proenzyme from the active 
enzyme activity of HPA52 in tissues. 
Colorimetric-Antibody Assay for both the plasminogen activator proenzyme and 
total enzyme content of the tissue homogenates were quantified by modification of the 
colorimetric assay method of Coleman & Green (1981) as described in Chapter 2, 
section 2.12 using monoclonal anti-plasminogen antibodies as previously described 
(see Chapter 3). 
Effect of DFP on Pro-activator and Activator using SOS-PAGE and 
Fibrin Overlay Zymogram 
The method of Granelli-Piperno & Reich (1978) was used to detect the effect of 
the various additions and DFP on the plasminogen activator proenzyme and active 
enzymes of the tissue homogenates, using the fibrin overlay development process 
after SOS-PAGE as described previously in Chapter 2, Section 2.6. 
RESULTS 
Zymograms of plasminogen activators in homogenates and the effect of 
monoclonal anti-pig 1 and DFP. 
To determine the nature of plasminogen activators expressed in colonic polyps 
and colon cancers, the SOS-PAGE fibrin overlay gel system was used to identify the 
different types of the enzyme and to determine whether they are represented in 
tumour tissues as proenzymes or in their active forms. As shown previously (Elliott 
et al., 1984), mucosa! homogenates from both adenomatous polyps and colon 
carcinomas express the ubiquitous 66,000 Mr enzyme of endothelial origin (HPA66) 
and the urokinase-type plasminogen activator of Mr 52,000 (HPA52). The latter also 
has an active degradation product of Mr 36,000 (HPA36) (lane 3, figures 4.1 and 4.2) 
which is formed when HPA52 is incubated in the presence of plasminogen containing 
traces of plasmin. 
Cleavage of the proenzyme of urokinase-type plasminogen activator to its 
active form was mediated by plasmin (see Chapter 3), and this finding was exploited in 
the experiments outlined here by using the ability of monoclonal antibodies inhibitory 
to plasmin and the plasmin inhibitor, Trasylol to inhibit the conversion of the 
proenzyme to its active form. 
As the plasminogen used in the assay contains trace amounts of plasmin, it was 
preincubated with the monoclonal antibody inhibitory to plasmin, anti-pig 1, for 2 hrs 
at 37 °c before incubation with the tissue homogenates. In other experiments, the 
plasmin inhibitor, Trasylol was added to both the plasminogen and the homogenates to 
inhibit in YillQ. activation of plasminogen by plasmin present in the tissue homogenates. 
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Figure 4.1 SDS-PAGE zymogram analysis of the effect of DFP and 
anti-plg 1 on the conversion of the plasminogen activators in 
homogenates of colorectal carcinomas treated with plasminogen 
preteated with:- anti-plg 1 (lane 1), anti-plg 1 and treated with DFP 
(lane 2), assay buffer only (lane 3), assay buffer and treated with 
DFP (lane 4), Trasylol (lane 5), Trasylol and treated with DFP 
(lane 6). Zones of lysis are : (A) Mr 85000 (plasmin), (B) Mr 66000 
(tissue type PA), (C) Mr 52000 (urokinase-type PA), (D) Mr 36000 
(degraded urokinase type PA) 
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Figure 4.2 SOS-PAGE zymogram analysis of the effect of DFP and 
anti-plg l on the conversion of the plasminogen activators in 
homogenates of adenomatous polyps treated with plasminogen pretreated 
with:- anti-plg l (lane 1), anti-plg land treated with DFP (lane 2), 
assay buffer only (lane 3), assay buffer and treated with DFP 
(lane 4), Trasylol (lane 5), Trasylol and treated with DFP (lane 6). 
zones of lysis as in Figure 4.1. 
Inhibition of plasmin in the plasminogen used in the assay and in the tissue homogenates 
prevented the degradation of HPA52 to its active breakdown product of Mr 36,000 
(HPA36) as shown in lanes 1 (anti-pig 1) and 5 (Trasylol). To discern the extent to 
which the plasminogen activators were present in proenzyme form, the tissue 
incubates were treated with the irreversible inhibitor of serine proteases, 
diisopropylfluorophosphate (DFP). As shown in lane 2 (Figure 4.1 & 4.2), HPA52 was 
expressed strongly after DFP treatment in both polyps and colorectal carcinoma, 
indicating that this enzyme is present predominantly in the proenzyme form, in which 
the active site is inaccessible to D FP. By contrast, only a small proportion of the 
HPA66 exists as proenzyme in adenomatous polyps (Zone B, Fig. 4.2, lanes 2 & 6) 
whereas only the active form of the enzyme is detectable in colorectal carcinoma 
(Zone B, Fig. 4.1, lanes 2 & 6). In the case of tissue homogenates incubated with 
untreated plasminogen and DFP, however, all the plasminogen activator bands 
disappeared (Figs. 4.1 & 4.2, lane 4) indicating that all the plasminogen activator 
proenzyme present had been activated and consequently the active site was then 
accessible to DFP. 
The plasmin band seen in the gels (Zone A, lanes 3 & 4) was due to the 
activation of plasminogen by traces of plasmin contained in the plasminogen 
preparation resulting in activation of the proenzyme to its active form, which in turn 
generated increasing amounts of plasmin from plasminogen at the location of the band 
on the SDS fibrin agarose gel. However, when the plasminogen preparation was 
incubated with either Trasylol or anti-pig 1 antibody, the plasmin band could not be 
seen since anti-pig 1 antibody and Trasylol bound to the plasmin present and hence 
prevented the conversion of the proenzyme to its active form, and the subsequent 
formation of more plasmin. 
Plasminogen activator HPA52) content 
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To determine the expression of plasminogen activator HPA52 in its active and 
proenzyme forms, and its relationship to the development of malignancy in more 
detail, quantitative assays were developed. The total content of HPA52 (i.e. 
proenzyme plus active enzyme) in homogenates of tissues could be measured by the 
colorimetric assay because the plasminogen substrate used contained trace amounts of 
plasmin sufficient to activate all of the proenzyme present (see Chapter 3 and also 
Figures 4.1 and 4.2, lane 3). Combination of the colorimetric assay with the selective 
use of monoclonal antibodies inhibitory to plasmin, allowed both the proenzyme and 
active enzyme content of tissues to be measured. 
The importance of this novel method rests on the ability of the monoclonal 
antibody not only to inhibit plasmin in the plasminogen substrate but also to rapidly 
inhibit any plasmin generated by pre-existing active enzyme during the assay. In 
addition, the antibody used did not inhibit plasminogen activation. Thus when anti-pig 3 
antibody was preincubated with plasminogen before the addition of tissue homogenates, 
the trace amounts of contaminating plasmin present in the preparation were inhibited, 
thereby preventing the conversion of proenzyme to its active form. 
The colorimetric assay, in the absence of added fibrin, measured exclusively 
HPA52 since negligible HPA66 activity was detected when cell-free culture 
supernatant of the human melanoma cell line MM-170 (Whitehead & Little 1973) was 
used as a source of HPA66 (data not shown). Direct hydrolysis of the lysine thioester 
plasmin substrate by plasminogen-independent neutral proteases in the tissue 
homogenates did not contribute significantly to color development. Under conditions 
identical to those used for tissue homogenates, 2 mPloug units (equivalent to about 
2.8m Committee on Thrombolytic Agents [CTA] units) of commercial urokinase 
produced an absorbance of 1.0 at 412 nm. As shown in Figure 4.3, the assay of known 
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activities of commercial HPA52 (urokinase) was unaffected by the presence of 
possible inhibitors in the tissue homogenates. 
Although the results are expressed as absorbance, nevertheless, this 
represents the activity in 200 ug of tissue. The homogenisation technique is 
reproducible since several separate homogenisations of specimens from the same 
normal mucosa all showed the same enzyme activity. Unfortunately, activity in the 
sedimented fractions was never assayed but little activity would be expected since the 
homogenisation technique used is efficient and reproducible. 
(i) Colorectal Carcinomas. The total and proenzyme plasminogen activator 
contents of the colon cancer homogenates, graded according to Dukes' classification, 
and their corresponding normal tissue homogenates are shown in Figures 4.4 and 4.5. 
When plasminogen activator activity was assayed in the homogenates of colon 
cancer tissue, the activity of all cancer grades was 1.22 + 0.41 for total enzyme and 
0.86 + 0.38 for the proenzyme. By contrast, the corresponding homogenates from 
histologically normal adjacent mucosa showed markedly lower activity of total 
enzyme (0.55 + 0.18) and proenzyme content (0.26 + 0.11 ). Thus the mean level of 
proenzyme was more than three times higher than in normal tissue homogenates. In 
addition, the proportion of HPA52 proenzyme present in cancer tissue was 
substantially higher (70 + 3°/o) than that found in histologically normal mucosa from 
cancer bearing colons (47 + 2°/o). 
In every case analysed, the total activator content of cancer homogenates was 
very much higher than that of the normal tissue homogenates from the same patient, 
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even though there were considerable individual variations in plasminogen activator 
activity. The ratio of absorbances for pairs of cancer to autologous normal mucosa! 
homogenates was 2.09 + 1.3 (unpaired 2.22) for the total enzyme and increased to 
3.94 + 3. 79 (unpaired 3.48) for the proenzyme. 
The relationship of HPA52 in colon cancers graded according to their stage of 
dissemination at surgery using the Dukes' classification was also examined. For total 
HPA52 activity, each of the Dukes' grades showed significant increases when 
compared to the activity present in adjacent normal mucosa but no statistically 
significant difference was detected between the grades (Fig. 4.4). Significant 
differences were observed however, in the proenzyme contents of the Dukes' grades 
A, B and C + D (Fig. 4.5). 
(ii) Colonic Polyps Both total HPA52 activities and the amount of proenzyme were 
assayed in metaplastic polyps and in adenomatous polyps which were classified as 
tubular, villous and tubulovillous. As shown in Figures 4.6 and 4.7, the total (0.43 + 
0.15) and proenzyme (0.31 + 0.1) content of metaplastic polyps were similar to those 
observed in histologically normal tissue (0.48 + 0.26 and 0.25 + 0.17 respectively). 
By contrast, all three histological types of adenomatous polyp, displayed significantly 
higher values for both the total and the pro enzyme activity. In addition, 68-72 °/o of 
the plasminogen activator content in the adenomatous polyps existed as preonzyme. 
Neither the size of polyps (range 3 to 45 mm) nor the degree of dyplasia 
correlated with either the total or the proenzyme content of the polyps (data not 
shown). However, when the polyps were assayed in sections correponding to the 
upper, middle and lower thirds and stalk, the highest activities were found in the upper 
third of the polyps and the lowest in the basal third or stalk as shown in Table 4.1. A 
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similar gradient was also observed for proenzyme content. In 6 cases where 
metachronous polyps were present in colons bearing cancers, both the total and 
proenzyme content were found to be immediate between those for the cancer and those 
for normal mucosa (data not shown). In the 2 cases of familial polyposis coli patients 
studied, both the histologically normal mucosa and the polyps expressed high HPA52 
activtiy (see arrows Figures 4.6 & 4.7). 
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normal mucosa homogenate only, ( D······{] ) assay buffer only. 
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Figure 4.4 The relationship of Dukes' grading of colorectal carcinoma to the total 
activity of HPA52 in tissue homogenates of colorectal carcinomas and normal adjacent 
mucosa. Activity is expressed as absorbance at 412 nM. Under the same assay 
conditions, an absorbance of 1.0 at 412 nM is equivalent to 2mPU of commercial 
urokinase. (see Figure 4.3). Non-parametric test: Mucosa vs Dukes' B & C + D (P < 
0.01 ). Dukes' A vs Dukes' C + D (P < 0.05) 
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Figure 4.s· The relationship of Dukes' grading of colorectal carcinoma to the 
proenzyme content of HPA52. Activity is expressed as in Figure 4.4. Non-parametric 
test: Mucosa vs Dukes' B & C + D (P < 0.01 ). Mucosa vs Dukes' A (P < 0.05). Dukes' A 
vs Dukes' 8, C + D (P < 0.01 ). Dukes' B vs Dukes' C + D (P < 0.05). 
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Figure 4.7 Proenzyme content of HPA52 in colonic adenomatous polyps, metaplastic 
polyps and normal adjacent mucosa . .__ 1,2 denotes polyposis coli patients. Mucosa vs 
tubular, villous and tubulovillous (P < 0.01 in all cases). Metaplastic vs tubular, 
villous and tubulovillous (P < 0.01 in all cases). 
TABLE 4.1 
TOTAL AND PROENZYME UROKINASE CONTENT OF COLORECTAL POLYPS 
AT DIFFERENT MORPHOLOGICAL LEVEL. 
ABSORBANCE 412 nm 
CASE TISSUE TOTAL ENZYME PRO ENZYME 
L.M.R. Upper Half 1.612 1.049 
Lower Half 1.203 0.721 
Mucosa 0.542 0.043 
H.E. (A) Upper Third 1.110 0.648 
Middle Third 0.661 0.373 
Lower Third 0.630 0.362 
(B) Upper Third 0.800 0.423 
Middle Third 0.880 0.501 
Lower Third 0.694 0.398 
Stalk 0.615 0.226 
W.M. Upper Half 0.543 0.327 
Lower Half 0.523 0.302 
Stalk 0.267 0.114 
J.B. Upper Half 0.683 0.503 
Lower Half 0.631 0.475 
Stalk 0.479 0.341 
J.J. Upper Half 1.560 1.336 
Lower Half 0.929 0.801 
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DISCUSSION 
Using a sensitive colorimetric assay under conditions which were highly 
favorable to HPA52 proenzyme activation and therefore measured total enzyme 
content (i.e. proenzyme and active enzyme), this study demonstrates marked 
increases in the level of HPA52 activity in both adenomatous polyps and colon cancer, 
compared to paired specimens of histologically normal mucosa. Similar findings have 
been reported by Corasanti and co-workers (1980) who used an azocaseinolytic assay 
but whether the activity measured in tissue homogenates represents active enzyme, 
proenzyme and active eznyme, or active enzyme with substantial contribution from 
the proenzyme is unclear. Although apparently conflicting results have been reported 
by several groups, who found higher levels of plasminogen activator activity in normal 
mucosa and in the non malignant elements of cancers than in cancer tissues, these 
workers used a fibrinolytic assay which measures both HPA52 and the ubiquitous 
tissue plasminogen activators (Franklin fil.al., 1978; Szczepanski .e.Lal., 1982; Tissot 
et al., 1984). In addition, the fibrinolytic assay is more sensitive to the latter type of 
plasminogen activator which is also found at much higher levels in normal mucosa and 
submucosa than in cancers (Kohga et al., 1985). The results of greatly increased 
HPA52 activity reported in this Chapter are therefore at variance with those obtained 
by the fibrinolytic assay because the latter assay essentially measures tissue 
plasminogen activators and does not adequately reflect HPA52 enzyme activity. 
The selective inhibition of plasmin using a monoclonal antibody inhibitory to 
human plasmin, has enabled the proenzyme and active enzyme content of HPA52 in 
tissue extracts to be determined for the first time. The results reported in this 
chapter demonstrate that a significant proportion of the plasminogen activator in 
adenomatous polyps and in colorectal carcinomas exists in the proenzyme form. 
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Moreover, all the normal tissues studied also contain low levels of HPA52 proenzyme. 
In the absence of anti-pig 3 which blocks plasmin, there was a considerable increase in 
the activity of the colorimetric assay, confirming that the predominant form of H PA52 
in adenomatous polyps and colorectal carcinomas was the proenzyme. In the absence 
of added fibrin in the colorimetric assay, the type of plasminogen activator activity 
could only be attributed to the HPA52 and not to the ubiquitous HPA66 enzyme 
produced by endothelial cells. The recent immunohistochemical studies of Kohga .e.Lal., 
(1985) using antibodies specific for urokinase supports this conclusion. 
The finding described in this chapter that the majority of the plasminogen 
activator was present as pro-HPA52 in both the colorectal carcinomas and 
adenomatous polyps was further substantiated by the results of DFP treatment 
followed by SDS-polyacrylamide electrophoresis and fibrin overlay gel zymography. 
Recent immunoblotting studies by Skriver et al., (1984) in the mouse Lewis lung 
carcinoma model have also shown that the majority of MPA48, the mouse analogue of 
HPA52, is present as the proenzyme. Taken together, the data suggest that the 
majority of plasminogen activator of the urokinase-type exists in tissues as the 
proenzyme. In support of this conclusion, the proenzyme forms of virus-transformed 
murine cells in culture (Skriver fil.Jll., 1982), and of human cells of neoplastic origin 
(Nielsen .e.Lal., 1982) have been well documented and have been shown to be the major 
enzyme form of plasminogen activators produced, and secreted, during culture. 
Andreasen et al. (1985) using fractions of t-PA from supernatants of 
human melanoma cell lines (Bowes) purified by a single step monoclonal antibody 
showed the incorporation of the active site reactant DFP into pro-t-PA but not into 
pro-urokinase PA. In the data shown in this chapter and by Stephens (personal 
communication), DFP was incorporated in similar manner to that seen in the pro-
urokinase PA. Whether this represents different properties in the t-PA in the 
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colorectal tissues compared to the Bowes cell lines is unclear. Electricwala & 
Atkinson (1985) describe the purification of two epithelial plasminogen activators 
from guinea pig keratocytes and human breast epithelial cells and showed that while 
these activators are immunologically identical to, and functionally behave like, human 
t-PA, their properties showed differences in isoelectric point, molecular mass and N-
terminal amino acid sequence from melanoma PA. Furthermore, the melanoma Bowes 
cell line is not necessarily representative of the corresponding cell types in the intact 
organism with respect to production and release of plasminogen activators, because 
selection of cells i.e. phenotypic changes may take place when cultures are established, 
and because they may be differences in the presence of regulatory factors between the 
microenvironments of cells in the intact organism and in culture. 
It is possible that t-PA as well as urokinase PA, could also have a role in 
tumour invasion and metastasis. Colombi .e.L.at., (1986) reported the sudden increased 
stimulation of t-PA type activity following injection of tumorigenic cells and the 
oradual increase of urokinase PA in plasma of Balb/C mice given injections of non 
metastasizing cell lines. The t-PA may function to maintain the vascular tree free of 
fibrin allowing the extravasation of tumorigenic cells to form metastases. 
The finding of similar proenzyme and total PA content in benign tumour 
(metaplastic polyps) with that of histologically normal mucosa is not surprising. The 
production of plasminogen activators per se does not induce malignant behaviours in 
cells, but possible defects in the control of enzyme activity (or the activation of the 
secreted proenzyme) at the pericellular level may account for several of the growth 
properties of individual cells in the heterogenous population of tumour cells (Dexter & 
Calabresi 1982). The decisive difference between cancer cells and normal cells with 
regard to the mechanisms of tissue degradation is related to its regulation. Loss of 
actin organisation after treatment with tumour promoters in cultured, histologically 
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'late-stage' cells from human pre-neoplastic colon adenoma was connected with 
increased production of PA by these cells, whereas the actin structure of 'early-stage' 
preneoplastic adenoma cells not producing PA was unaffected by the promoters used 
(Friedman et al., 1984). This might indicate that the observed loss of actin 
organisation linked with production of plasminogen activators marks the transition 
from non-invasive early-stage tumours to invasively growing late-stage tumours. 
Plasmin is thought to play a crucial role in this transition. This observation could now 
be confirmed with the use of the monoclonal antibodies inhibitory to human plasmin 
( chapter 3). 
In the study of the transplantable invasive and metastasizing murine Lewis lung 
tumour (Skriver .e.t..al., 1984), it was consistently found that the tumour contained both 
urokinase PA immunoreactivity and extractable urokinase PA enzyme activity. The 
most intensive staining was observed in areas with invasive growth and degradation of 
normal tissue, while in large parts of the tumours, where no invasion and degradation 
of normal tissue occurred, there was no demonstrable urokinase PA immunoreactivity. 
No immunocytochemical studies of the occurrence of urokinase PA in benign tumours 
and of t-PA in malignant and benign tumours have been reported. 
Proteolytic activation of proenzyme to active enzyme has been definitively 
demonstrated to be mediated by plasmin (see Chapter 3) since the monoclonal 
antibodies used have absolute specificity compared to Trasylol. The extent of this 
conversion 1..o_ vivo, is clearly important for the extracellular expression of 
plasminogen activator. 
The role of plasmin in invasiveness by cancer cells has also been suggested by 
immunofluorescence studies using anti-plasminogen antibodies which stained the 
contours of tumour foci and tumour cells (Burtin .et...a.l., 1985). Plasmin may therefore 
be required to activate the proenzyme of HPA52 in vivo thereby equipping tumour cells 
with a mechanism for their migration through restraining tissue structures both to 
invade and metastasize. The expression of HPA52 activity and the consequent 
initiation and amplification of a proteolytic cascade in the intercellular matrix in vivo 
is therefore likely to be influenced by the availability of proteases, such as plasmin, in 
the extracellular fluids. 
Studies of HPA52 proenzyme levels in colon cancers show significantly 
increased levels for the Dukes' B and C + D stages when compared to the Dukes' A 
stage and normal mucosa! levels. Although the numbers are small, there appears to be 
a gradient of proenzyme activity corresponding to the extent of invasion of the 
tumour. In addition, the proportion of proenzyme to active enzyme was substantially 
higher in the advanced stages B and C + D (69 & 76°/o) compared to Dukes' A (45°/o) 
and normal tissue (47°/o). A similar correlation showing that the higher the HPA52 
content in cancer tissue, the worse is the prognosis has also been reported recently 
for breast cancer (Yang .fil....al., 1982). Recent reviews have summarized systematic 
studies that also showed that the mean PA content of human tumours of the lung, colon, 
prostate and breast was higher than in the presumed normal tissues of origin 
(Corasanti .e.t.al ., 1980; Markus et al., 1980; Evers et al., 1982; Camiolo .fil....al., 1 984). 
In the case of the breast tumours, using an assay carried out in the absence of fibrin, 
Evers .et..al. {1982) concluded that urokinase PA was the main form of PA in human 
breast carcinomas. O'Grady .e.t.at., {1985) showed that t-PA is the dominant form in 
benign breast tumours with urokinase PA only contributing approximately 10°/o of the 
total PA activity. However, all the malignant groups (primary carcinomas, axillary 
node metastasis and recurrences) contained significantly higher urokinase PA activity 
compared with the benign samples. 
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Further studies however are required to determine the significance of these findings 
to the invasive process of malignancy. In this context, immunohistochemistry of the 
murine Lewis lung carcinoma suggests that the mouse analogue of HPA52 is expressed 
principally at areas of invasive cancer growth and associated normal tissue 
degradation (Skriver et al., 984) whereas in the human carcinoma HEp3 model, 
antibodies which inhibit H PA52 activity prevent metastasis but not the primary 
tumour growth (Ossowski et al., 1983). Thus HPA52 may subserve different 
functions at different phases of cancer developmwent. 
Significantly increased levels of HPA52 enzyme activity were found in all three 
types of adenomatous polyps when compared to metaplastic polyps and normal colonic 
mucosa. The majority of HPA52 was present as proenzyme as was found for the 
invasive stages of colon carcinoma. These findings support the histopathological data 
as to the premalignant nature of the adenomatous polyps and offer a biochemical 
correlate of epithelial cell transformation. However, these findings suggest a 
mechanism by which the hallmark of the malignant process, invasion of normal tissue, 
may occur. Although the numbers are small, no correlation was found between the 
degree of epithelial dysplasia and the level of HPA52 expression. The variations in the 
degree of dysplasia within single polyps however, made the study of the relationship 
between dysplasia and HPA52 levels very difficult. Largers numbers of more 
uniformly dysplastic polyps are required to establish or refute such a relationship. 
When the site of HPA52 expression in polyps was studied, there was 
significantly greater proenzyme activity in the upper or apical third of the polyp than 
in the basal third or stalk. This may suggest that the site of biochemical 
transformation to increased HPA52 levels occurs first in the most exposed part of the 
polyp and correlates with recent histopathological studies showing that the earliest 
site of malignant transformation in adenomatous polyps usually occurs in the apical 
third (Haggitt et al., 1985). Both histologically normal colonic mucosa, and 
adenomatous polyp tissue from two patients with familial polyposis coli, displayed high 
levels of HPA52. These finding are at variance with those of Corasanti .e.1....al., (1980) 
who reported low levels of plasminogen activator activity in both non-polypoid and 
cancer tissue from polyposis coli patients. This discrepancy may be due to the 
relative insensitivity of the azocaseinolytic assay used in that study. 
Other enzymes that have been found to be elevated in colorectal cancer 
have included collagenases (for a review see Woolley 1982) and P-hexosaminidase 
(Plucinsky .e.t..a.1., 1986). In the report by Plucinsky .eLaI. (1986), the authors found 
that the mean P-hexosaminidase activity and specific activity in crude supernatants of 
malignant colon tissue were significantly increased compared to those in the adjacent, 
uninvolved normal tissue. This increased enzymatic activity could be involved in 
tumour invasion of adjacent tissues and the metastatic spread of colorectal cancer, 
since P-hexosaminidase is a degradative enzyme that can hydrolyze glycoconjugate 
components of membranes and extracellular matrices. 
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CHAPTER 5 
CORRELATION AND QUANTITATION OF PROENZYME OF UROKINASE TYPE 
PLASMINOGEN ACTIVATORS IN INFLAMMATORY BOWEL DISEASE 
INTRODUCTION 
Despite intensive research, the aetiopathogenesis of ulcerative colitis and 
Crohn's disease remains unknown. In the absence of a defineable aetiological agents(s) 
[e.g. bacterium, virus, toxin], interest has centred on elucidating the mechanisms of 
tissue injury in the inflammatory lesion of the mucosa so as to provide opportunities for 
more rational therapeutic intervention. 
As mentioned in Chapter 1, plasminogen activators have been implicated in the 
mediation of tissue damage. 
The aim of the experiments reported here was to determine whether the HPA52 
enzyme is selectively expressed at the site of the inflammatory injury in ulcerative 
colitis and Crohn's disease. 
MATERIALS AND METHODS 
Patients 
Biopsies of intestinal mucosa from 23 patients obtained at colonoscopy or 
immediately after intestinal resection were studied. The diagnosis of Crohn's disease, 
ulcerative colitis and infectious colitis were established by accepted clinical, 
microbiological, radiological, colonoscopic and histological criteria. The Crohn's group 
comprised 9 patients, 1 male and 8 females age range 14 to 70 years. Of the 4 in the 
ulcerative colitis group, there were 2 males and 2 females age range 33 to 63 years. 
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Biopsies were obtained from one patient suffering from Campylobacter jejuni colitis and 
from one patient suffering from an acute dysentery where no pathogen was isolated. In a 
further three cases, colonoscopies were performed on patients suffering from 
intermittent abdominal pains and diarrhoea but no definitive diagnosis was apparent at 
colonoscopy or from the histology of the colonic biopsies. 
Multiple biopsies were taken from each patient and where possible involved and 
apparently uninvolved areas of mucosa were sampled from the same patient. Disease 
activity was assessed by colonoscopic appearances and by the histology of mucosa! 
biopsies. The patients were then classified as active or quiescent. 
Uninflamed mucosa was obtained from colonoscopies and intestinal resection 
performed on two groups of patients. The first comprised patients suffering from 
diarrhoea attributed to the irritable bowel syndrome or diverticular disease in whom 
the intestinal mucosa appeared uninflamed, stool microscopy showed no evidence of pus 
cells or red blood cells and the histologically appearances of the biopsy specimens were 
normal. The second control group consisted of tissues from uninvolved colonic or ileal 
mucosa obtained from polyp or cancer-bearing colons. 
Mucosa! tissues, dissected free of muscularis were stored frozen at -20°c in 
homogenisation buffer (50 mM glycine buffer pH 7.8 containing 0.5°/o Triton X100) 
until assayed. Thawed tissues (wet tissues) were later weighed and homogenised as 
previously described in Chapter 4 of Materials and Methods. 
Colorimetric-antibody assay of plasminogen activators 
The modified colorimetric assay of Coleman & Green as described in Chapter 2, 
section 2.12 with the selective use of monoclonal antibodies inhibitory to plasmin was 
used to quantify the proenzyme and total plasminogen activator content of the tissue 
homogenates. The results for the plasminogen activator activities were expressed after 
correction for the direct hydrolysis of the lysine thioester plasmin substrate used in the 
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assay by plasminogen-independent proteases in the tissue extracts by subtraction of 
absorbances obtained in an identical system to which no plasminogen and antibody had 
been added. This usually accounted for less than 5°/o of the total activity. 
SDS-PAGE Fibrin Overlay Gel 
The method of Granelli-Piperno & Reich as described in Chapter 2, section 2.6 
was used to assess the effect of DFP on proactivator and activator as described in detail in 
Chapter 2, section 2.18. 
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RESULTS 
SDS-PAGE zymogram analysis of the effect of monoclonal anti-pig 1 and 
DFP on the plasminogen activators in the tissue homogenates. 
SDS-polyacrylamide gel electrophoresis (SOS-PAGE} with a fibrin overlay gel 
containing plasminogen was used to determine the types of PA present in the mucosa! 
tissue homogenates from IBD and to ascertain the presence of inactive proenzyme PA. 
As shown in chapter 3, inactive proenzyme of HPA52 can be converted to its 
active form by limited proteolysis involving the action of plasmin. Hence, the absolute 
specificity and ability of the monclonal antibodies, anti-pig 1, to selectively inhibit the 
plasmin mediated conversion of prourokinase to its active form was exploited. 
Proenzyme activation was monitored by DFP treatment followed by SOS-PAGE/fibrin 
overlay. 
A preparation of plasminogen containing traces of plasmin was preincubated with 
or without anti-pig 1 antibody for 2 hr at 20° C before the incubate was added to the 
tissue homogenates and incubated at 37° C for a further 45 mins, after which the 
mixtures were incubated in the presence or absence of DFP for 6 hr at 20° C. 
Figure 5.1, lane 5 shows the typical enzyme pattern produced by the 180 
homogenate. A major band of Mr 52,000 daltons (HPA52} was present. Trasylol, a 
rapid and potent inhibitor of plasmin was added to plasminogen containing traces of 
plasmin and the tissue homogenates in these incubations to prevent in vitro activation as 
a result of the presence of plasmin in both the tissues and the plasminogen preparation. 
When this incubate was treated with DFP, an irreversible inhibitor of serine proteases, 
the HPA52 band was unaffected (lane 6). This result indicates that the enzyme of HPA52 
existed predominantly in the tissue as its inactive proenzyme form, whose active site is 
inaccessible to DFP. 
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F i g u r e  5 . 1  S D S - P A G E  z y r n o g r a r n  a n a l y s i s  o f  t h e  e f f e c t  o f  D F P  a n d  a n t i - p l g  1  o n  t h e  c o n v e r s i o n  o f  
t h e  p l a s r n i n o g e n  a c t i v a t o r s  i n  h o m o g e n a t e s  o f  i n f l a m m a t o r y  b o w e l  d i s e a s e  ( C r o h n ' s  d i s e a s e )  t r e a t e d  
w i t h  p l a s r n i n o g e n  p r e t r e a t e d  w i t h : - a n t i - p l g  1  ( l a n e  1 ) ,  a n t i - p l g  1  a n d  t r e a t e d  w i t h  D F P  ( l a n e  2 ) ,  
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( u r o k i n a s e - t y p e  P A ) ,  ( C )  M r  3 6 0 0 0  ( d e g r a d e d  u r o k i n a s e  t y p e  P A ) .  
By contrast, when plasminogen preincubated in the absence of anti-pig 1 
antibody or Trasylol was added to likewise untreated tissue homogenate, a substantial 
proportion of the HPA52 (Zone B) was converted to an active form with a lower Mr of 
36,000 daltons (HPA36; Zone C, lane 3 cf. lanes 1 and 5 when either anti-pig 1 
antibody or Trasylol was present). As shown in lane 4, when the same homogenate was 
treated with DFP, both the HPA52 and HPA36 bands disappeared as expected, since the 
proenzyme form had been activated to its active form and the active site had now become 
accessible to DFP. 
When anti-pig 1 antibody was used to block the plasmin mediated conversion of 
the proenzyme form to its active counterpart, however, a single major band of HPA52 in 
similar pattern to that displayed in Lane 5 was seen (lane 1 ). Again, when the same 
homogenate was treated with DFP, the same lysis band of the same Mr was still present 
indicating that the enzyme existed predominantly in tissue as an inactive proenzyme 
(lane 2). 
The plasmin band with a Mr 85,000 daltons seen in lanes 3 & 4 (Zone A) was the 
result of the activation of plasminogen by HPA52 formed from the action of trace 
amounts of plasmin in the plasminogen preparation acting on the inactive proenzyme 
form of HPA52. The plasmin at the gel surface diffused into the agarose/fibrin 
containing overlay gel causing a lysis band. However, when the plasminogen preparation 
was incubated with either Trasylol or anti-pig 1 antibody, no plasm in band could be seen 
since both anti-pig 1 antibody and Trasylol bound to and inhibit the trace plasmin 
present, and therefore also prevented the conversion of the proenzyme form to its active 
form. 
Plasminogen Activator Content of IBD Tissue Homogenates. 
1 1 1 
By the selective use of the monoclonal antibodies inhibitory to plasmin (see 
chapter 3), it was possible to use the Coleman & Green assay to quantify the proenzyme 
and total enzyme content of IBD tissues as described in chapter 2, section 2.12. The 
novelty of this assay method depended upon the ability of the antibodies to inhibit quickly 
any plasmin formed in the assay and on the absence of inhibition of plasminogen 
activation by the antibodies. 
The monoclonal antibody inhibitory to the plasmin present in the preincubation 
with plasminogen prior to the addition of diluted tissue homogenates, inhibited these 
trace amounts of plasmin and thereby prevented the conversion of the HPA52 proenzyme 
to its active form. 
The level of HPA52 activity was assessed for diseased, quiescent and unaffected 
mucosa! tissues from the IBD intestine. The level was determined for both proenzyme 
and total enzyme (i.e. proenzyme plus active enzyme) as shown in Figures 5.2 and 5.3. 
A significantly higher level of HPA52 was found in diseased mucosa from both 
ulcerative colitis and Crohn's disease patients when compared to paired normal biopsies 
(Table 5.1) or normal resected specimens from the same patients or to mucosa tissues 
from quiescent patients (P < 0.01). Quiescent tissue samples gave a mean activity of 
0.480 + 0.170 for total enzyme content and a mean activity of 0.250 + 0.15 for 
proenzyme content (Figures 5.2 and 5.3), which was in the range determined for 
normal mucosa from carcinoma-bearing colons. The mean total and proenzyme content 
for the uninvolved mucosa (0.45 ± 0.20) and (0.230 ± 0.15) respectively was almost 
identical with that of the quiescent mucosa (0.480 + 0.170) and (0.250 + 0.15). 
When the PA activity was measured in the disease/involved mucosa, the mean 
activity was 1.1 O + 0.39 for the total enzyme content and a corresponding mean value of 
0.80 + 0.27 for the proenzyme content. 
In both the ulcerative colitis and Crohn's disease, the presence of active disease 
corresponded to increased levels of PA activity. The area of the bowel where the tissue 
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displayed the most severe disease, as assessed histologically, was also the area with the 
highest level of active PA. The majority (average 70°/o) of the HPA existed as 
proenzyme consistent with the earlier findings in the colorectal carcinomas and polyps 
(Chapter 4). 
Table 5.2 shows the results for the two disease controls groups studied; 
infectious colitis and a group of undiagnosed chronic diarrhoea patients who were 
suspected of having Crohn's disease but in whom no definite diagnosis could be made. 
Although the numbers are small, the results indicate that the increase in both the total 
and proenzyme content of HPA52 found in inflamed mucosa! tissues is not a finding 
specific to ulcerative colitis or Crohn's disease. 
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TABLE 5.1 
PAIRED SPECIMENS OF INFLAMMATORY BOWEL DISEASE SHOWING 
PROENZYME AND TOTAL ENZYME CONTENT OF HPA52 
DISEASED NORMAL 
TQ!al PrQenzJ'.'.me Total ProenzJ'.'.me 
SC Ileum 1.404 0.973 Rectum* 0.601 0.449 
Caecum1 .029 0.688 Sigmoid* 0.655 0.466 
JM Sigmoid 1 .096 0.598 Descending 0.666 0.252 
Hepatic 0.914 0.614 colon 
flexure 
JT Ileum 0.907 0.729 Rectum 0.614 0.485 
LJ Ileum 1.058 0.857 Rectum 0.127 0.07 
LL Sigmoid 1.041 0.802 Ileum 0.453 0.229 
DB Hepatic 0.878 0.646 Rectum 0.297 0.102 
flexure Sigmoid 0.309 0.058 
RF Sigmoid 0.993 0.695 Sigmoid 0.521 0.228 
(normal) 
-------------------------------------------------------------
* microscopically very mild inflammation but normal colonoscopic appearances 
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TABLE 5.2 
MUCOSAL SPECIMENS OF INFLAMMATORY DISEASE CONTROLS AND 
UNDIAGNOSED CHRONIC DIARRHOEA SHOWING TOTAL AND PROENZYME 
CONTENT OF HPA52 
I nfla m mato ry Disease Controls 
Total Proenzyme 
J L * Ileum 1.037 0.689 
Transverse colon 1 .141 0.668 
Sigmoid colon 1.230 0.776 
Rectum 0.926 0.599 
WG** Rectum 0.430 0.005 
Undiagnosed Chronic Diarrhoea associated with abdominal pain 
CM 
SM 
HR 
Ileum 
Caecum 
Ileum 
Caecum 
Transverse colon 
Ileum 
* - Infective organism unknown 
Total 
0.468 
1.216 
0.608 
0.898 
0.904 
0.482 
** - Campylobacter colitis 
Proenzyme 
0.350 
1.064 
0.565 
0.411 
0.609 
0.296 
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DISCUSSION 
The roles of the plasminogen activators in various biological processess have 
been documented in many studies. Indeed, a number of recent findings, especially in the 
area of cancer, have contributed substantially to a better understanding of the 
biochemistry of the complex proteolytic cascade of reactions leading to the formation of 
plasmin and the participation of PA in a diverse range of tissue degradation processes. 
The association between PA and inflammation has always been guided by the 
hypothesis that the release of PA from inflammatory cells migrating to the site of 
inflammation, caused the proteolysis of components of the extracellular matrix and 
hence played a decisive role in the degradation of normal tissues leading to injury. 
This Chapter reports for the first time, quantitative studies of the expression of 
HPA52 and its different forms (i.e. active enzyme and/or their inactive proenzyme 
form) that were expressed in chronic IBD. 
The SOS-PAGE fibrin overlay gel was used to determine the types of PA and to 
ascertain the presence of proenzyme forms, while the sensitive colorimetric assay was 
used to quantify the amounts of HPA52 in the tissue homogenates. 
The use of the sensitive colorimetric assay with the selective addition of a 
monoclonal antibody inhibitory to human plasmin (see Chapter 3) demonstrated that 
there was a significant increase in the level of HPA52 in the chronic inflammatory 
tissues in comparison with uninvolved tissues or tissues from quiescent patients 
(P<0.01 ). 
The majority of the HPA52 in chronic IBD was presented to the extracellular 
milieu in its inactive form. Although it is impossible to define the cellular origin of the 
urokinase PA found in IBD using the enzyme assays, nevertheless, it is intriguing to 
speculate that the source of the urokinase PA might be from the activated macrophages or 
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from the epithelial cells. A definitive answer would certainly have to involve the use of 
immunocytochemistry. Both Crohn's disease and ulcerative colitis are chronic 
inflammatory disorders of the intestine of unknown aetiology. Macrophages are 
prominent in the inflammatory cell infiltrate in both conditions, but in Crohn's disease, 
a hallmark of the condition is the granuloma, where macrophages are particularly 
conspicuous. Evidence (Tanner .ei_m., 1984) has been presented to indicate that in IBD, 
circulating monocytes are in an activated state and recuitment of these monocytes to the 
sites of tissue injury is evident both on histological grounds and on kinetic data. 
Therefore, the release of PA could just be one of the secretory products of the activated 
macrophages. Alternatively, the studies on pemphigus indicate that cells obtained from 
the normal dermis can be induced to secrete plasminogen activators when treated with 
the autoantibody that is found in the circulation of pemphigus patients. 
To date, no studies have been performed on isolated human colonic epithelial 
cells to determine its ability to secrete HPA52 when either stimulated or induced. A 
report by Electricwala & Atkinson (1985) described the purification of two epithelial 
plasminogen activators from guinea pig keratocytes and human breast epithelial cells. 
These authors showed that while these activators are immunologically identical to, and 
functionally behave like, human t-PA, their properties showed differences in isoelectric 
point, molecular mass and N-terminal amino acid sequence from melanoma PA. These 
finding are not representative of all epithelial cell PA since the COLO 394 cell reported 
in Chapter 3 showed the secretion of HPA52. 
On the other hand, the secretion of PA has been shown to correlate well with 
macrophage activation (Unkeless .e.Lal.., 1974a) suggesting that the induction of the 
synthesis and secretion of PA may well depend on a number of sequential metabolic 
changes. 
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No quantitative data are available on the proportions of macrophages present in 
IBD tissue and in colon carcinoma tissue and no attempt was made to isolate macrophages 
from these tissues in order to measure pro PA and PA since it was not possible to obtain 
sufficient tissues to undertake the task. 
The expression of the HPA52, whether in term of proenzyme or total enzyme, 
appears to be uninfluenced by the therapeutic administration of steroids in the therapy 
of these patients. 
Previous studies of enzyme markers of inflammatory cells in the IBD 
using rectal biopsies showed that patients with ulcerative colitis have decreased activity 
of the lysosomal marker enzymes, N-acetyl-~-glucosaminidase, and acid phosphatase 
in both active and quiescent colitis. ~-glucuronidase was only significantly reduced in 
acute colitis (O'Morain et al., 1984). Danovitch fil...al. (1972) have found decreased 
concentrations of arylsulphatases and ~-glucuronidase but surprisingly, increased 
concentrations of acid phosphatases in biopsy tissue homogenates from patients with 
ulcerative colitis. This anomalous result probably was attributed to the fact that only 4 
patients were examined. In another study by O'Morain QLal. {1983), results showed 
that homogenates of rectal biopsies from patients with rectal Crohn's disease and active 
ulcerative colitis have increased levels of vitamin 81 2 binding protein, lysozyme and 
myeloperoxidase, specific markers for neutrophils. In contrast, in Crohn's disease 
when the rectum is spared, the activity of the neutrophils markers was similar to 
control values. 
Monocytes isolated from subjects with IBD have higher N-acetyl-~-
glucosaminidase and ~-glucuronidase enzyme activities than corresponding controls 
(Ganguly .e.t..aJ..1978; Mee & Jewel 1980; Doe .e.t.al., 1980) and secretion of plasminogen 
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activators by monocytes is also markedly enhanced in patients with Crohn's disease and 
ulcerative colitis and this correlates with disease activity (Doe & Oarsman, 1982). 
The results reported here established an association between the HPA52 and the 
inflamed mucosa of ulcerative colitis and Crohn's disease, since biopsies from patients in 
remission or from uninvolved mucosa failed to show an increase in the level of the PA 
activity. These studies established that HPA52 may represent an important pathway in 
the pathogenesis of mucosal tissue injury and could therefore offer fresh insights into 
the pathogenesis of ulcerative colitis and Crohn's disease. The PA could promote injury 
through the generation of plasmin in the extracellular milieu resulting in generalised 
proteolysis, collagenolysis, complement activation, kinin generation and the initiation of 
the coagulation cascade. 
Hence, future therapy could involve the use of substances modulating HPA52 
production or plasmin generation and might therefore constitute a valuable contribution 
to current therapy. 
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CHAPTER 6 
SUBCELLULAR FRACTIONATION OF HUMAN INTESTINAL MACROPHAGES: 
EVIDENCE FOR A L YSOSOMAL NON-SPECIFIC ESTERASE NOT FOUND IN 
MONOCYTES 
INTRODUCTION 
Intestinal macrophages are a prominent cell type in the normal intestinal mucosa 
(Golder & Doe1983). They derive from blood monocytes and display many of the diverse 
functional capabilities associated with macrophages in both immune and inflammatory 
networks (Reiko & Werb 1984). 
The state of differentiation of macrophages is reflected in the composition and 
properties . of the plasma membrane (Edelson 1981; Zuckerman & Douglas 1979). 
Particularly, the role of ectoenzymes in the human intestinal macrophages has received 
little attention. Before the commencement of the work reported in this chapter, both 
plasminogen activator (see Chapter 1, section 1 .7) and non-specific esterase had been 
reported to be expressed as ectoenzymes on related cells. The work of Bozdech & Bainton 
(1981) concluded from cytochemical studies that human monocyte alpha-naphthyl 
butyrate esterases was a plasma membrane ectoenzyme and that there was negligible 
intracellular activity. By contrast, the granule activity seen cytochemically in the light 
microscope was interpreted as lysosomal and designated "non-specific acid esterase" 
(Parwaresch et al., 1981 ). A non-lysosomal cytoplasmic granular distribution of 2-
naphthyl thiol acetate activity was seen in human monocytes under the electron 
microscope (Kim fil...al., 1982) 
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Hence, subcellular fractionation of human intestinal macrophage (HIM¢) was 
performed as reported in this chapter to define the localisation of the plasminogen 
activators and non-specific esterases. The isolation and characterisation of plasma 
membranes from purified preparations of intestinal macrophages using subcellular 
fractionation techniques also allowed the analysis of the localisation and properties of 
biochemical differentiation markers and comparison with the results previously 
reported for blood monocytes (Fayle .et..al., 1985). These may help to elucidate the 
changes that characterize the differentiation state of intestinal macrophages and their 
adaptation to the mucosa! environment. 
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MATERIALS AND METHODS 
Isolation and purification of human intestinal macrophages, surface labelling of 
plasma membrane using wheat germ agglutinin, nitrogen cavitation and subcellular 
fractionation were performed as described in Chapter 2, section 2.20-2.23. 
Analytical Methods 
An Atago type 500 refractometer was used to measure sucrose density. The 
binding of 1251-labelled WGA was detected by counting each fraction in a Packard Auto-
Gamma 500 counter. 
Methods of assay for the following enzymes are described in detail in Chapter 2, 
section 2.1. P-hexosaminidase (B-N-acetyl-D-galactosaminidase EC 3.2.1.53) was 
measured according to Leaback and Walker (1961) using 4-methylumbelliferyl-2-
acetamido-2-deoxy-B-D-galactopyranoside as substrate while B-Glucuronidase (EC 
3.2.1.31) was assayed by the fluorimetric method of Mead .e!_gj_., (1955). Arylsulfatase 
C (EC 3.1.6.1) was detected by the method of Canonico .ru_ru., (1978). Catalase (EC 
1.11 .1. 7) was detected by oxidation of the fluorescent compound scopoletin (7-
hydroxy-6-methoxy-coumarin) by H202 in the presence of horseradish peroxidase. 
Galactosyltransferase or UDP galactose: B-D-N-acetylglucosaminyl-glycoprotein 
galactosyltransferase (EC 2.4.1.38) was assayed according to Baxter and Durham 
(1979) using ovomucoid rather than desialo, degalacto-fetuin as acceptor (Fayle fil..al., 
1985). Lactate dehydrogenase (EC 1.1.1.27) was assayed by the method of Kornberg 
(1954), using 0.75 mM sodium pyruvate and 0.33 mM NADH. Leucine-2-
naphthylamidase (EC 3.4.11.2) was detected using 0.2 mM L-leucine 2-naphthylamide 
and deamination of [14c] tyramine was used to detect monoamine oxidase (EC 1.4.3.4). 
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Alpha-naphthyl acetate esterase (EC 3.1.1) was determined at pH 7.5 by the method of 
Laug et al., {1983b) for gradient fractions and according to Yam et al., (1971) for 
cytocentrifuge preparations. 5'-Nucleotidase (EC 3.1 .3.5) was assayed by the method of 
Edelson and Cohn (1976) and NAO+ nucleotidase (EC 3.2.2.5) was assayed by a 
modification of the method of Nakazawa .et.al., (1968). 
Plasminogen activator (urokinase EC 3.4.21.31) was assayed by the 
colorimetric assay method of Coleman & Green {1981) as described in Chapter 2, 
section 2.12. 
lmmunofluorescence was carried out in 96 well trays according to Loken & Stall 
(1982) using F(ab')2 goat anti-mouse lgG (heavy + light chain; Cappel Laboratories, 
Cochranville, P .A, USA) as second antibody as described in Chapter 2, section 2.24. 
SDS-PAGE Fibrin Overlay zymogram 
The SOS-PAGE fibrin overlay gel method of Granelli-Piperno & Reich (1978) as 
described in Chapter 2, section 2.6 was used to determine the types of PA present in the 
pooled PA enriched membranes fractions and to ascertain the presence of inactive 
proenzyme PA using anti-pig monoclonal antibody. The samples applied to an 11 o/o SOS 
electrophoresis gel under non-reducing conditions consisted of either plasminogen alone 
in assay buffer or plasminogen (1 O ul, 1 ug) preincubated with monoclonal anti-pig 1 
antibody for 2 hr at 200 C and further incubated with 30 ul of pooled PA enriched 
membranes fractions at 370 C for 45 min before stopping with SOS sample buffer to 
give a final volume of 100 ul. After electrophoresis, the gels slabs were washed in 
Triton X-100 and developed by contact lysis of fibrin in an agarose fibrin overlay gel. 
Monoclonal antibody 25F9 & SC11 were the gifts of Prof. C. Sorg (Dept. 
Experimental Dermatology, Universitats-Hautklinik, D-4400 Munster, FRG) and Dr. 
R. I. Fox (Research Institute of Scripps Clinic, La Jolla, CA, USA) respectively. GAP-
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8.3, L-243, 5E9, 6303 & 4F2 were obtained from the American Type Culture 
Collection (Rockville, MD,USA). M02 was purchased from Coulter Electronics, anti-
CR3 & OKia were from Ortho Diagnostics systems. Anti-cytokeratin 18 was from 
Boehringer Mannheim. 
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RESULTS 
Isolation and Purification of Highly Enriched Human Intestinal 
Macrophages by Centrifugal Elutriation 
In order to isolate human intestinal macrophage plasma membranes, a highly 
purified population of human intestinal macrophages was prepared by centrifugal 
elutriation followed by centrifugation over Percoll. This procedure resulted in an 8.5 
fold enrichment and a mean purity of 85 + 3°/o. Of the total disaggregated lamina 
propria cells, between 10-15 °/o were macrophages. Similar recoveries of intestinal 
macrophage at lower purity were recently reported by Beeken et al., (1984). 
Morphology, May-Gruenwald Giemsa staining, non-specific esterase staining, adherence 
and surface antigenic phenotype were used to verify the purity and suitability of the 
intestinal macrophages for plasma membrane preparation. 
Contaminating cell types after Percoll treatment included large lymphocytes, 
residual granulocytes and occasionally, aggregated erythrocytes. Epithelial cell 
contamination, assessed by immunofluorescence using a monoclonal antibody against 
cytokeratin 18 (Debus et al., 1982), a constituent of colonic epithelial cells, was 
negligible. 
Not all of the cells characterised morphologically as macrophages contained 
characteristic non-specific esterase staining; esterase positivity was found in about 
75°/o of the cells in the final preparation. A similar proportion of cells displayed HLA-
DR antigens (detected using the OKia monoclonal antibody). Approximately 26o/o 
expressed the mature macrophage marker 25F9 (Hume et al., 1986), and 36°/o 
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expressed the M02 antigen (Todd~-, 1981) at low levels. Only 5°/o of the macrophage 
preparation expressed the CR3 receptor found on monocytes, immature macrophages and 
residual granulocytes. Over 90°/o of the cells expressed the common leukocyte antigens 
detected by GAP-8.3 & SC 11, 80o/o expressed the transferrin receptor (5E9), and 84°/o 
& 41 °/o carried the monocyte antigens detected by 4F2 (Haynes et al., 1981) and 6303 
(Ugolini et al., 1981) respectively. 
Identification of plasma membrane after subcellular fractionation 
Both ectoenzyme activities and trace radiolabelling were investigated for the 
identification of plasma membrane on the sucrose gradients. Nitrogen cavitation was 
used to disrupt the macrophage preparation which had been trace-labelled with the 
1251-labelled wheat germ agglutinin (WGA) and washed free of the unbound lectin. 
The membrane fractions recovered from sucrose gradients after centrifugation to 
equilibrium showed that the distribution of bound WGA (Fig 6.1 A) paralleled that of the 
ectoenzyme activities 5'-nucleotidase (Fig 6.1 B) and Mn2+-stimulated leucine 2-
naphthylamidase (Fig 6.1 D). The mean peak concentration of the plasma membrane 
determined from 16 separate preparations was at a density of 1.126 + 0.005 g.cm-3, 
in close agreement with that of the plasma membrane markers obtained for blood 
monocytes (Fayle et al., 1985). However, unlike human blood monocytes, human 
intestinal macrophage expressed very low levels of NAO+ nucleotidase (data not shown). 
The plasma membrane 5'-nucleotidase activity was abolished by 0.1 mM ZnSO 4 but was 
unaffected by 1 O mM sodium tartrate (data not shown). The proportions of each marker 
found in the density range 1.10-1.17 g.cm-3 were: 51°/o for 5'-nucleotidase. 39°/o for 
WGA and 38°/o for leucine 2-naphthylamidase. 
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Figure s.1 Plasma membrane marker distribution on sucrose gradients. 
The 1000 x g supernatants from disrupted human intestinal macrophage were 
centrifuged to equilibrium on sucrose gradients either without (A,B,D,F ••--,a• ) or 
with (C,E,G • •) pretreatment with digitonin. Results are plotted as the activity or 
binding in the fraction, as a percentage of the total recovered on the gradient, versus the 
density of the fraction. (A) 1251-WGA (B,C) 5'-nucleotidase (D,E) leucine 2-
naphthylamidase (F,G) plasminogen activator. Recoveries (sum of the activity of 
fractions with respect to the activity of the 1000 x g supernatants) are: 90 ±. 10°/o for 
5'-nucleotidase; 85 ±. 5°/o for leucine 2-naphthylamidase; 107 ±. 11 °/o for plasminogen 
activator without digitonin treatment. In digitonin treatment, recoveries are: 87 ±. 6°/o 
for 5'-nucleotidase; 75 ±. 3°/o for leucine 2-naphthylamidase; 85 ±. 4°/o for 
plasminogen activator. 
Effect of digitonin on plasma membrane marker distribution 
Digitonin, the cholesterol-binding detergent was used to distinguish the plasma 
membrane from intracellular membranes containing less cholesterol. Digitonin is 
believed to form a complex with cholesterol, which remains io. fillll, resulting in an 
increase in the density of cholesterol-rich membranes. 
As shown in Fig 6.1, the distribution of the plasma membranes ectoenzymes 5'-
nucleotidase (Fig. 6.1 C) and Mn2+-stimulated leucine 2-naphthylamiodase (Fig. 6.1 E) 
was similarly altered, to a fraction with adensity of 1.18 g.cm-3 when digitonin was 
added to the homogenate before subcellular fractionation, in amounts approximately 
equimolar with the cholesterol. 
Distribution of Intracellular membranes and Cytosol markers after 
subcellular fractionation 
Cytosol: 
The distribution of the cytoplasmic enzyme lactate dehydrogenase on the gradient 
was largely that of a non-sedimentable enzyme (Fig 6.2A). However, about 8°/o of the 
activity penetrated into the heavier density region of the gradient (greater than 1.20 
g.cm-3). 
Golgi apparatus: 
The marker for the Golgi apparatus, UDP galactosyltransferase (Strous fil..al., 
1983) was found predominantly in a density peak of 1.111 + 0.005 g.cm-3 (Fig. 6.2C) 
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almost superimposed on the plasma membrane. An estimated 71 °/o of the activity was 
found in the density 1.10-1 .20 g .cm-3. Triton X-100 was used in this assay for the 
full expression of this activity. Digitonin treatment resulted in only a slight increase in 
the average density of this peak (Fig. 6.20) to 1.125 g.cm-3, indicating the presence of 
a low cholesterol concentration in the Golgi membranes. 
Endoplasmic recticulum 
Arylsulfatase C, a marker enzyme for endoplasmic recticulum in monocytes 
(Fayle et al., 1985), was distributed predominantly in a peak of density 1.21 g.cm-3 
(Fig. 6.28), a density somewhat greater than that found for human blood monocytes 
(Fayle et al., 1985). Triton X-100 was included in this assay to allow for the full 
detection of this activity. An estimated 57°/o of the activity was found in the density 
range 1 .171-1 .231 g .cm-3. 
Mitochondria 
The mitochondrial outer membrane enzyme, monoamine oxidase was found in a 
peak of a distinctly heavier fraction than the plasma membrane (1.16 g .cm-3) but 
overlapping it (Fig. 6.2E). Digitonin treatment resulted in a slight increase in the 
density of this peak (Fig. 6.2F). 
Peroxisomes 
Most of the catalase activity was distributed throughout the free fraction and the 
lowest densities of the gradient (Fig. 6.2G). A small proportion of the catalase activity 
was found in a peak of density 1 .18-1.22 g.cm-3 (mean 1.196 + 0.006 g.cm-3) · 
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figure 6.2 Distribution of markers of cytosol and intracellular 
membranes on sucrose gradients. The 1 ooo x g supernatants from disrupted 
human intestinal macrophage were pretreated with either with {D,F,H ..... ) or without 
{A,B,C,E,G ....._.) digitonin before centrifugation to equilibrium on sucrose gradients. 
Results are plotted as described in Figure 6.1. Markers, with their subcellular location 
in brackets were {A) lactate dehydrogenase {cytosol); {B) arylsulfatase C {endoplasmic 
reticulum); {C,D) galactosyltransferase {Golgi); {E,F) monoamine oxidase 
{mitochondria); {G,H) catalase {peroxisomes). Recoveries are: 98 ± 7°/o for {A); 129 
±. 10°/o for {B); 89 ±. 8°/o for {C); 85 ±. 9°/o for {D); 98 ±. 10°/o; {E) 94 ±. 4°/o for 
{F); 120 ±. 10°/o for {G); 115 ±. 15°/o for {H). 
Digitonin did not alter the profile of this distribution (Fig. 6.2H). Higher digitonin 
concentrations would be expected to disrupt peroxisomes, releasing the catalase (Amar-
Costesec 1974). 
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Lysosomal vesicles 
The lysosomal acid hydrolases p-glucuronidase and b-hexosaminidase were found 
in a relatively heavy fraction of peak density 1.21 g.cm-3 (Fig. 6.3A & 6.38). Nitrogen 
cavitation resulted in the release of substantial amounts of free enzyme, and p-
glucuronidase was sometimes found in addition in a fraction of similar density to the 
plasma membrane (not shown). Digitonin treatment did not alter the density of the 
lysosomal membranes, but released most of the enzymes into the free fraction (Fig. 
6.3C). 
Non-Specific esterase 
About 12°/o of the alpha-naphthyl acetate esterase activity was found in a fraction 
of density 1.165-1.242 g.cm-3 (Fig. 6.30). Over 67°/o of the esterase activity was 
found in the free fraction. Unlike the monocyte enzymes, the human intestinal 
macrophage esterases were partially resistant to 40 mM NaF (Fig. 6.30). Again, 
digitonin did not alter the distribution but did solubilize most of the alpha-naphthyl 
acetate activity in the fraction of density 1.165-1.242 g.cm-3 (Fig. 6.3E). 
The residual esterase activity present at a density of 1 .21 g.cm-3 exhibited the 
same characteristics as the lysosomal enzymes, both in terms of density and release into 
the free fraction in the presence or absence of digitonin (compare Figs. 6.3A-E). 
Figure 6.3 Distribution of lysosomal hydrolases and non-specific 
esterases on sucrose gradients. 
The 1000 x g supernatants from the disrupted human intestinal macrophage 
were centrifuged to equilibrium on sucrose gradients either without (A,B,D, • • ) or 
with (C,E • • ) pretreatment with digitonin. Results are plotted as in Figures 6.1 & 
6.2. (A) ~-Glucuronidase; (B) N-acetyl-galactosaminidase; (C) ~-Glucuronidase; 
(D ,E) Non-specific esterase with ( ................ ) or without ( • • ) 40 mM sodium 
fluoride. Recoveries are: 92 + 2°/o for (A); 87 + 5°/o for (B); 98 + 5°/o for (C); 101 + 
7°/o for (D) and 95 + 9°/o for ( E). 
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TABLE 6.1 
Cytosol and Intracellular membrane content of plasma membrane fraction 
Marker Enzyme 
Galactosyltransferase 
Monoamine Oxidase 
Arylsulfatase 
Non-Specific esterase 
N-Acetylgalactosaminidase 
~-Glucuronidase 
Catalase 
Lactate dehydrogenase 
Location 
Golgi 
Markers in density range 
(1.10-1.17 
g,cm-3)** 
O/o 
48 
Mitochondria outer membrane 18 
Endoplasmic reticulum 7 
Lysosome (membrane-associated) 9 
Lysosome 4 
Lysosome 6 
Peroxisome 17 
Cytosol 10 
** The percentage of each marker in the plasma membrane fraction (density range 
1 .1 0-1.17 g .cm-3) was estimated by the integral of the curve in this density range X 
100, divided by the integral of the complete curve. 
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Intracellular Membrane Content of plasma membrane preparation. 
In order to ascertain the purity of the plasma membrane preparation, the content 
of appropriate markers in the plasma membrane fraction (1.10-1.170 g.cm-3) was 
used to indicate the non-plasma membrane content of this preparation (Table 6.1 ). 
[v1itochondrial (monoamine oxidase) and Golgi (galactosyltransferase) membranes were 
the most prominent contaminants of the plasma membrane preparation. Other 
contaminants were minor. The selection of the peak plasma membrane fractions 
increased the purity in all cases but decreased the yield. 
Plasminogen Activators 
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A cell-associated plasminogen activator activity with a peak density of 1.126 .±.. 
0.003 g.cm-3 was consistently found (Figure 6.1 F). In most fractionation 
experiments, this peak density corresponded to the density of the plasma membrane 
markers. About 40°/o of the plasminogen activator activity was found in the density 
range 1.10-1 .15 g .cm-3. Digitonin treatment resolved the plasminogen activator 
activity into two fractions (Fig. 6.1 G). Typically, 44°/o of the activity normally found 
in the density range 1.10-1.15 g.cm-3 co-distributed with the plasma membrane 
markers (Fig. 6.1 G; compare Fig.6.1 C & E), whilst 28°/o co-distributed with the Golgi 
marker giving a peak density of 1.11 O g.cm-3 (Figure 6.1 G; compare Fig. 6.20). 
Zymogram of plasminogen activators in pooled sucrose gradient fractions 
and the effect of monoclonal anti-pig 1 antibody. 
To determine the nature of PA expressed in the membrane-fractions, the SOS-
PAGE fibrin overlay gel system was used to determine whether the PA are represented as 
proenzymes or in their active forms. The principle used in these experiments was 
defined in Chapter 4. 
Untreated pooled sucrose gradients fraction produced only one major band of lysis 
on the fibrin-agrose zymogram after SOS-PAGE (Figure 6.4 lane 5). This band was 
produced by a plasminogen-dependent enzyme migrating with the same mobility as 
human urokinase (HPA52). A lysis band was formed in this system, apparently due to 
activation of the H PA52 in .fil1.U. by plasmin present as a trace contaminant in the 
plasminogen used for the overlay gel. When the same plasminogen preparation was 
incubated with the pooled sucrose gradient fractions, activation of HPA52 occurred, with 
the concomitant formation of an active breakdown product of Mr 36,000 (Figure 6.4, 
lane 2, Zone 0, cf control stopped at zero time with SOS, lane 1 ). The Mr 48,000 form 
(lane 2, Zone C) is a partial breakdown product of HPA52. 
When the plasminogen used in the assay which contains trace amounts of plasmin 
was preincubated with the monoclonal antibody inhibitory to plasmin, anti-pig 1, for 2 
hr at 370c begore incubation with the pooled sucrose gradients fractions, the degradation 
of HPA52 to its active breakdown product of Mr 36,000 (HPA36) was prevented (lane 
4). When SOS-PAGE sample buffer was added to the preincubation mixtures at zero 
time before addition of the pooled sucrose gradient fractions, neither a plasmin band, nor 
evidence for the degradation of HPA52 was apparent, because of the inhibition of 
plasminogen activation by SOS sample buffer (Figure 6.4 lanes 1 & 3). 
This result hence indicated that the PA in the HIM~ is predominantly present in 
the form of a proenzyme. Unfortunately, insufficient PA enzyme content in either the 
Golgi or plasma membrane fraction could be obtained to produce reliable and consistent 
gel patterns. 
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( A )  8 5 0 0 0  
( B )  5 2 0 0 0  
( C )  4 8 0 0 0  
( D )  3 6 0 0 0  
1  2  
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F i g u r e  6 . 4  S D S - P A G E  f i b r i n  o v e r l a y  g e l  s h o w i n g  t h e  t y p e s  a n d  n a t u r e  o f  P A  i n  
p o o l e d  s u c r o s e  g r a d i e n t  f r a c t i o n s  ( l a n e  5 )  p r e t r e a t e d  w i t h : - L a n e s  ( 1 )  p l a s r n i n o g e n  
w i t h  S D S  s a m p l e  b u f f e r  a d d e d  a t  z e r o  t i m e  ( 2 )  p l a s m i n o g e n  ( 3 )  a n t i - p l g  1  a n d  
p l a s r n i n o g e n  p r e v i o u s l y  i n c u b a t e d  f o r  2  h r s  a t  2 0 ° c  a n d  w i t h  S D S  s a m p l e  b u f f e r  
a d d e d  a t  z e r o  t i m e  ( 4 )  a n t i - p l g  1  a n d  p l a s m i n o g e n  m i x t u r e  p r e v i o u s l y  i n c u b a t e d  f o r  
2  h r s  a t  2 0 ° c  
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DISCUSSION 
The subcellular fractionation presented in this chapter provides a basic 
framework for the analysis of possible changes in the subcellular distribution or 
properties of many enzymes implicated in the differentiation of monocytes/macrophages. 
In order to define the localisation of PA and non-specific esterase, a characterisation of 
the extracellular and intracellular compartments is necessary. 
The human intestinal macrophage PA, of the urokinase-type and predominantly 
in the form of proenzyme, was found to localise in the Golgi and plasma membrane 
fractions. Non-specific esterase was found in the lysosomal fraction and results also 
indicated that the membrane bound esterase of monocytes, which may be in the smooth 
endoplasmic reticulum, is also present in HIM,0. No evidence was found for a plasma 
membrane fraction. 
Subcellular Fractionation: 
The combination of centrifugal elutriation and subcellular fractionation by 
isopycnic centrifugation has proved suitable for the preparation of human intestinal 
macrophage plasma membrane and the subsequent analysis of the distribution of enzyme 
markers of intracellular membranes. 
M n2+-stimulated leucine 2-naphthylamidase, a plasma membrane ectoenzyme, 
was also demonstrated for the first time on these cells. 
The use of centrifugal elutriation to produce a well-defined cell preparation 
abolishes the need for an adherence step, and thus minimizes the functional and surface 
antigenic alterations to the cells. Traditionally, macrophages have been isolated by their 
propensity to adhere to glass or plastic surfaces but this approach has two drawbacks. 
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Firstly, it is not easy to release adherent cells without causing injury during scraping, 
exposure to local anaesthetics, chelators or cold. Secondly, macrophage function and 
biochemical characteristics may be altered by adherence. The elutriation procedure 
reported here gives an 8.5 fold enrichment of macrophages from the starting population 
of disaggregated lamina propria cells at high purity (85°/o + 3°/o). These results 
compare favorably with those reported previously (Beeken .fil..fil., 1984) although the 
yields obtained in this studies are much higher. 
Plasma membrane Marker Enzymes Distribution: 
Plasma membrane vesicles prepared from isolated intestinal macrophages 
exhibited a characteristic density of 1.126 + 0.0005 g.cm-3, as judged by the presence 
in this fraction of three markers characteristic of the plasma membranes of monocytes 
and other cells; namely 5'-nucleotidase, Mn2+-stimulated leucine-2 naphthylamidase 
activity and wheat germ agglutinin binding sites (Fayle fil.fil., 1985). 
5'-nucleotidase has been widely used as a marker of macrophage 
differentiation (Bianco & Edelson 1978), and was readily detected in the present work 
reported in this chapter. The absence of the inhibition of the enzyme activity by 
glycerol 2-phosphate (used to inhibit alkaline phosphatase) or sodium tartrate (used to 
inhibit acid phosphatase), together with the inhibition of AMPase activity by zinc 
sulphate, indicated that the activity was due to 5'-nucleotidase. The 5'-nucleotidase 
enzyme has been identified as an ectoenzyme of the plasma membrane in many species. 
Although this enzyme had been reported to be absent in freshly isolated monocytes 
(Johnson et al.J 977), work from our laboratory had found that this enzyme was 
readily detectable (Fayle fil-al., 1985). 
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Mn2+.stimulated leucine 2-naphthylamidase, which we had previously 
found to be present in monocytes, was present in HIM0 and displayed a distribution 
profile paralleling that of 5'-nucleotidase. This report established for the first time, 
the presence of leucine 2-naphthylamidase enzyme in HIM¢. This enzyme has been 
extensively studied in mouse peritoneal macrophages (Wachsmuth & Wust 1982) and 
has also been demonstrated in the rabbit alveolar macrophages (Andrew fil_fil., 1980) 
and recently on human moncytes and macrophages as an ectoenzyme (Fayle et al., 1 985). 
A similar enzyme is a prominent component ileal brush border (Kenny & Maroux 
1982) and had also been detected in the mucosa and the isolated microvillous fraction of 
the proximal colon of newborn pigs (Sepulveda & Smith 1979) and also in the human 
jejunal biopsy homogenates (Peters .e.Lfil., 1975; Peters 1976). 
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In addition, the labelling of the cell surface glycoproteins and glycolipids by 
wheat germ agglutinin displayed a similar buoyant density profile to that of 5'-
nucleotidase and Mn2+-stimulated leucine 2-naphthylamidase plasma membrane 
markers. Digitonin was also used to distinguish the plasma membrane from the 
intracellular membranes. The plasma membrane markers of 5'-nucleotidase, Mn2+_ 
stimulated leucine 2-naphthylamidase and wheat germ agglutinin without the addition of 
the cholesterol binding detergent were found in a light membrane fraction of density 
range 1.10-1.15 g.cm-3, with a peak density at 1.12 g.cm-3. However, when digitonin 
was added to the homogenate before subcellular fractionation, in amounts approximately 
equimolar with the cholesterol content, the density profile was altered and the plasma 
membrane markers were then found in a sharp peak at a much heavier density of 1.18 
g .cm-3. These findings indicate that as with other cell types, the plasma membrane of 
the HIM¢ is richer in cholesterol than other intracellular membranes. By contrast, 
digitonin treatment had little effect on the other subcellular markers investigated. 
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The above criteria established the unequivocal identification and isolation of 
HIM¢ plasma membrane. 
Intracellular Marker Enzymes: 
In order to characterize the plasma membrane preparation fully, the content of 
contaminating intracellular membranes and soluble proteins were assessed using 
enzyme markers characteristic of the Golgi apparatus, endoplasmic reticulum, 
mitochondria, peroxisomes, lysosomal vesicles and cytoplasm. 
Galactosyltransferases comprise a family of enzymes of the Golgi apparatus, 
each of which exhibits a characteristic acceptor specificity using UDP galactose as the 
substrate (Gerber fil..al., 1979; Kaplan & Hechtman 1984). The results reported here 
indicate that although this activity was found predominantly in a peak of density similar 
to that of the plasma membrane, less cholesterol was present in the Golgi membranes 
since digitonin treatment caused only a marginal shift of the buoyant density profile. 
Galactosyl transferase, although found in the plasma membrane of several 
cell types (Hopper et al.,1986) is nevertheless specific for the Golgi in our cell type. 
The hardly noticeable shift in the density gradient following digitonin treatment unlike 
p.m. indicated that galactosyl transferase is useful as a marker in this instance and 
consequently the possible golgi localisation of PA is therefore convincing since the PA 
activity is separated from all other enzymic markers. The difference in density 
gradients of PA relative to catalase, 2 lysosomal enzymes and esterase, were sufficiently 
marked to support the conclusion that PA is not associated with peroxisomes, lysosomes 
or the endoplasmic reticulum. 
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Arylsulfatase C is an integral component of endoplasmic reticulum 
membranes, unlike the lysosomal arylsulfatases A and B (Milsom et al., 1972; Roy 
1976; Moriyasu & Ito 1982). HIM¢ arylsulfatase C, as expected, was found over a wide 
density range. The HIM¢ endoplasmic reticulum membranes were considerably denser 
overall (mean density 1 .21 g .cm-3) than their counterparts in monocytes [1 .17 g .cm-
3, Fayle et al., (1985)] and the levels of arylsulfatase C activity detected were lower 
than those found in human blood monocytes on a cellular basis. 
The outer mitochondrial membrane enzyme monoamine oxidase (Schnaitman 
.et.al., 1967) was used to identify the mitochondrial component. The peak density of the 
mitochondrial marker (1.16 g.cm-3) agreed with the published values for other cell 
types, which generally range over 1.16-1.18 g.cm-3. However, the major contaminant 
of the plasma membrane fraction was mitochondrial particles. 
Monoamine oxidase has been claimed to be an unsatisfactory marker for 
mitochondria as it is found in plasma membrane and enoplasmic reticulum fractions in 
certain cell types. In our study with HIM¢, monoamine oxidase is a satisfactory marker 
for mitochondria as it is not found in the p.m and the e.r fractions of this cells. Evidence 
to support this observation came from Table 6.1 where the monoamine contamination in 
the p.m marker density range 1.10-1.17 g.cm-3 was only 18°/o and furthermore, the 
use of digitonin caused only a marginal shift in the mitochondria fraction unlike the p.m. 
fraction. Although succinate dehydrogenase would have been a much more satisfactory 
marker for mitochondria, unfortunately we have not been able to assay this marker in a 
reproducible manner. 
Catalase, a component of peroxisomes displayed a membrane-associated peak at 
1.18 g.cm-3, with the remainder in the very low density or free fractions. The lack of 
effect of digitonin indicated that the peroxisomal membranes were cholesterol-poor. A 
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similar peak density and pattern of distribution for catalase has also been reported for 
peripheral blood monocytes (Fayle .e.Lal., 1985) and mouse peritoneal macrophages 
(Darte & Beaufay 1983): The current results do not exclude the possibility that some of 
the catalase found in the free fraction may be contributed by cytoplasmic catalase (Roels 
et al., 1977). 
The HIM¢ lysosomal acid hydrolases gave the highest buoyant density of all 
the intracellular membranes studied. Two representative lysosomal acid hydrolases, ~ -
glucuronidase and N-acetylgalactosaminidase, gave a peak density at 1.21 g.cm-3. An 
additional peak of similar density to the plasma membrane was sometimes found for ~ -
glucuronidase, which otherwise had a similar distribution to that of N-
acetylgalactosaminidase. As noted previously (Fayle et al., 1985), some ~-
glucuronidase may well be present on the endoplasmic reticulum. 
HIM0 PA and Alpha-Naphthyl Acetate Esterase 
The profile of HIM0' alpha-naphthyl acetate esterase activity after 
digitonin treatment closely resembled that previously seen in monocytes (Fayle .e.Lal., 
1985). These results suggest that the membrane-bound esterase of monocytes, which 
may be in the smooth endoplasmic reticulum (Fayle et al., 1985), is also present in 
HIM0. Residual activity at a density of 1.21 g.cm-3 however, reflected the presence of 
an additional component of HIM.0 esterase activity, that was more readily detectable 
without digitonin treatment (Figure 6.30). This peak of esterase activity exhibited the 
same characteristics as the lysosomal enzymes, both in terms of density and release into 
the free fraction in the presence or absence of digitonin. The studies reported in this 
chapter indicate that HIM~ possess an esterase, probably lysosomal, which is not 
present in monocytes. The appearance of this enzyme may also be linked to the 
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appearance in HIM.0 of esterase activity partially resistant to 40 mM NaF. Monocyte 
esterase activity was abolished by such treatment (Fayle .e.t..al., 1985). Changes in the 
esterase isoenzyme spectrum with maturation of human monocytes and monocyte-like 
cell lines have been well-documented (Parwaresch .e..L.al., 1981 ). In human leukocytes, 
the non-specific esterase isoenzyme profile correlates with the cell lineage and 
differentiation status. Despite some discrepancies, there is universal agreement that 
alpha-napthyl acetate esterase activity in cells of the monocyte lineage resides 
predominantly in 4-5 isoenzymes of pl 5.5-6.3 (Parwaresch et al., 1981; Scott et al., 
1984; Yourno & Mastropaolo 1981). Recently it was discovered - that monocytes 
differentiating in culture undergo pronounced alterations to this pattern. Thus the band 
at pl 6.1 rapidly decreases in relative activity, whilst a new isoenzyme appears at pl 
6.3 within a day. The new band increases in intensity by day 3, when a second new band 
(pl 6.45) appears. The resulting pattern is identical to that of human resident 
peritoneal macrophages (Parwaresch .e.1...al., 1981 ). Patterns almost identical to the 
monocyte and macrophage profiles (designated Mon-2 and Mon-3 respectively) were 
recently reported in different cases of acute myeloid leukaemia (Scott et al., 1984). 
Taken together, these results suggest that the alpha-naphthyl acetate isoenzyme profile 
is highly-correlated with differentiation status in monocytes. Indeed, Oertel et al., 
(1985) using the alpha-naphthyl acetate esterase inhibitor, bis [4-nitrophenyl]-
phosphate showed that human monocytes alpha-napthyl acetate esterases were involved 
in the spontaneous cytotoxicity of monocytes toward tumour cells. Whether the alpha-
naphthyl acetate esterase in HIM¢ may act against colorectal tumour cells requires 
further study. 
The PA distribution closely paralleled the distribution of the plasma 
membrane enzyme, 5' nucleotidase, WGA and Mn2+-stimulated leucine aminopeptidase 
before digitonin treatment. After digitonin treatment, the PA distribution resolved into 
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2 peaks, one paralleled the Golgi fraction and the other with the plasma membrane 
fraction. The implication that part of PA was associated with Golgi membrane fractions 
suggests that the PA has the potential to be incorporated into the plasma membrane and 
subsequently gain excess to the extracellular environment. Despite the finding that the 
PA is membrane associated and exists predominantly as proenzyme in the plasma and 
Golgi membrane fractions, macrophages isolated from histologically normal mucosa have 
little urokinase PA in comparison to activated monocytes and tumour cells and therefore 
argue against PA from macrophages isolated from histologically normal mucosa having a 
significant function in regulating extracellular proteolysis. Whether the HIMJo could 
produce its own plasminogen, hence amplifying the effect of the small amount of PA in 
the generation of a proteolytic cascade, remains to be studied. 
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It has often been suggested that treatment of intact cells rather than homogenates 
with digitonin including the use of ecto-enzyme inhibitors like DFP could have helped 
clarify the plasma membrane localisation of the plasminogen activators. The use of DFP 
or whole cells with digitonin or ectoenzyme inhibitors to show whether PA can be 
liberated in soluble form does not necessarily argue against a localisation within carrier 
vesicles if it is not liberated in soluble forms. In fact, PA could be bound at the internal 
surface of the membrane of the secretory vesicles and become exposed on the cell surface 
after fusion of the vesicles with the plasma membrane. It could then display its 
enzymatic action either on the cell surface or after shedding into the pericellular space. 
Since digitonin resolved PA into 2 peaks: (a) Golgi and (b) plasma membrane, this 
suggested that the PA in the golgi could become incorporated into the plasma membrane 
and subsequently gain acess to the extracellular environment. As our result indicated 
that the PA is released as proenzyme urokinase type PA and that plasmin activated the 
proenzyme of urokinase type PA into active enzyme (chapter 3), then the definitive 
localisation of the PA in the cell could involve the use of the monoclonal antibodies 
inhibitory to plasmin. An experimental approach would be to gently activate whole HIM¢' 
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cells in the presence or absence of plasmin and in the presence or absence of plasmin and 
the monoclonal antibody inhibitory to plasmin together using conditions that do not 
impair cell viability. If PA is localised at the plasma membrane, then we would expect 
the activation of the proenzyme to active enzyme and subsequently we could then use the 
"activated" PA in the plasma membrane of HIM¢ to activate the plasminogen in the yellow 
colorimetric assay. 
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The newly found membrane receptor for urokinase PA on human 
monocytes maintained in culture (Vassalli et a!., 1985; Stoppelli et al., 1984) is 
intriguing. Tumour cells ( and probably macrophages or epithelial cells in IBD) start to 
release inactive pro-urokinase PA during their differentiation/transformation. How 
and where the activation takes place, still remains unsolved but this process clearly 
involves plasmin. Plasminogen dependent fibrinolysis on the surface-attached parts of 
the human monocyte membrane indicates that these contact areas somehow trigger the 
activation of pro-urokinase PA. The presence of a receptor for two chain urokinase PA 
on the monocyte-macrophage plasma membrane (Vassalli fil_fil., 1985; Stoppelli .e.1 
.al., 1984) may protect the enzyme from inhibitors at the contact areas of the cells and 
help to focus the proteolytic effect. 
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CHAPTER 7 
GENERAL DISCUSSION 
The main findings of the work presented in this thesis were discussed in the 
concluding sections of each chapter and were outlined in the Summary (page viii). This 
chapter discusses these findings in the context of the importance and biological role of 
proteolytic enzymes as summarised up recently by Neurath (1984). 
"Proteolytic enzymes are not only a physiological necessity but also a potential 
hazard, since, if uncontrolled, they can destroy the protein components of cells and 
tissue." 
7 .1 Colorectal carcinomas 
The hypothesis of PA playing a role in tissue degradation in cancer and the 
documentation that most cell types in the normal organism do not produce detectable 
amounts of PA, imply that an abberration in the regulation of PA activity exists in 
tumour cells. 
It has been suggested that the production of PA by invasive tumour cells and the 
generation of plasmin are key events in the hydrolysis of all matrix components, since 
glycoprotein removal from the matrix is required for the maximal degradations of 
collagens and elastin. The availability of the monoclonal antibodies inhibitory to human 
plasmin (chapter 3) will now be able to be used to elucidate this mechanism in the same 
manner as in the study performed by Ossowski and Reich (1983) where antibodies to 
urokinase were shown to inhibit experimental metastasis. 
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It is generally believed that the total PA activity in a tissue is the net result of 
several factors; including the rate of biosynthesis, release of the enzyme from the 
producer cells, the rate of proenzyme activation and the presence of stimulatory factors 
and/or inhibitors in the extracellular milieu. 
A putative regulatory mechanism at the level of activation of the proenzyme to 
plasminogen activator is only likely to be of any significance if the proenzyme in intact 
tissues is not always converted to its active counterparts immediately after secretion 
e.g. by trace amounts of plasmin that might be present in the extracellular space. The 
findings in chapters 4 and 5 indicated that this is the case. Furthermore, the finding 
that the majority of the plasminogen activators of the urokinase type existed as 
proenzyme in these tissues deserved comments. 
The lack of inhibition between proteinase inhibitors and pro-urokinase PA is a 
consistent finding(Eaton et al., 1984; Vassalli et al., 1984; Andreasen et al., 1986). 
The demonstration of the lack of reaction of the inhibitors with pro-uokinase PA may 
have important regulatory implications. Even if inhibitor and pro-urokinase PA coexist 
extracellularly, no reaction will occur until pro-urokinase is converted to active 
urokinase PA. But conversion will be followed by the rapid inhibition of the enzyme 
activity of active urokinase PA. In the intact organism, this may serve to confine PA 
activity to times and places with high rates of conversion of pro-urokinase PA to the 
active enzyme. This role of the inhibitor may be particularly important in the biology 
of tumours. Although it is at present unknown whether tumours in vivo have high 
production of PA inhibitors like the HT 1080 cell line (Andreasen .fil...fil., 1986) , it may 
be speculated that production of PA inhibitor by the cancer cells, together with 
urokinase PA, may help to confine plasminogen activation mediated proteolysis to areas 
of contact between the tumour and the normal tissue and thereby protect the tumour 
against the tissue destruction that it imposes upon the surrounding normal tissue. 
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Whether tumour cells possess a receptor for two chain urokinase PA like the monocyte-
macrophage cells (Stoppelli .e.Lal., 1984; Vassalli et al., 1985) which might protect the 
pro-urokinase PA once activated from inhibitors as well as focusing proteolytic effect, 
is also unknown. 
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The cascade reactions leading to plasminogen activation provide effective 
proteolytic activity, which can be regulated at the level of single cells and used for 
strictly controlled proteolysis and degradation of extracellular matrix. The mere 
secretion of PA has no actual correlation with disturbances of cell growth. It may be a 
prerequisite for certain steps of neoplastic growth, such as metastasis and invasion by 
tumour cells. The differences between physiological proteolysis and proteolysis related 
to neoplasia may be in the control of either the pericellular activation of proenzymes or 
removal of the active proteinases from the microenvironment of cells, for example 
through alpha 2 macroglobulin. Removal of proteinases from the extracellular and 
intravascular fluid is the best characterised function of alpha 2 macroglobulin. The 
differences in alpha 2 macroglobulin levels in normal and malignant tissues are 
consistent with the widely held notion that proteolytic activity accompanies 
transformation. Defects in the regulation of pericellular proteolysis might be involved 
in the disruption of cell-matrix connections and in the altered phenotype of transformed 
cells. 
Comparison of the studies of the occurrence of plasminogen activators in tumours 
with those of their occurrence in the normal organism (chapter 4) indicates that 
plasminogen activators of the urokinase type may prove to be a useful but not specific 
tumour marker especially when expressed in proenzyme forms. 
Further studies are needed to explore this possibility, including histochemical 
studies of the occurrence of urokinase PA in benign tumours and in pre-malignant 
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conditions. The considerable amount of urokinase PA immunoreactivity detected 
extracellularly or attached to the cell membrane in malignant tumours (see Dano .e.1 
al., 1985) and the low content of urokinase PA immunoreactivity in some organs (e.g. 
brain and liver) also points to a possible use of radio labelled antibodies against 
urokinase PA for detection of tumours and metastases by radio imaging. 
It was not possible to define the cellular origin of the urokinase type PA using the 
colorimetric enzyme assay, although the variability in the amount of PA detected in 
tumours could be accounted for by tumour cell heterogeneity. The major cause of this 
heterogeneity is probably a genetic instability of cancer cells, which may give rise to 
new variant subclones during tumour development (Nowell 1976). A strong candidate 
for the source of urokinase type PA, however, could be transformed epithelial cells 
within tumours, as other studies have shown the production of these enzymes by 
epithelial cells derived from both colorectal carcinomas (Carretero et al., 1985; 
Friedman et al., 1984) and adenomatous polyps (Friedman et al., 1984) in culture. 
lmmunocytochemical studies have also shown urokinase to be associated with neoplastic 
epithelial cells in colonic cancer (Kohga et al., 1985; Burtin et al., 1985) and it has 
been postulated that urokinase may be released by tumour epithelial cells into the 
stroma, where it has also been detected (Kohga et al., 1985). However, 
immunocytochemical studies of normal mouse tissues have localised urokinase PA to a 
variety of cell types, in particular connective tissue cells with a fibroblast-like 
morphology (Larsson et al., 1984) and these occurr in high frequency in the lamina 
propria of the gastrointestinal tract. No other cell types, other than fibroblast-like 
cells, displayed urokinase PA in the gastrointestinal tract. Double staining using both 
the urokinase PA antibodies and the monoclonal antibodies inhibitory to human plasmin 
(chapter 3) might help to define the cellular origin more precisely since we would 
expect a localisation of the plasmin in areas where there is a high concentration of PA. 
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The contribution of PA by infiltrating white cells represents a further potential source 
of protease activity in tumours especially when activated or transformed since it was 
demonstrated that lymphocytes produce negligible amounts of PA unless they were 
transformed - for example, by human T cell lymphotropic virus type Ill - when 
appreciable amounts of PA of urokinase type were apparent (Hinuma ~-, 1985). 
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However, the studies reported in chapter 5 that the urokinase PA content of 
colonic mucosa from IBD was very much higher than from normal mucosa imply that the 
production of this enzyme is not a specific feature of transformed cells, even though a 
contradictory study from ours had been reported (Verspaget ~-, 1986). 
A hypothetical mechanism for the activation of plasminogen in vivo is 
schematically represented in Figure 7 .1. 
Initially, the pro-urokinase may directly activate plasminogen to plasmin. The 
generated plasmin then converts cellular or tissue inactive pro-urokinase into active 
two chain urokinase PA which in turn activates plasminogen to plasmin. In a plasma 
milieu, activation is prevented by competitive inhibition of a yet uncharacterised 
inhibitor of the activation of plasminogen. However, the addition of fibrin prevents the 
inactivation of plasminogen activation by the competitive inhibitor. This concept is 
supported by the work of Lijnen et al., (1986). Using recombinant pro-urokinase 
(Rec-pro-UK), obtained by the expression of the human pro-urokinase gene in 
Escherichia coli, Lijnen et al., (1986) in an in vitro purified system showed that in 
mixtures of Rec-pro-UK and plasminogen, both active urokinase and plasmin are 
quickly generated. Addition of plasmin inhibitors (aprotinin or a2-anti plasmin) 
abolishes the conversion of Rec-pro-UK to urokinase but not the activation of 
plasminogen to plasmin; suggesting that the Rec-pro-UK activates plasminogen directly. 
However, evidence that the conversion of Rec-pro-UK to urokinase is abolished but not 
the activation of plasminogen to plasmin cannot be conclusive owing to the possibility of 
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contaminant protease activity in the plasmin preparation and the plasmin inhibitors 
used in the experiment. A definitive answer would involve the use of the specific 
monoclonal antibody inhibitory to human plasmin generated in chapter 3. 
Since plasmin and soluble active urokinase PA are rapidly inhibited by 
circulating and cell-secreted inhibitors, plasminogen and PA activation therefore 
occurred at the cellular contact area (receptor), thus being protected from the 
inhibitors. 
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The finding that autologous normal mucosa contained little HPA52 compared with 
colon cancer tissue (chapter 4) requires comment. The low level of PA activity may 
result from normal mucosa making HPA52 as well as an excess of HPA52 inhibitor. The 
net effect would be the absence of detectable activity as was the case reported for human 
umbilical vein endothelial cells (Dosne .e.L.al.1978). Tumour cells, on the other hand, 
may make HPA52 but no inhibitor. However, the findings of a higher proportion of 
active enzyme in the normal mucosa homogenates (53°/o) against 30°/o in tumours (see 
II' chapter 4) would argue against the increased production of HPA52 inhibitor in normal 
mucosa compared to the tumours. Furthermore, if the normal mucosa produced 
relatively more endogenous HPA52 inhibtor, then the inhibition of the colorimetric 
assay in normal mucosa would be seen. This was not the case (see chapter 4). 
Rather, the increase in the level of HPA52 activity in tumour compared to 
adjacent normal mucosae is more likely to result from a change in transcription and 
translation of the HPA52 gene (Becker et al., 1981; Hamilton 1983; Nagamine .fil 
1, · 
.al., 1983). Experiments with inhibitors of mRNA have suggested that these agents may 
affect the rate of PA gene transcription (see review by Dano et al., 1985). With the 
probes of cloned cDNA for PA mRNA becoming available, it will be possible to study in 
detail the regulation of HPA52 in normal and neoplastic tissue . 
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Further studies are also required on factors capable of affecting the HPA52 
proenzyme conversion. These include the availability of plasmin to activate HPA52 and 
the interaction of inhibitors released by other cells for example, minactivin (from 
activated monocytes; Golder & Stephens 1983) and protease-nexin (from human 
fibroblast; Baker et al., 1980). Such inhibitors could regulate PA activity directly or 
by influencing PA synthesis. 
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The possible role of macrophages in the regulation of proteolysis around tumours 
must also be taken into account. Subcellular fractionation of HIM~ was performed to 
define the localisation of the serine hydrolases, PA and non-specific esterase. The 
analysis of HIM$2>' plasma and intracellular membranes at high purity represents a 
valuable approach to elucidating the changes that characterize the differentiation of 
intestinal macrophages. 
The finding that the serine hydrolase, alpha-naphthyl acetate esterase in the 
intestinal macrophages was partially resistant to 40mM NaF, in contrast to human blood 
monocytes, is of interest. The HIM~ alpha-naphthyl acetate esterase may be involved in 
the mediation of cytotoxicity against colorectal tumour cells in view of recent report by 
Oertel .e.1...al., (1985) who showed that human monocyte alpha-naphthyl acetate esterases 
were involved in the spontaneous cytotoxicity of monocytes toward tumour cells. Whilst 
the alpha-naphthyl acetate esterases are a major and characteristic enzyme in cells of 
the monocyte lineage, their role and physiological substrates are unknown. 
The finding that the PA in the HIMW is membrane-associated might have 
widespread implications (see chapter 6) especially in the interactions with other cell 
types which might induce changes in the production or metabolism of PA. However, the 
amount of PA released by HIMS:O isolated from histologically normal mucosa is relatively 
small compared with activated monocytes and tumours and this finding argues against 
HIM~ plasma or Golgi membrane PA having a significant function in regulating any 
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possible extracellular proteolysis on its own. No attempt was made to study the pro 
PA/PA of activated macrophages from either inflammatory tissues or colon carcinomas 
since it is not possible to obtain sufficient tissues. Activated blood monocytes were 
studied by Fayle .fil...a!. who showed an elevated PA secretion in the proenzyme form 
(unpublished observations). The use of the macrophages isolated from normal mucosa at 
least serves as a comparison in the absence of a more suitable tissue. In the event that 
monoclonal antibody markers are developed to distinguish between activated 
macrophages from those resident in the tissues, a qualitative study of activated 
macrophages and their potential for secreting urokinase PA could be undertaken using 
immunohistochemical techniques. 
The effects of interactions between different types of cell leading to modulation of 
production of PA has been documented in many studies (for a review, see Saksela 1985). 
Such interactions between various types of cell, which induce changes in the metabolism 
of plasminogen activators, are particularly interesting in connection with the possible 
correlation between PA and malignancy. Enhancement of local proteolytic activity 
brought about by contacts between certain cell types, may be involved in determining 
which cell in a tumour can metastasize and where the secondary tumours can arise. Such 
mechanisms also suggest a possible alternative to the PA production by the malignant 
cell itself. In this respect, whether HIMfZ> could be induced to secrete large amounts of 
PA perhaps in conjunction with other enzymes or cells or even to produce their own 
substrate for PA, plasminogen, and hence regulate extracellular proteolysis remains to 
be studied. 
The studies reported in this thesis indicate that PA may be a useful early 
correlate of the development of malignancy in the colon. However, further studies are 
still required to delineate as yet unknown factors which might contribute to the 
regulation of PA production in cancer cells. In particular, the monoclonal antibodies 
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inhibitory to human plasmin could be used to complement further studies in the human 
carcinoma HEp3 model where it was demonstrated that antibodies which inhibited HPA52 
activity also prevented metastasis but not the primary tumour growth (Ossowski .fil 
.al., 1983). The use of the antibodies might shed more light into the role of plasmin in 
vivo in the regulation of invasion and metastasis. 
In summary, the hypothesis of a causative role of PA in tissue degradation in 
neoplasia ( and in normally scheduled events of tissue degradation) is based on the 
assumption that PLASMIN, in combination with other proteases, can degrade the 
extracellular matrix, including the basement membrane. The generation of the 
monoclonal antibodies to plasmin reported in chapter 3 will now enable the many 
proposed roles of plasmin to be delineated further. 
7. 2 Inflammatory Bowel Disease (Crohn's disease and 
Ulcerative colitis). 
The aetiology of inflammatory bowel disease remains elusive. Among the many 
attempts to identify the pathogenesis of these diseases have included the characterisation 
of mediators of inflammation in tissues. 
The results reported in chapter 5 established an assocaition between increased 
HPA52 activity and the inflamed mucosa of the ulcerative colitis and Crohn's disease. 
The increased production of HPA52, most probably by epithelial cells, might 
involve anti-colon antibodies. These antibodies could bind to the epithelial cells and 
trigger the increased secretion and production of PA. Anti-colon antibodies have been 
found in sera of up to 90°/o of patients with IBD (for review see Kirsner & Shorter 
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1982). They react with the mucus of epithelial globlet cells of the small and large 
intestine. Immune complexes have also been detected in sera of patients with IBD, 
although little is known of the nature of their antigen composition (see review by 
Kirsner & Shorter 1982). In this respect, the immune complex, such as epithelial 
cells coated with autoantibody, could also act as the first or initiation signal by binding 
to the Fe receptors of the macrophages (and neutrophils) triggering a sequential 
metabolic changes (Gordon .et..a!..,1974) in the human intestinal macrophages causing 
activation. The necessary secondary/second signal may be provided from lymphokine or 
endotoxin excreted by commensal enteric organisms entering the privileged environment 
of the lamina propria. Activated HIM.0 may then release tissue damaging oxygen 
metabolites and other degradative enzymes like lysosomal enzymes (Mee & Jewell 1980; 
Doe et al., 1980) as well as stimulating a secondary tissue damaging immunological 
mechanisms. The release of oxygen-derived free radicals may also promote 
inflammation through the inactivation of serum inhibitors of protease activity resulting 
in increased tissue damage (Carp & Janoff 1979; Matheson .et...a.1.., 1979). Proteases 
liberated at the sites of inflammation may then remain free to attack the tissue 
structures if high enough concentration of oxidants are present. 
Although anti-colon antibodies in the intestinal mucosa have not been directly 
demonstrated, one must ask whether the intestinal plasma and B cells are capable of 
producing auto-reactive antibodies. Unfortunately, few plasma cells appear to survive 
the conventional isolation of lamina propria by collagenase digestion of mucosa stripped 
of its epithelium with EDT A. The percentage of B cells is also decreased (MacDermott fil 
.al. , 1 9 8 1 ) . 
A similar observation had been described in the bullous skin disorder pemphigus 
where autoantibodies are produced against an uncharacterised intercellular substance of 
skin and mucosa. The binding of these antibodies to human epidermal cells in an 
f 
experimental system stimulates synthesis and secretion of HPA52 by the cells 
(Hashimoto .e.1...al., 1984; Hashimoto .et..al., 1983). 
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Further evidence that the interaction of epithelial cells and autoantibodies might 
contribute to the increased production of PA came from a report described by Becker fil 
.al., (1981 ). These authors purified the lgG of rabbit antisera raised against two cell 
lines - LLC-PK1 derived from pig kidney and from Kirsten sarcoma virus transformed 
BALB/3T3 cells and using in vitro cell cultures of respective target cells, they found a 
progressive rise in PA production after lgG addition. The induction of PA synthesis was 
reversible and required the continued presence of lgG for its maintenance. The increase 
in PA production depended on gene transcription and translation. 
Beside the possibility of anti-colon antibodies, whether other cell types like 
macrophages, once activated could release a factor which subsequently modify PA 
production by the epithelial cells is as yet unknown. Macrophages are prominent in the 
inflammatory cell infiltrate in both conditions; in Crohn's disease, a hallmark of the 
condition is the granuloma, where macrophages are particularly conspicuous. There is 
no doubt that macrophages play a prominent role in a variety of chronic inflammatory 
conditions. Evidence has been presented to indicate that, especially in IBD, circulating 
monocytes are in an activated state. 
The possible role of plasminogen activator inhibitors in the regulation of PA in 
IBD requires comment. Although inhibitors of PA have yet to be isolated from IBD 
tissues, nevertheless it is conceivable that extracellular PA activity in these inflamed 
tissues may be regulated at the level of biosynthesis, secretion from producer cells and 
the activation of inactive proenzyme forms and by the stimulation or inhibition of the 
enzyme activity of the activation, in the same manner as that proposed for tumour cells. 
The possible interactions of plasminogen activators with cell-derived components 
include binding of activated urokinase PA by protease nexins and miniactivin. These 
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proteinase inhibitors have been found mainly in fibroblastoid cells and activated 
monocytes respectively and may play a central role in the cellular metabolism of 
urokinase PA and some other serine proteinases (Knauer & Cunningham 1984). 
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A very recent study by Lawrence & Loskutoff (1986) showed that PA inhibitor 
purified from cultured bovine aortic endothelial cells could be inactivated by oxidants in 
similar manner to the human a1 -protease inhibitor. At this point in time, no direct 
studies have as yet been performed to determine whether the inhibitors of urokinase 
type PA could be inactivated by oxidants released by activated macrophages in IBD 
particularly since they are conspicuous in these diseases. The sensitivity of the PA 
inhibitor purified from cultured bovine aortic endothelial cells to oxidants suggests that 
oxidants liberated by activated inflammatory cells (Weiss & Regiani 1984) in IBD may 
also inactivate PA inhibitor and this unleash a whole cascade of tissue-destructive 
proteinases, including elastase and plasmin. The recent demonstration of dramatically 
elevated plasmin in rheumatoid synovial fluid (Inman & Harpel 1986) is consistent 
with this hypothesis. The plasmin, generated through the action of PA is probably 
required for mediation of diapedesis of inflammatory cells through the vessel wall and 
onto the site of inflammation in addition to its capacity to mediate tissue injury. The 
availability of monoclonal antibodies inhibitory to plasmin will now be able to test this 
hypothesis in IBD to indicate elevated levels of plasmin and together with monoclonal 
antibodies to urokinase type PA in a double staining immunochemistry, might also help 
to delineate the cellular origin of PA in this inflamed tissues. 
Finally, it is unlikely that total PA content and pro-PA could serve as specific 
markers in the IBD since two disease control groups studied; infectious colitis and a 
group of undiagnosed chronic diarrhoea patients who were suspected of having crohn's 
disease but in whom no definite diagnosis could be made (chapter 5) also indicated 
increased levels of pro-PA and total PA. However, the enzyme might be a useful 
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biochemical marker of inflammation and a thorough appreciation and understanding of 
the role of proteinases in the biochemical mechanism of inflammation may assist in the 
early diagnosis of IBD and in the development of therapeutic agents for the prevention or 
treatment of this diseases. 
In summary, the pathogenesis of 180 could involve anti-colon antibodies reacting 
with epithelial cells, causing an elevated level of PA leading to chronic tissue injury. PA 
release is able to promote injury through the generation of plasmin with subsequent 
fibrinolysis, complement activation, kinin generation and the initiation of the 
coagulation cascade as well as activating collagenase (Gordon .e.t.al., 1978). 
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The above comments on the possible pathogenesis of 180 provide a useful working 
model for further investigation of the pathogenesis of IBD, even though future findings 
may invalidate some of its aspects. In particular, the availability of a novel monoclonal 
antibody against colonic epithelial cells (Sim, Gibson & Doe, manuscript in preparation) 
and the monoclonal antibodies inhibitory to plasmin will help to either support or refute 
some aspects of the hypothesis in particular with regard to increased PA production by 
colonic epithelial cells and the roles of plasmin in these inflamed tissues. 
In conclusion, Figure 7.2 shows a hypothetical model illustrating the mechanism 
of regulation of urokinase plasminogen activator and its subsequent mediation in 
extracellular matrix degradation. Plasminogen activator and collagenolytic metallo 
proteases both produced by metastasizing cells or transformed I inflammatory cells in 
its inactive form may act in concert to degrade the whole basement membrane after its 
activation. Plasminogen activator can generate plasmin from the extracellular 
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plasminogen (see chapter 1 & Figiure 7.2). The plasmin produced by this reaction can 
directly degrade non-collagenous extracellular matrix components such as laminin and 
fibronectin. In addition, plasmin can activate latent metallo proteases which would 
degrade extracellular matrix collagenous and proteoglycan components. Other 
degradative enzymes could also be involved, like for example ~-hexosaminidase. This 
lysosomal glycosidase can hydrolyse glycoconjugate components of membranes and 
extracellular matrices. The actual cascade of extracellular matrix degradation in vivo 
probably occurs adjacent to the tumour or inflammatory cell surface where the local 
concentration of enzymes is enough to override natural protease inhibitors and this is 
also help by the presence of putative urokinase receptors on these cells. The presence of 
these receptors on the plasma membrane also enables "focal and localised" proteolysis to 
occur at the cell surface in such a way that it is protected from circulating inhibitors 
like a 2-antiplasmin or a 2-macroglobulin. Such inhibitors are ubiquitous throughout 
the extracellular matrix and are present in serum. At any point in time only a small 
proportion of the total tumour or inflammatory cell population may be expressing 
extracellular matrix degrading protease activity. Although the inter-relationship 
between the coagulation, fibrinolysis and kallikrein systems are not shown in the model, 
nevertheless they should also be considered, particularly their involvement in the 
migration of these tumour or transformed/inflammatory cells. 
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